

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|---|---|
| (51) International Patent Classification n ⁷ : C12N 15/12, C07K 14/47, C12Q 1/68, A61K 38/17, C07K 16/18 | | A2 | (11) International Publication Number: WO 00/34477 |
| | | | (43) International Publication Date: 15 June 2000 (15.06.00) |
| (21) International Application Number: PCT/US99/30408 | | (72) Inventors; and (75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). AU-YOUNG, Janice [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). YANG, Junming [CN/US]; 7136 Clarendon Street, San Jose, CA 95129 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). | |
| (22) International Filing Date: 10 December 1999 (10.12.99) | | (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). | |
| (30) Priority Data: Not furnished 11 December 1998 (11.12.98) US 09/210,083 11 December 1998 (11.12.98) US 60/119,365 9 February 1999 (09.02.99) US 60/124,687 16 March 1999 (16.03.99) US | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). | |
| (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US Not furnished (CIP) Filed on 11 December 1998 (11.12.98) US 60/119,365 (CIP) Filed on 9 February 1999 (09.02.99) US 60/124,687 (CIP) Filed on 16 March 1999 (16.03.99) US 09/210,083 (CIP) Filed on 11 December 1998 (11.12.98) | | Published Without international search report and to be republished upon receipt of that report. | |
| (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). | | | |
| (54) Title: NEURON-ASSOCIATED PROTEINS | | | |
| <pre>1 MA-----GSPSRAAGRRLOLP----- 2417014 1 MEFSLLLPRLECNGAISAHRLNLRLLPGSSDS GI 3002527 17 -----LLCLFLQ----- 2417014 31 PASASPVAGITGMCTHARLILYFFELVEMEP GI 3002527 24 ---GATAVLFAVF-----VRYNHKT 2417014 61 LHVGGAGLELPTSDDPSVSASQSARXRTGH GI 3002527 41 DAAL-----WH----- 2417014 91 HARLCLANFCGRNRVSLMCPSSWSPCLKQST GI 3002527 47 -----RSNHSNADNEFYFRY---PKESHHS 2417014 121 CLSLPKCWDYRRAAVPGLFILFFLRHRCPT GI 3002527 68 VAQAGVQRRNLGSLQSPSPR----- 2417014 151 LTQDEVQWCDHSSLQPSLTPFIKHPPASASQ GI 3002527 88 -----W-----SFALVA 2417014 181 VAGTKDMHHYTWLIFIFIFNFLRQSLNSVIT GI 3002527</pre> | | | |
| (57) Abstract | | | |
| The invention provides human neuron-associated proteins (NEUAP) and polynucleotides which identify and encode NEUAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of NEUAP. | | | |

121

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------|----|-----------------------|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | Republic of Macedonia | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's | NZ | New Zealand | | |
| CM | Cameroon | | Republic of Korea | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

NEURON-ASSOCIATED PROTEINS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of neuron-associated proteins and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative disorders including cancer; neuronal and neurological disorders; and autoimmune/inflammation
5 disorders.

BACKGROUND OF THE INVENTION

The human nervous system, which regulates all bodily functions, is composed of the central nervous system (CNS), consisting of the brain and spinal cord, and the peripheral nervous system
10 (PNS), consisting of afferent neural pathways for conducting nerve impulses from sensory organs to the CNS, and efferent neural pathways for conducting motor impulses from the CNS to effector organs. The PNS can be further divided into the somatic nervous system, which regulates voluntary motor activity such as for skeletal muscle, and the autonomic nervous system, which regulates involuntary motor activity for internal organs such as the heart, lungs, and viscera.

15 The central nervous system (CNS) is composed of more than 100 billion neurons at the spinal cord level, the lower brain level, and the higher brain or cortical level. Neurons transmit electric or chemical signals between cells. The spinal cord, a thin, tubular extension of the central nervous system within the bony spinal canal, contains ascending sensory and descending motor pathways, and is covered by membranes continuous with those of the brainstem and cerebral hemispheres. The
20 spinal cord contains almost the entire motor output and sensory input systems of the trunk and limbs, and neuronal circuits in the cord also control rhythmic movements, such as walking, and a variety of reflexes. The lower areas of the brain such as the medulla, pons, mesencephalon, cerebellum, basal ganglia, substantia nigra, hypothalamus, and thalamus control unconscious activities including arterial pressure and respiration, equilibrium, and feeding reflexes, such as salivation. Emotions, such as
25 anger, excitement, sexual response, and reaction to pain or pleasure, originate in the lower brain. The cerebral cortex or higher brain is the largest structure, consisting of a right and a left hemisphere interconnected by the corpus callosum. The cerebral cortex is involved in sensory, motor, and integrative functions related to perception, voluntary musculoskeletal movements, and the broad range of activities associated with consciousness, language, emotions, and memory. The cerebrum
30 functions in association with the lower centers of the nervous system.

A nerve cell (neuron) contains four regions, the cell body, axon, dendrites, and axon terminal. The cell body contains the nucleus and other organelles. The dendrites are processes which extend

outward from the cell body and receive signals from sense organs or from the axons of other neurons. These signals are converted to electrical impulses and transmitted to the cell body. The axon, whose size can range from one millimeter to more than one meter, is a single process that conducts the nerve impulse away from the cell body. Cytoskeletal fibers, including microtubules and neurofilaments, run the length of the axon and function in transporting proteins, membrane vesicles, and other macromolecules from the cell body along the axon to the axon terminal. Some axons are surrounded by a myelin sheath made up of membranes from either an oligodendrocyte cell (CNS) or a Schwann cell (PNS). Myelinated axons conduct electrical impulses faster than unmyelinated ones of the same diameter. The axon terminal is at the tip of the axon away from the cell body. (See Lodish, H. et al. (1986) Molecular Cell Biology Scientific American Books New York NY, pp. 715-719.)

CNS-associated proteins have roles in neuronal signaling, cell adhesion, nerve regeneration, axon guidance, neurogenesis, and other functions. Certain CNS-associated proteins form an integral part of a membrane or are attached to a membrane. For example, neural membrane protein 35 (NMP35) is closely associated with neuronal membranes and is known to be highly expressed in the rat adult nervous system. (Schweitzer, B. et al. (1998) *Mol. Cell. Neurosci.* 11:260-273.) Synaptophysin (SY) is a major integral membrane protein of small synaptic vesicles. The chromosomal location of SY in human and mouse is on the X chromosome in subbands Xp11.22-p11.23. This region has been implicated in several inherited diseases including Wiskott-Aldrich syndrome, three forms of X-linked hypercalciuric nephrolithiasis, and the eye disorders retinitis pigmentosa 2, congenital stationary night blindness, and Aland Island eye disease. (Fisher, S. E. et al. (1997) *Genomics* 45:340-347.) Peripherin or retinal degeneration slow protein (rds) is an integral membrane glycoprotein that is present in the rims of photoreceptor outer segment disks. In mammals, rds is thought to stabilize the disk rim through heterophilic interactions with related nonglycosylated proteins. Rds is a mouse neurological mutation that is characterized by abnormal development of rod and cone photoreceptors followed by their slow degeneration. (Kedzierski, W.J. et al. (1999) *Neurochem.* 72:430-438.)

43 KD postsynaptic protein or acetylcholine receptor-associated 43 KD protein (RAPSIN) is thought to play a role in anchoring or stabilizing the nicotinic acetylcholine receptor at synaptic sites. RAPSIN is involved in membrane association and may link the nicotinic acetylcholine receptor to the underlying postsynaptic cytoskeleton. (Buckel, A. et al. (1996) *Genomics* 35:613-616.) Neuritin is a protein whose gene is known to be induced by neural activity and by neurotrophins which promotes neuritogenesis. Neuraxin is a structural protein of the rat central nervous system that is believed to be immunologically related to microtubule-associated protein 5 (MAP5). Neuraxin is a novel type of neuron-specific protein which is characterized by an unusual amino acid composition,

12 central heptadecarepeats and putative protein and membrane interaction sites. The gene encoding neuraxin is unique in the haploid rat genome and is conserved in higher vertebrates. Neuraxin is implicated in neuronal membrane-microtubule interactions and is expressed throughout the rodent central nervous system (CNS). (Rienitz, A. et al. (1989) EMBO J. 8:2879-2888.)

- 5 NudC, a nuclear movement protein, interacts with the lissencephaly gene product Lis1, a protein involved in neuronal migration. People with Miller-Dieker syndrome (MDS) or isolated lissencephaly sequence (ILS) have a hemizygous deletion or mutation in the LIS1 gene. Both conditions are characterized by a smooth cerebral surface, a thickened cortex with four abnormal layers, and misplaced neurons. LIS1 is highly expressed in the ventricular zone and the cortical plate.
- 10 The interaction of Lis1 with NudC, in conjunction with the MDS and ILS phenotypes, raises the possibility that nuclear movement in the ventricular zone is closely related to neuronal fates and to cortical architecture. (Morris, S. M. et al. (1998) Curr. Biol. 8:603-606.)

- CNS-associated proteins can also be phosphoproteins. For example, ARPP-21 (cyclic AMP-regulated phosphoprotein) is a cytosolic neuronal phosphoprotein that is highly enriched in the striatum and in other dopaminoceptive regions of the brain. The steady-state level of ARPP-21
- 15 mRNA is developmentally regulated. But, in the neonatal and mature animal, ARPP-21 mRNA is not altered following 6-hydroxydopamine lesions of the substantia nigra or by pharmacologic treatments that upregulate the D1- or D2-dopamine receptors. (Ehrlich, M. E. et al. (1991) Neurochem. 57:1985-1991.)

- 20 CNS-associated signaling proteins may contain PDZ domains. PDZ domains have been found in proteins which act as adaptors in the assembly of multifunctional protein complexes involved in signaling events at surfaces of cell membranes. PDZ domains are generally found in membrane-associated proteins including neuronal nitric oxide synthase (NOS) and several dystrophin-associated proteins. (Ponting, C. P. et al. (1997) Bioessays 19:469-479.)

- 25 CNS-associated proteins may also contain epidermal growth factor (EGF) domains. The Notch proteins are transmembrane proteins which contain extracellular regions of repeated EGF domains. Notch proteins, such as the Drosophila melanogaster neurogenic protein Notch, are generally involved in the inhibition of developmental processes. Other members of the Notch family are the lin-12 and glp-1 genes of Caenorhabditis elegans. Genetic studies indicate that the lin-12 and
- 30 glp-1 proteins act as receptors in specific developmental cell interactions which may be involved in certain embryonic defects. (Tax, F. E. et al. (1994) Nature 368:150-154.) Pecanex, a maternal-effect neurogenic locus of D. melanogaster is believed to encode a large transmembrane protein. In the absence of maternal expression of the pecanex gene, an embryo develops severe hyperneuralization similar to that characteristic of Notch mutant embryos. (LaBonne, S. G. et al. (1989) Dev. Biol.

136:1-116.) Other CNS-associated signaling proteins contain WW domains. The WW domain is a protein motif with two highly conserved tryptophans. It is present in a number of signaling and regulatory proteins, including Huntingtin interacting protein.

Alzheimer's disease (AD) is a degenerative disorder of the CNS which causes progressive memory loss and cognitive decline during mid to late adult life. AD is characterized by a wide range of neuropathologic features including amyloid deposits and intra-neuronal neurofibrillary tangles. Although the pathogenic pathway leading to neurodegeneration and AD is not well understood, at least three genetic loci that confer genetic susceptibility to the disease have been identified.

(Schellenberg, G.D. (1995) Proc. Natl. Acad. Sci. 92:8552-8559; Sherrington, R. et al. (1995) Nature 375:754-760.)

Neuronal Thread Proteins (NTP) are a group of immunologically related molecules found in the brain and neuroectodermal tumor cell lines. NTP expression is increased in neuronal cells during proliferation, differentiation, brain development, in Alzheimer's disease (AD) brains, and in pathological states associated with regenerative nerve sprouting (de la Monte, S.M. et al. (1996) J. Neuropathol. Exp. Neurol. 55:1038-1050). Monoclonal antibodies generated to a recombinant NTP, AD7c-NTP, isolated from an end-stage AD brain library, showed high levels of NTP immunoreactivity in perikarya, neuropil fibers, and white matter fibers of AD brain tissue. In vitro studies also demonstrated NTP upregulation, phosphorylation, and translocation from the perikarya to cell processes and growth cones during growth factor-induced neuritic sprouting and neuronal differentiation. Additionally, increased NTP immunoreactivity was found in Down syndrome brains beginning in the second decade, prior to establishment of widespread AD neurodegeneration, and at an age when a low-level or an absence of NTP expression was observed in control brains. These findings indicated that abnormal expression and accumulation of NTP in brain may be an early marker of AD neurodegeneration in Down syndrome (de la Monte, S.M. et al. (1996) J. Neurol. Sci. 135:118-125). Furthermore, the increased expression and accumulation of NTP in AD brain tissue was paralleled by corresponding elevations of NTP in cerebrospinal fluid (CSF), and elevated levels of NTP were detectable in the CSF early in the course of the disease.

Astrocytomas, and the more malignant glioblastomas, are the most common primary tumors of the brain, accounting for over 65% of primary brain tumors. These tumors arise in glial cells of the astrocyte lineage. Following infection by pathogens, astrocytes function as antigen-presenting cells and modulate the activity of lymphocytes and macrophages. Astrocytomas constitutively express many cytokines and interleukins that are normally produced only after infection by a pathogen (de Micco, C. (1989) J. Neuroimmunol. 25:93-108). In the course of identifying genes related to astrocyte differentiation, one cDNA was isolated from an astrocytoma cDNA library that encodes a

protein structurally related to the plant pathogenesis-related (PR) proteins (Murphy, E.V. et al. (1995) Gene 159:131-135). The glioma pathogenesis-related protein (GliPR) is highly expressed in glioblastoma, but not in fetal or adult brain, or in other nervous system tumors. PR proteins are a family of small (10-20 kDa), protease resistant proteins induced in plants by viral infections, such as tobacco mosaic virus. The synthesis of PR proteins is believed to be part of a primitive immunological response in plants (van Loon, L.C. (1985) Plant Mol. Biol. 4:111-116). GliPR shares up to 50% homology with the PR-1 protein family over a region that comprises almost two thirds of the protein, including a conserved triad of amino acids, His-Glu-His, appropriately spaced to form a metal-binding domain (Murphy et al., supra).

10 Fe65-like protein (Fe65L2), a new member of the Fe65 protein family, is one of the ligands that interacts with the cytoplasmic domain of Alzheimer beta-amyloid precursor protein (APP). Transgenic mice expressing APP are known to simulate some of the prominent behavioral and pathological features of Alzheimer's disease, including age-related impairment in learning and memory, neuronal loss, gliosis, neuritic changes, amyloid deposition, and abnormal tau phosphorylation. Proteins that interact with the cytoplasmic domain of APP provide new insights into the physiological function of APP and, in turn, into the pathogenesis of Alzheimer's disease. (Duilio, A. et al. (1998) Biochem. J. 330:513-519.)

Contact from one neuron to another occurs at a specialized site called the synapse. At this site, the axon terminal from one neuron (the presynaptic cell) sends a signal to another neuron (the postsynaptic cell). Synapses may be connected either electrically or chemically. An electrical synapse consists of gap junctions connecting the two neurons, allowing electrical impulses to pass directly from the presynaptic to the postsynaptic cell. In a chemical synapse, the axon terminal of the presynaptic cell contains membrane vesicles containing a particular neurotransmitter molecule. A change in electrical potential at the nerve terminal resulting from the electrical impulse triggers the release of the neurotransmitter from the synaptic vesicle by exocytosis. The neurotransmitter rapidly diffuses across the synaptic cleft separating the presynaptic nerve cell from the postsynaptic cell. The neurotransmitter then binds receptors and opens transmitter-gated ion channels located in the plasma membrane of the postsynaptic cell, provoking a change in the cell's electrical potential. This change in membrane potential of the postsynaptic cell may serve either to excite or inhibit further transmission of the nerve impulse.

30 Neurotransmitters comprise a diverse group of some 30 small molecules which include acetylcholine, monoamines such as serotonin, dopamine, and histamine, and amino acids such as gamma-aminobutyric acid (GABA), glutamate, and aspartate, and neuropeptides such as endorphins and enkephalins. (McCance, K.L. and Huether, S.E. (1994) PATHOPHYSIOLOGY, The Biologic

Basis for Disease in Adults and Children, 2nd edition, Mosby, St. Louis, MO, pp 403-404.) Many of these molecules have more than one function and the effects may be excitatory, e.g. to depolarize the postsynaptic cell plasma membrane and stimulate nerve impulse transmission, or inhibitory, e.g. to hyperpolarize the plasma membrane and inhibit nerve impulse transmission.

5 Neurotransmitters and their receptors are targets of pharmacological agents aimed at controlling neurological function. For example GABA is the major inhibitory neurotransmitter in the CNS, and GABA receptors are the principal target of sedatives such as benzodiazepines and barbiturates which act by enhancing GABA-mediated effects (Katzung, B.G. (1995) Basic and Clinical Pharmacology, 6th edition, Appleton & Lange, Norwalk, CT, pp. 338-339). Diazepam
10 binding inhibitor (DBI), also known as endozepine and acyl-Coenzyme (CoA)-binding protein, is an endogenous GABA receptor ligand which is thought to down-regulate the effects of GABA. DBI binds medium- and long-chain acyl-CoA esters with very high affinity and may function as an intracellular carrier of acyl-CoA esters (*125950 Diazepam Binding Inhibitor; DBI, Online Mendelian Inheritance in Man (OMIM); PROSITE PDOC00686 Acyl-CoA-binding protein
15 signature). Aberrant activity of neurotransmitters and their receptors is involved in various neurological conditions, including Alzheimer's disease, myasthenia gravis, stroke, epilepsy, and Parkinson's disease. (See Planells-Cases, R. et al. (1993) Proc. Natl. Acad. Sci. USA 90:5057-5061.)

Each of over a trillion neurons in adult humans connects with over a thousand target cells (Tessier-Lavigne, M. et al. (1996) Science 274:1123-1133). These neuronal connections form during
20 embryonic development. Each differentiating neuron sends out an axon tipped at the leading edge by a growth cone. Aided by molecular guidance cues, the growth cone migrates through the embryonic environment to its synaptic target. Semaphorins are growth cone guidance signals that may function during embryogenesis by providing local signals to specify territories inaccessible to growing axons (Puschel, A.W. et al. (1995) Neuron 14:941-948).

25 Axon growth is guided in part by contact-mediated mechanisms involving cell surface and extracellular matrix (ECM) molecules. Many ECM molecules, including fibronectin, vitronectin, members of the laminin, tenascin, collagen, and thrombospondin families, and a variety of proteoglycans, can act either as promoters or inhibitors of neurite outgrowth and extension (Tessier-Lavigne et al., supra). Receptors for ECM molecules include integrins, immunoglobulin superfamily
30 members, and proteoglycans. ECM molecules and their receptors have also been implicated in the adhesion, maintenance, and differentiation of neurons (Reichardt, L.F. et al. (1991) Ann. Rev. Neurosci. 14:531-571). The proteoglycan testican is localized to the post-synaptic area of pyramidal cells of the hippocampus and may play roles in receptor activity, neuromodulation, synaptic plasticity, and neurotransmission (Bonnet, F. et al. (1996) J. Biol. Chem. 271:4373-4380).

Other nervous system-associated proteins have roles in neuron signaling, cell adhesion, nerve regeneration, axon guidance, and neurogenesis. The neurexophilins are neuropeptide-like proteins which are proteolytically processed after synthesis. They are ligands for the neuron-specific cell surface proteins, the α -neurexins. Neurexophilins and neurexins may participate in a neuron signaling pathway (Missler, M. and T.C. Sudhof (1998) J. Neurosci. 18:3630-3638; Missler, M. et al. (1998) J. Biol. Chem. 273:34716-34723). Ninjurin is a neuron cell surface protein which plays a role in cell adhesion and in nerve regeneration following injury. Ninjurin is up-regulated after nerve injury in dorsal root ganglion neurons and in Schwann cells (*602062 Ninjurin; NINJ1 OMIM; Araki, T. and Milbrandt, J. (1996) Neuron 17:353-361). Mammalian Numb is a phosphotyrosine-binding (PTB) domain-containing protein which may be involved in cortical neurogenesis and cell fate decisions in the mammalian nervous system. Numb's binding partner, the LNX protein, contains four PDZ domains and a ring finger domain and may participate in a signaling pathway involving Numb. PDZ domains have been found in proteins which act as adaptors in the assembly of multifunctional protein complexes involved in signaling events at surfaces of cell membranes (Ponting, C.P. (1997) Bioessays 19:469-479). LNX contains a tyrosine phosphorylation site which may be important for the binding of other PTB-containing proteins such as SHC, an adaptor protein which associates with tyrosine-phosphorylated growth factor receptors and downstream effectors (Dho, S.E. et al. (1998) J. Biol. Chem. 273:9179-9187).

The discovery of new neuron-associated proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative disorders including cancer; neuronal and neurological disorders; and autoimmune/inflammation disorders.

SUMMARY OF THE INVENTION

The invention features substantially purified polypeptides, neuron-associated proteins, referred to collectively as "NEUAP" and individually as "NEUAP-1," "NEUAP-2," "NEUAP-3," "NEUAP-4," "NEUAP-5," "NEUAP-6," "NEUAP-7," "NEUAP-8," "NEUAP-9," "NEUAP-10," "NEUAP-11," "NEUAP-12," "NEUAP-13," "NEUAP-14," "NEUAP-15," "NEUAP-16," "NEUAP-17," "NEUAP-18," "NEUAP-19," "NEUAP-20," "NEUAP-21," "NEUAP-22," "NEUAP-23," "NEUAP-24," "NEUAP-25," "NEUAP-26," "NEUAP-27," and "NEUAP-28." In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof. The invention also includes a polypeptide comprising an amino acid sequence that differs by one or more conservative amino acid substitutions from an amino acid sequence selected from the group consisting of SEQ ID NO:1-27.

The invention further provides a substantially purified variant having at least 90% amino acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-27 and fragments thereof. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof.

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof.

The invention also provides a method for detecting a polynucleotide in a sample containing nucleic acids, the method comprising the steps of: (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54 and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54 and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54 and fragments thereof.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-27. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing a polynucleotide of the

invention under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected from the group consisting of SEQ ID NO:1-27 and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of NEUAP, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of NEUAP, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof.

BRIEF DESCRIPTION OF THE FIGURES AND TABLES

Figures 1A and 1B show the amino acid sequence alignment between NEUAP-1 (2417014; SEQ ID NO:1) and a human neuronal thread protein, AD7c-NTP (GI 3002527; SEQ ID NO:55), produced using the multisequence alignment program of LASERGENE software (DNASTAR, Madison WI).

Figures 2A, 2B, and 2C show the amino acid sequence alignment between NEUAP-2 (2634931; SEQ ID NO:2) and a human glioma pathogenesis-related protein, GliPR (GI 847722; SEQ ID NO:56), produced using the multisequence alignment program of LASERGENE software.

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding NEUAP.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods, algorithms, and searchable databases used for analysis of NEUAP.

Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding NEUAP were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze NEUAP, along with applicable descriptions, references, and threshold parameters.

5

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

25 DEFINITIONS

"NEUAP" refers to the amino acid sequences of substantially purified NEUAP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of NEUAP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of NEUAP either by directly interacting with NEUAP or by acting on components of the biological pathway in which NEUAP participates.

An "allelic variant" is an alternative form of the gene encoding NEUAP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in

polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

“Altered” nucleic acid sequences encoding NEUAP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as NEUAP or a polypeptide with at least one functional characteristic of NEUAP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding NEUAP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding NEUAP. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent NEUAP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of NEUAP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms “amino acid” and “amino acid sequence” refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where “amino acid sequence” is recited to refer to an amino acid sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

“Amplification” relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term “antagonist” refers to a molecule which inhibits or attenuates the biological activity of NEUAP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of NEUAP either by directly interacting with NEUAP or by acting on components of the biological pathway in which

NEUAP participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind NEUAP polypeptides can be prepared using intact polypeptides or using
5 fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize
10 the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures
15 on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the
20 complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the
25 capability of the natural, recombinant, or synthetic NEUAP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" and "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules
30 may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acid strands, and in the design and use of peptide nucleic acid

(PNA) molecules.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution.

5 Compositions comprising polynucleotide sequences encoding NEUAP or fragments of NEUAP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

10 "Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of one or more Incyte Clones and, in some cases, one or more public domain ESTs, using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI).
15 Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded
20 as conservative amino acid substitutions.

| | Original Residue | Conservative Substitution |
|----|------------------|---------------------------|
| | Ala | Gly, Ser |
| | Arg | His, Lys |
| | Asn | Asp, Gln, His |
| 25 | Asp | Asn, Glu |
| | Cys | Ala, Ser |
| | Gln | Asn, Glu, His |
| | Glu | Asp, Gln, His |
| | Gly | Ala |
| 30 | His | Asn, Arg, Gln, Glu |
| | Ile | Leu, Val |
| | Leu | Ile, Val |
| | Lys | Arg, Gln, Glu |
| | Met | Leu, Ile |
| 35 | Phe | His, Met, Leu, Trp, Tyr |
| | Ser | Cys, Thr |
| | Thr | Ser, Val |
| | Trp | Phe, Tyr |
| | Tyr | His, Phe, Trp |
| 40 | Val | Ile, Leu, Thr |

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

5 A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative
10 polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "fragment" is a unique portion of NEUAP or the polynucleotide encoding NEUAP which is
15 identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues
20 in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

25 A fragment of SEQ ID NO:28-54 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:28-54, for example, as distinct from any other sequence in the same genome. A fragment of SEQ ID NO:28-54 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:28-54 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:28-54 and the region of
30 SEQ ID NO:28-54 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-27 is encoded by a fragment of SEQ ID NO:28-54. A fragment of SEQ ID NO:1-27 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-27. For example, a fragment of SEQ ID NO:1-27 is useful as an immunogenic peptide

for the development of antibodies that specifically recognize SEQ ID NO:1-27. The precise length of a fragment of SEQ ID NO:1-27 and the region of SEQ ID NO:1-27 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

5 The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization
10 assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to
15 one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

20 The phrases "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

25 Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS
30 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms

is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a

standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

5 Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default
10 residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.9
15 (May-07-1999) with blastp set at default parameters. Such default parameters may be, for example:

15 *Matrix: BLOSUM62*
 Open Gap: 11 and Extension Gap: 1 penalties
 Gap x drop-off: 50
 Expect: 10
 Word Size: 3
20 *Filter: on*

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least
25 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for
30 stable mitotic chromosome segregation and maintenance.

The term "humanized antibody" refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a

complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid

support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

5 "Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

10 The terms "element" and "array element" in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of NEUAP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of NEUAP.

15 The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a
20 functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which
25 comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Probe" refers to nucleic acid sequences encoding NEUAP, their complements, or fragments
30 thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target

DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel et al., 1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis et al., 1990, PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for

example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding NEUAP, or fragments thereof, or NEUAP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers,

microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

The invention is based on the discovery of new human neuron-associated proteins (NEUAP), the polynucleotides encoding NEUAP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative disorders including cancer; neuronal and neurological disorders; and autoimmune/inflammation disorders.

Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding NEUAP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each NEUAP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. The Incyte clones in column 5 were used to assemble the consensus nucleotide sequence of each NEUAP and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows the identity of each polypeptide; and column 7 shows analytical methods and in some cases, searchable databases to which the analytical methods were applied. The methods of column 7 were used to characterize each polypeptide through sequence homology and protein motifs.

As shown in Figures 1A and 1B, NEUAP-1 has chemical and structural similarity with a human neuronal thread protein, AD7c-NTP (GI 3002527; SEQ ID NO:55). In particular, NEUAP-1 and AD7c-NTP share 24% identity, including a region of NEUAP-1 between residues S89 and Y127 in which the two proteins share 79% identity as well as two potential phosphorylation sites at S117 and S123.

MOTIFS, BLOCKS, and PFAM indicate that NEUAP-2 has an SCP-like extracellular protein signature, common to plant PR-1 proteins, between approximately residues S4 and G173. The conserved His-Glu-His triad of PR family proteins is found in NEUAP-2 at residues H78, E109, and H128. As shown in Figures 2A, 2B, and 2C, NEUAP-2 has chemical and structural similarity with a human glioma pathogenesis-related protein, GliPR (GI 847722; SEQ ID NO:56). In particular, the two proteins share 27% identity, the His-Glu-His triad, and ten of the twelve cysteine residues found in NEUAP-2, including C163, known to be involved in disulfide bond formation in PR-1 proteins.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions

associated with nucleotide sequences encoding NEUAP. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:28-54 and to distinguish between SEQ ID NO:28-54 and related polynucleotide sequences. The

5 polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express NEUAP as a fraction of total tissues expressing NEUAP.

Column 4 lists diseases, disorders, or conditions associated with those tissues expressing NEUAP as a fraction of total tissues expressing NEUAP. Of particular note is the expression of NDAP-2 in five neuronal tissues. Northern analysis shows the expression of NEUAP-1 in four tissues, three of which

10 are cancerous, including a neuronal teratocarcinoma. Of particular interest is the tissue-specific expression of SEQ ID NO:31 and SEQ ID NO:32. SEQ ID NO:31 is highly expressed and SEQ ID NO:32 is exclusively expressed in nervous tissue. Of particular interest is the expression of SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:55, SEQ ID NO:56, and especially SEQ ID NO:51 in nervous tissues; and the expression of SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48, and SEQ ID NO:51 in tissues associated with neurological disorders.

15 Column 5 lists the vectors used to subclone each cDNA library.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding NEUAP were isolated. Column 1 references the nucleotide SEQ ID NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

The invention also encompasses NEUAP variants. A preferred NEUAP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the NEUAP amino acid sequence, and which contains at least one functional or structural characteristic of NEUAP.

25 The invention also encompasses polynucleotides which encode NEUAP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:28-54, which encodes NEUAP.

The invention also encompasses a variant of a polynucleotide sequence encoding NEUAP. In particular, such a variant polynucleotide sequence will have at least about 80%, or alternatively at least about 90%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding NEUAP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:28-54 which has at least about 80%, or alternatively at least about 90%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting

of SEQ ID NO:28-54. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of NEUAP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding NEUAP, some bearing minimal
5 similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring NEUAP, and all such variations are to be considered
10 as being specifically disclosed.

Although nucleotide sequences which encode NEUAP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring NEUAP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding NEUAP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-
15 naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding NEUAP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a
20 greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode NEUAP and NEUAP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce
25 mutations into a sequence encoding NEUAP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:28-54 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.*
30 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-

Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV),
5 PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Perkin-Elmer). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Perkin-Elmer), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short
10 Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding NEUAP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed,

15 restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.)

Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids

20 Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences

25 are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060).

Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using

commercially available software, such as OLIGO 4.06 Primer Analysis software (National

30 Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include

chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

5 In order to express a biologically active NEUAP, the nucleotide sequences encoding NEUAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in
10 polynucleotide sequences encoding NEUAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding NEUAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding NEUAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional
15 transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used.
20 (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

 Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding NEUAP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A
25 Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

 A variety of expression vector/host systems may be utilized to contain and express sequences encoding NEUAP. These include, but are not limited to, microorganisms such as bacteria
30 transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode NEUAP may be cloned in recombinant DNA molecules that direct expression of NEUAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express NEUAP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter NEUAP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding NEUAP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, NEUAP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of NEUAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid

sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode NEUAP may be cloned in recombinant DNA molecules that direct expression of NEUAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express NEUAP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter NEUAP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding NEUAP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, NEUAP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of NEUAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid

chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

5 In order to express a biologically active NEUAP, the nucleotide sequences encoding NEUAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in
10 polynucleotide sequences encoding NEUAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding NEUAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding NEUAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional
15 transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used.
20 (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding NEUAP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A
25 Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding NEUAP. These include, but are not limited to, microorganisms such as bacteria
30 transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding NEUAP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding NEUAP can be achieved using a multifunctional *E. coli* vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding NEUAP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for *in vitro* transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of NEUAP are needed, e.g. for the production of antibodies, vectors which direct high level expression of NEUAP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of NEUAP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, *supra*; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of NEUAP. Transcription of sequences encoding NEUAP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding NEUAP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses NEUAP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma

virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of NEUAP in cell lines is preferred. For example, sequences encoding NEUAP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* and *ap^r* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding NEUAP is inserted within a marker gene sequence, transformed cells containing

sequences encoding NEUAP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding NEUAP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

5 In general, host cells that contain the nucleic acid sequence encoding NEUAP and that express NEUAP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

10 Immunological methods for detecting and measuring the expression of NEUAP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on NEUAP is preferred, but a
15 competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

20 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding NEUAP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding NEUAP, or any fragments thereof, may be cloned into a vector
25 for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for
30 ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding NEUAP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence

and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode NEUAP may be designed to contain signal sequences which direct secretion of NEUAP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding NEUAP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric NEUAP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of NEUAP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the NEUAP encoding sequence and the heterologous protein sequence, so that NEUAP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled NEUAP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid

precursor, for example, ^{35}S -methionine.

Fragments of NEUAP may be produced not only by recombinant means, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, *supra*, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A peptide synthesizer (Perkin-Elmer). Various fragments of NEUAP may be synthesized separately and then combined to produce the full length molecule.

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of NEUAP and neuron-associated proteins. In addition, the expression of NEUAP is closely associated with nervous tissue, neurological disorders, cell proliferation including cancer, inflammation, and the immune response. Therefore, NEUAP appears to play a role in cell proliferative disorders including cancer; neuronal and neurological disorders; and autoimmune/inflammation disorders. In the treatment of disorders associated with increased NEUAP expression or activity, it is desirable to decrease the expression or activity of NEUAP. In the treatment of disorders associated with decreased NEUAP expression or activity, it is desirable to increase the expression or activity of NEUAP.

Therefore, in one embodiment, NEUAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of NEUAP. Examples of such disorders include, but are not limited to, a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease; prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis; inherited, metabolic, endocrine, and toxic myopathies; myasthenia gravis, periodic paralysis; mental disorders including mood, anxiety, and schizophrenic disorders; seasonal affective disorder (SAD); akathisia, amnesia,

catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary
5 thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an autoimmune/inflammatory disorder such as acquired
10 immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins,
15 erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus,
20 systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma.

In another embodiment, a vector capable of expressing NEUAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased
25 expression or activity of NEUAP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified NEUAP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of NEUAP including, but not limited to, those provided above.

30 In still another embodiment, an agonist which modulates the activity of NEUAP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of NEUAP including, but not limited to, those listed above.

In a further embodiment, an antagonist of NEUAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of NEUAP. Examples of such

disorders include, but are not limited to, those cell proliferative disorders including cancer; neuronal and neurological disorders; and autoimmune/inflammation disorders described above. In one aspect, an antibody which specifically binds NEUAP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express
5 NEUAP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding NEUAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of NEUAP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary
10 sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic
15 efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of NEUAP may be produced using methods which are generally known in the art. In particular, purified NEUAP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind NEUAP. Antibodies to NEUAP may also be generated using methods that are well known in the art. Such antibodies may include, but are
20 not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with NEUAP or with any fragment or oligopeptide thereof
25 which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Cornebacterium parvum are especially preferable.

30 It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to NEUAP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of NEUAP

amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to NEUAP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci. USA* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce NEUAP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) *Proc. Natl. Acad. Sci. USA* 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299.)

Antibody fragments which contain specific binding sites for NEUAP may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) *Science* 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between NEUAP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering NEUAP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for NEUAP. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of NEUAP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions.

- 5 The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple NEUAP epitopes, represents the average affinity, or avidity, of the antibodies for NEUAP. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular NEUAP epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in
10 which the NEUAP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of NEUAP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J.E. and Cryer, A. (1991) A Practical Guide to
15 Monoclonal Antibodies, John Wiley & Sons, New York NY).

- The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of NEUAP-
20 antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

- In another embodiment of the invention, the polynucleotides encoding NEUAP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the
25 complement of the polynucleotide encoding NEUAP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding NEUAP. Thus, complementary molecules or fragments may be used to modulate NEUAP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments
30 can be designed from various locations along the coding or control regions of sequences encoding NEUAP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used

to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding NEUAP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding NEUAP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding NEUAP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding NEUAP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may be employed. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding NEUAP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques

for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding NEUAP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA
5 constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages
10 within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable
15 for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat.
Biotechnol. 15:462-466.)

20 Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the
25 therapeutic effects discussed above. Such pharmaceutical compositions may consist of NEUAP, antibodies to NEUAP, and mimetics, agonists, antagonists, or inhibitors of NEUAP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be
30 administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's

5 Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

10 Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose,
15 hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar
20 solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of
25 gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

30 Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily

injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acids. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of NEUAP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example NEUAP or fragments thereof, antibodies of NEUAP, and agonists, antagonists or inhibitors of NEUAP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Pharmaceutical compositions

which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μ g to 100,000 μ g, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind NEUAP may be used for the diagnosis of disorders characterized by expression of NEUAP, or in assays to monitor patients being treated with NEUAP or agonists, antagonists, or inhibitors of NEUAP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics.

Diagnostic assays for NEUAP include methods which utilize the antibody and a label to detect NEUAP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring NEUAP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of NEUAP expression. Normal or standard values for NEUAP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to NEUAP under conditions suitable for complex formation. The amount of standard complex

formation may be quantitated by various methods, such as photometric means. Quantities of NEUAP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

5 In another embodiment of the invention, the polynucleotides encoding NEUAP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of NEUAP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess
10 expression of NEUAP, and to monitor regulation of NEUAP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding NEUAP or closely related molecules may be used to identify nucleic acid sequences which encode NEUAP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a
15 conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding NEUAP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the NEUAP encoding sequences. The hybridization probes of the subject
20 invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:28-54 or from genomic sequences including promoters, enhancers, and introns of the NEUAP gene.

Means for producing specific hybridization probes for DNAs encoding NEUAP include the cloning of polynucleotide sequences encoding NEUAP or NEUAP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may
25 be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding NEUAP may be used for the diagnosis of disorders
30 associated with expression of NEUAP. Examples of such disorders include, but are not limited to, a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other

demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease; prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, 5 encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis; inherited, metabolic, 10 endocrine, and toxic myopathies; myasthenia gravis, periodic paralysis; mental disorders including mood, anxiety, and schizophrenic disorders; seasonal affective disorder (SAD); akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, bipolar disorder, dementia, depression, Down's syndrome, peripheral neuropathy, bipolar disorder, dementia, depression, Down's syndrome, peripheral neuropathy, and Tourette's disorder; a 15 cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall 20 bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune 25 polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, 30 myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma. The

polynucleotide sequences encoding NEUAP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered NEUAP expression. Such qualitative or quantitative methods are well known in the art.

5 In a particular aspect, the nucleotide sequences encoding NEUAP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding NEUAP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a
10 standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding NEUAP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

15 In order to provide a basis for the diagnosis of a disorder associated with expression of NEUAP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding NEUAP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from
20 normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

 Once the presence of a disorder is established and a treatment protocol is initiated,
25 hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

 With respect to cancer, the presence of an abnormal amount of transcript (either under- or
30 overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding NEUAP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding NEUAP, or a fragment of a polynucleotide complementary to the polynucleotide encoding NEUAP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

Methods which may also be used to quantify the expression of NEUAP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) *Proc. Natl. Acad. Sci. USA* 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding NEUAP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355; Price, C.M. (1993) *Blood Rev.* 7:127-134; and Trask, B.J. (1991) *Trends Genet.* 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra,

pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding NEUAP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder.

5 The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, 10 may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping 15 to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, NEUAP, its catalytic or immunogenic fragments, or 20 oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between NEUAP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds 25 having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with NEUAP, or fragments thereof, and washed. Bound NEUAP is then detected by methods well known in the art. Purified NEUAP can also be coated directly onto plates for use in the aforementioned drug screening techniques. 30 Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding NEUAP specifically compete with a test compound for binding NEUAP. In this manner, antibodies can be used to detect the presence of any peptide which shares

one or more antigenic determinants with NEUAP.

In additional embodiments, the nucleotide sequences which encode NEUAP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, are hereby expressly incorporated by reference.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 60/124,687, U.S. Ser. No. 60/119,365, and U.S. Ser. No. [Attorney Docket No. PF-0637 US, filed December 11, 1998], are hereby expressly incorporated by reference.

EXAMPLES

I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A⁺) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA

libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic
5 oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g.,
10 PBLUEScript plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

15 Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN.
20 Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in
25 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

cDNA sequencing reactions were processed using standard methods or high-throughput
30 instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene

families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:28-54. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

100

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding NEUAP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation, trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

V. Extension of NEUAP Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:28-54 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this

fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target
5 sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR
10 was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and β -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C,
15 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN
20 quantitation reagent (0.25% (v/v) PICOGREEN: Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by
25 electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For
30 shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on

antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:28-54 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

15 VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:28-54 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 µCi of [γ-³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

30 VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array

elements on the surface of a substrate. (See, e.g., Baldeschweiler, supra.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After
5 hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise
10 the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking
15 followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

VIII. Complementary Polynucleotides

20 Sequences complementary to the NEUAP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring NEUAP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of NEUAP. To
25 inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the NEUAP-encoding transcript.

IX. Expression of NEUAP

Expression and purification of NEUAP is achieved using bacterial or virus-based expression
30 systems. For expression of NEUAP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3).

Antibiotic resistant bacteria express NEUAP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of NEUAP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding NEUAP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, NEUAP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from NEUAP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified NEUAP obtained by these methods can be used directly in the following activity assay.

X. Demonstration of NEUAP Activity

NEUAP may be detected by the immunoreactivity of tissues to monoclonal antibodies (MAb) raised against recombinant NEUAP. Mabs to recombinant NEUAP may be prepared by methods well known in the art, and used to detect the expression of NEUAP in tissues by western blot analysis. Western blot analysis is carried out as described by de la Monte et al. (1996) J. Neuropathol. Exp. Neurol. supra. Cytosolic protein extracts of tissues are prepared and electrophoresed in SDS-PAGE Laemmli gels, and immunoblotted using Mabs raised against NEUAP. Antibody binding is detected with horseradish peroxidase-conjugated secondary antibody (IgG), and enhanced chemiluminescence reagents (Amersham Corp, Arlington Heights, IL). The amount of MAb immunoreactivity measured is proportional to the activity of NEUAP in the tissue preparation.

Alternatively, NEUAP, or biologically active fragments thereof, are labeled with ¹²⁵I

Bolton-Hunter reagent (see, eg., Bolton et al. (1973) *Biochem. J.* 133:529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled NEUAP, washed, and any wells with labeled NEUAP complex are assayed. Data obtained using different concentrations of NEUAP are used to calculate values for the number, affinity, and association of NEUAP with the candidate molecules.

XI. Functional Assays

NEUAP function is assessed by expressing the sequences encoding NEUAP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of NEUAP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding NEUAP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding NEUAP and other genes of interest can be analyzed by northern

analysis or microarray techniques.

XII. Production of NEUAP Specific Antibodies

NEUAP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington. M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to
5 immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the NEUAP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well
10 described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-
15 KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-NEUAP activity by, for example, binding the peptide or NEUAP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XIII. Purification of Naturally Occurring NEUAP Using Specific Antibodies

Naturally occurring or recombinant NEUAP is substantially purified by immunoaffinity
20 chromatography using antibodies specific for NEUAP. An immunoaffinity column is constructed by covalently coupling anti-NEUAP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing NEUAP are passed over the immunoaffinity column, and the column is
25 washed under conditions that allow the preferential absorbance of NEUAP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/NEUAP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and NEUAP is collected.

XIV. Identification of Molecules Which Interact with NEUAP

NEUAP, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter
30 reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled NEUAP, washed, and any wells with labeled NEUAP complex are assayed. Data obtained using different concentrations of NEUAP are used to calculate values for the number, affinity, and

association of NEUAP with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be
5 understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

| Protein SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|--------------------------|--------------------------|----------|-----------|--|
| 1 | 28 | 2417014 | HNT3AZT01 | 2417014H1, 2417014F6, and 2417014T6 (HNT3AZT01) |
| 2 | 29 | 2634931 | BONTNOT01 | 159164X11 (BLADNOT03), 1840865R6 (COLNNOT07), 2634931H1 (BONTNOT01), 3016948F6 (MUSCNOT07), SBDA02985F1, SBDA03153F1, and SBAA04561F1 |
| 3 | 30 | 110960 | PITUNOT01 | 110960F1, 110960H1, and 110960X31 (PITUNOT01), 1413173F6 (BRAINT02), 2708730F6 (PONSATZT01) |
| 4 | 31 | 380721 | HYPONOB01 | 380721H1 (HYPONOB01), 530184R1 (BRAINT03), 4313795H1 (BRAENOT01) |
| 5 | 32 | 829443 | PROSTUT04 | 829443H1 and 829443T6 (PROSTUT04), 1356856F1 (LUNGNOT09), 1561879F1 (SPLNNOT04), 2454553F6 (ENDANOT01), 5113377H1 (ENDITXT01), SBDA04734F1 |
| 6 | 33 | 1470058 | PANCTUT02 | 620887R6 (PGANNOT01), 667364R6 (SGORNOT01), 1001616R1 (BRSTNOT03), 1382686T1 (BRAITUT08), 3440580H2 (PENCNOT06), 4900807H1 (OVARDIT01) |
| 7 | 34 | 1554947 | BLADTUT04 | 444399R1 (MPHGNOT03), 1554947H1 (BLADTUT04), 2552447H1 (LUNGNOT06), 2776779H1 (PANCNOT15), 3140190H1 (SMCCNOT02), 3327533H1 (HEAONOT04), 4737377H1 (THYMNOR02) |
| 8 | 35 | 1690245 | PROSTUT10 | 380137R6 (HYPONOB01), 459187R6 (KERANOT01), 982488R1 (THYRNOT02), 1421177F1 (KIDNNOT09), 1690245F6 and 1690245H1 (PROSTUT10), 2880352H1 (UTRSTUT05) |
| 9 | 36 | 1878262 | LEUKNOT03 | 1878262F6 and 1878262H1 (LEUKNOT03), 3705684F6 (PENCNOT07) |

Table 1 (Cont.)

| Protein SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|--------------------------|--------------------------|----------|-----------|--|
| 10 | 37 | 2253519 | OVARTUT01 | 917470R1 (BRSTNOT04), 1285941H1 (COLNNOT16), 1452424H1 (PENITUT01), 2101405H1 (BRAITUT02), 2253519H1, 2253519R6, and 2253519X308F2 (OVARTUT01), 2849605H1 (BRSTTUT13), 2941769F6 (PROSNOT28), 4540901H1 (THYRTMT01), 4699204F6 (BRALNOT01) |
| 11 | 38 | 2888437 | LUNGFET04 | 550739H1 (BEPINOT01), 639134R6 and 1004296R1 (BRSTNOT03), 1456837H1 (COLNFET02), 1576159F6 (LNODNOT03), 1813822F6 (SKINBIT01), 1965103R6 (BRSTNOT04), 2888437F6 and 2888437H1 (LUNGFET04), 3041589F6 and 3041589T6 (BRSTNOT16), 3316465F6 (PROSBPT03), 3416354H1 (PTHYNOT04), 3987261F6 (UTRSTUT05), 4527360H1 (LYMBTXT01) |
| 12 | 39 | 3201753 | PENCNOT02 | 060572X51 (LUNGNOT01), 1417168H1 (BRAINOT12), 1514580F1 (PANCTUT01), 1601609F6 (BLADNOT03), 1853144T6 (LUNGFET03), 2551341H1 (LUNGTUT06), 2967827F6 (SCORNOT04), 3201753F6 and 3201753H1 (PENCNOT02), 3435884F6 (PENCNOT05) |
| 13 | 40 | 3800639 | SPLNNOT12 | 152838R6 (FIBRAGT02), 820077H1 (KERANOT02), 1482425F1 (CORPNOT02), 1686313T6 (PROSNOT15), 1855749F6 (PROSNOT18), 2212060F6 (SINTFET03), 2679094H1 (SINIUCT01), 2685279H1 (LUNGNOT23), 2751789R6 (THP1AZS08), 3287040H1 (HEAONOT05), 3575146H1 (BRONNOT01), 3598393H1 (FIBPNOT01), 3798890H1 and 3800639H1 (SPLNNOT12), 4521233H1 (HNT2TXX01), 4988152F6 (LIVRTUT10), 5377369H1 and 5379308H1 (BRAXNOT01) |
| 14 | 41 | 533825 | BRAINOT03 | 533825H1 (BRAINOT03), 1661317F6 (BRSTNOT09), 3271477F6 (BRAINOT20), 3532613H1 (KIDNNOT25), 4338159H1 (BRAUNOT02), SBEA00478F1, SBEA02751F1 |

Table 1 (Cont.)

| Protein SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|--------------------------|--------------------------|----------|-----------|---|
| 15 | 42 | 1311833 | COLNFET02 | 1311833F6 (COLNFET02), 1311833H1 (COLNFET02), 1311833T1 (COLNFET02), 1492314H1 (PROSNON01), 1742220H1 (HIPONON01), 2279875R6 (PROSNON01), 2279875T6 (PROSNON01) |
| 16 | 43 | 1342819 | COLNTUT03 | 231227F1 (SINTNOT02), 1319329F1 (BLADNOT04), 1342819H1 (COLNTUT03), 1381830F1 (BRAITUT08), 3244424F7 (BRAINOT19) |
| 17 | 44 | 1871288 | SKINBIT01 | 1871288F6 (SKINBIT01), 1871288H1 (SKINBIT01), 1891163F6 (BLADTUT07) |
| 18 | 45 | 2587338 | BRAITUT22 | 2587338F6 (BRAITUT22), 2587338H1 (BRAITUT22) |
| 19 | 46 | 2821211 | ADRETUT06 | 2666281T6 (ADRETUT06), 2821211H1 (ADRETUT06), 2821211T6 (ADRETUT06), 2821626H1 (ADRETUT06), 3973838F6 (ADRETUT06) |
| 20 | 47 | 2824832 | ADRETUT06 | 2137150F6 (ENDCNOT01), 2137150T6 (ENDCNOT01), 2824832H1 (ADRETUT06), SBLA01910F1, SBLA01493F1, SBLA02371F1, SBLA01241F1 |
| 21 | 48 | 3070147 | UTRSNOR01 | 1399942F1 (BRAITUT08), 3070147F6 (UTRSNOR01), 3070147H1 (UTRSNOR01) |
| 22 | 49 | 3271841 | BRAINOT20 | 531341F1 (BRAINOT03), 531341R6 (BRAINOT03), 1368113R1 (SCORNON02), 3271841H1 (BRAINOT20), 4227380F6 (BRAMDIT01) |
| 23 | 50 | 3537827 | SEMVNOT04 | 1376729F1 (LUNGNOT10), 1472735R6 (LUNGNOT03), 1995972T6 (BRSTTUT03), 2913592H1 (KIDNTUT15), 3174642F6 (UTRSTUT04), 3537827H1 (SEMVNOT04), 4261946F6 (BSCNDIT02), SBRA05006D1, SBRA01069D1 |
| 24 | 51 | 3729267 | SMCCNON03 | 925471R1 (BRAINOT04), 988166R6 (LVENNOT03), 1303573F1 (PLACNOT02), 2176845F6 (ENDCNOT03), 3729267H1 (SMCCNON03) |

Table 1 (Cont.)

| Protein SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|--------------------------|--------------------------|----------|-----------|---|
| 25 | 52 | 3768771 | BRSTNOT24 | 550415R6 (BEPINOT01), 1700822F6 (BLADTUT05), 1732040F6 (BRSTTUT08), 2028053R6 (KERANOT02), 2579651F6 (KIDNTUT13), 2731787F6 (OVRTUT04), 3447610H1 (THYMNOT08), 3498679H1 (PROSTUT13), 3606095H1 (LUNGNOT30), 3685266F6 (HEANOT01), 3768771H1 (BRSTNOT24) |
| 26 | 53 | 4248993 | BRADDIR01 | 4248993F6 (BRADDIR01), 4248993H1 (BRADDIR01) |
| 27 | 54 | 5402418 | BRAHNOT01 | 270323F1 (HNT2NOT01), 950513T1 (PANCNOT05), 2083217F6 (UTRSNOT08), 2744356F6 (BRSTTUT14), 5402418H1 (BRAHNOT01) |

Table 2

| Polypeptide Seq ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods and Databases |
|---------------------------|---------------------------|--|-------------------------------------|--|--|---|
| 1 | 198 | S117, S51, S123 | N49 | M1-A27: Signal Peptide | AD7c-NTP (g3002527) | Motifs BLAST SPScan HMMER |
| 2 | 463 | T29, T50, T156, S195, S202, S299, T137, S218, S227, T323, S394 | N114, N403, N409 | M1-A27: Signal peptide Potential intramolecular disulfide-bridging site cysteine residues: C5, C74, C120, C126, C142, C147, C163, C183, C186, C192, C197, C283 SCP-like extracellular protein signature: S4-G173 PR family protein signature: H78, E109, H128 | GlIPR Human glioma pathogenesis- related protein (g847722) | Motifs SPScan BLAST BLOCKS PFAM |

Table 2 (Cont.)

| Polypeptide Seq ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods and Databases |
|---------------------------|---------------------------|--|-------------------------------------|---|--|--|
| 3 | 316 | S283 S37 T42 S74 S92 T125 T216 S285 T313 | N191 | G184-T210, V226- L244, V106-V121 and Y289-N314 Transmembrane Regions; V264-E316 Syntaptophysin Signature; G224-M277 Peripherin Signature | Neural Membrane Protein 35 (NMP35) (g3426268) | BLAST HMM BLOCKS |
| 4 | 89 | S56 T17 S33 S76 | | | Cyclic AMP- Regulated Phosphoprotein (ARPP-21) (g238781) | BLAST |
| 5 | 273 | S96 S273 T54 S136 T190 S205 S252 S258 T64 S142 S268 | | C107-C134 and C141- C176 EGF-Like Domain Signature; R130-D132 Cell Attachment Sequence; C152-C163 Aspartic Acid and Asparagine Hydroxylation Site; M1-G19 Signal Peptide | Multiple EGF Protein (MEGF6) (g3449294) | BLAST Motifs SPScan HMM PFAM |

Table 2 (Cont.)

| Polypeptide Seq ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods and Databases |
|---------------------------|---------------------------|---|-------------------------------------|---|--|--|
| 6 | 263 | S216 S47 S109 S125 T126 S216 S248 S29 T95 T240 | | R97-D99 Cell Attachment Sequence; M1-S29 Signal Peptide | Fe65L2 Protein (g2293387) | BLAST Motifs SPScan |
| 7 | 165 | S44 T56 S108 T111 S137 | | | Brain Expressed (BRX) Protein (g2196874) | BLAST |
| 8 | 424 | T373 S131 T257 T275 S284 T303 T322 T360 T361 T421 S312 Y266 | N129 | L251-P280 WW/rsp5/WWP Domain Signature | Huntingtin Interacting Protein (g3319282) | BLAST Motifs PFAM |
| 9 | 164 | S71 T129 T133 | | M1-A34 Signal Peptide | Neuritin (g2062678) | BLAST SPScan HMM |
| 10 | 796 | T147 S285 S353 S442 T475 S476 S591 S767 T135 S319 S383 S442 S543 T738 S753 S775 T780 Y60 Y133 | N590 | S661-G664, S704-G707 and S706-G709 Glycosaminoglycan Attachment Site | Pecanex Protein (SW:P18490) | BLAST Motifs |

Table 2 (Cont.)

| Polypeptide Seq ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods and Databases |
|---------------------------|---------------------------|--|--|---|--|--|
| 11 | 854 | T249 S398 T757 S88 T159 S175 T265 S330 S340 S387 S398 T557 S582 T594 S614 T626 T677 S712 T800 S99 T377 S494 T507 T649 T668 S750 Y422 Y593 | N48 N153 N369 N375 N492 N561 N697 N747 N798 | S373-Y422 Neuraxin Signature; L358-A409 43 Kd Postsynaptic Protein Signature | CNS Expressed Protein | Motifs BLOCKS |
| 12 | 856 | S370 T475 S604 S69 S71 S73 S238 T253 S284 S296 T414 T475 S625 T705 T835 T20 S119 S263 T337 T341 S386 T390 S599 S633 S634 T690 Y118 | N18 N199 N369 N389 N531 N568 N721 | M1-P65, M136-N218, H269-E349, T415- D497, T511-I592, T648-G733 and S773- S856 PDZ Domain Signature; R819-D821 Cell Attachment Sequence; S144-G147 Glycosaminoglycan Attachment Site | Brain Expressed Multi-PDZ Protein (g2959979) | BLAST Motifs Pfam |
| 13 | 361 | S120 T122 T197 T296 S48 S223 T243 | N189 N264 | | MNUDC Protein (g2654358) | BLAST Motifs |

Table 2 (Cont.)

| Polypeptide Seq ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods and Databases |
|---------------------------|---------------------------|---|-------------------------------------|---|---|--|
| 14 | 632 | S48 S486 T549 S90 S91 S100 T159 S291 S292 T406 S431 S474 S574 S104 S107 T119 S124 S178 S191 S356 T397 Y440 Y499 | N108 N157 N289 N384 | PDZ domains: S178-E262; H285- Q367; V411-V496; D542-W627 Signal Peptide: M1-I18 | LNxp70 (g3041881) | BLAST PFAM BLOCKS_Pfam SPScan MOTIFS |
| 15 | 391 | T77 S185 S203 S238 S36 T42 T63 S171 T191 T205 S223 T302 T334 S181 S220 S233 | N324 | Glycosaminoglycan attachment site: S85-G88 Protein Repeat Neurofilament: E123-K148; S111-P136 Transmembrane region: Y368-L388 | heavy neurofilament subunit (g1841430) | BLOCKS_PRODOM BLAST MOTIFS HMM |
| 16 | 490 | S474 S90 T99 S105 S150 S269 S317 S335 S361 T26 S49 S87 T134 S238 S247 T255 T275 T329 T388 T401 T415 T454 S469 T476 | N61 N189 N204 N359 | Signal Peptide: M1-T19 | neurofilament protein (g463250) | BLAST SPScan MOTIFS |

Table 2 (Cont.)

| Polypeptide Seq ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods and Databases |
|---------------------------|---------------------------|---|-------------------------------------|---|--|---|
| 17 | 252 | S116 S118 T155 T196 S219 S33 T81 S147 S164 | N153 | Glycosaminoglycan attachment site: S65-G68 Signal Peptide: M1-S33 Transmembrane region: I9-L27 | bipolar disorder- associated protein (g2271473) | BLAST MOTIFS SPScan HMM |
| 18 | 142 | S3 S32 S36 T29 | N106 | Transmembrane region: L66-L84 | ninjurin (g1644368) | BLAST HMM |
| 19 | 67 | T34 | | | CNS-expressed protein (g862343) | BLAST |
| 20 | 455 | S39 T43 S104 T109 S185 S189 S204 S224 S226 S349 S365 T131 S358 S414 | N58 N307 | Acyl-CoA binding protein (DBI) signature: H41-P129 | membrane- associated diazepam binding inhibitor MA-DBI (g244503) | PFAM BLOCKS PRINTS MOTIFS BLAST |
| 21 | 252 | S189 S54 S93 T119 Y242 | N62 N127 N137 N143 | Signal Peptide: M1-G22 | neurexophilin (g508574) | BLAST SPScan |

Table 2 (Cont.)

| Polypeptide Seq ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods and Databases |
|---------------------------|---------------------------|--|-------------------------------------|--|---|--|
| 22 | 149 | S64 S40 S86 S10 | N74 | Transmembrane region: L125-L145 | BM88 antigen; neuron-specific membrane protein (g557673) | BLAST HMM |
| 23 | 204 | S204 S16 T146 S157 T114 | N6 N176 | Transmembrane region: L66-A85 T114-W136 | P24; neuron- specific membrane protein (g1890141) | BLAST HMM |
| 24 | 367 | S52 S55 T148 S181 T265 S303 T143 Y207 | | Glycosaminoglycan attachment site: S231-G234 Leucine-rich repeat: Y42-V88; K89-K134; E135-P180; S181-I228 | leucine rich neuronal protein (g3135309) | PFAM BLOCKS BLAST MOTIFS |
| 25 | 681 | T70 T111 S155 S175 T206 S247 S375 S417 S502 T624 S633 T645 S653 S657 S66 T237 T349 S393 T539 S587 S647 | N9 N254 N369 N474 | Transmembrane region: C566-Y582 | semaphorin (g854328) | BLAST HMM |

Table 2 (Cont.)

| Polypeptide Seq ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods and Databases |
|---------------------------|---------------------------|---------------------------------------|-------------------------------------|--|--|--|
| 26 | 137 | T11 T77 S134 | | Microbodies C- terminal targeting signal: A135-F137 | myelin- associated/oligod endrocyte basic protein | BLAST MOTIFS |
| 27 | 117 | | N81 | | GEF-2;ganglioside expression factor-2 (g2104570) | BLAST MOTIFS |

Table 3

| Nucleotide SEQ ID NO: | Selected Fragment | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | Vector |
|--------------------------|------------------------|---|--|-------------|
| 28 | 110-154 434-478 | | Cancer (0.750) | pINCY |
| 29 | 1083-1127 1407-1451 | | Cancer (0.590) | pINCY |
| 30 | 71-145 | Nervous (0.727) Urologic (0.068) Endocrine (0.045) | Cell Proliferation (0.455) Neurological (0.205) Inflammation (0.227) | PBLUESCRIPT |
| 31 | 379-438 | Nervous (1.000) | Cell Proliferation (0.222) Inflammation (0.222) Neurological (0.222) | PBLUESCRIPT |
| 32 | 255-314 | Reproductive (0.222) Cardiovascular (0.176) Nervous (0.157) | Cell Proliferation (0.620) Inflammation (0.315) | PSPORT1 |
| 33 | 898-972 | Reproductive (0.319) Nervous (0.191) Developmental (0.106) Gastrointestinal (0.106) | Cell Proliferation (0.766) Inflammation (0.298) | pINCY |
| 34 | 258-317 | Gastrointestinal (0.179) Reproductive (0.179) Cardiovascular (0.143) Nervous (0.143) Hematopoietic/Immune (0.143) | Cell Proliferation (0.572) Inflammation (0.393) | pINCY |

Table 3 (Cont.)

| Nucleotide SEQ ID NO: | Selected - Fragment | Tissue Expression (Fraction ----- of Total) | Disease or Condition (Fraction of Total) | Vector |
|--------------------------|------------------------|--|--|---------|
| 35 | 184-243 | Nervous (0.238) Reproductive (0.222) Gastrointestinal (0.127) | Cell Proliferation (0.603) Inflammation (0.254) | pINCY |
| 36 | 306-380 | Reproductive (0.500) Cardiovascular (0.250) Hematopoietic/Immune (0.250) | Cell Proliferation (0.750) Inflammation (0.250) | pINCY |
| 37 | 88-147 433-507 | Reproductive (0.355) Nervous (0.226) Musculoskeletal (0.129) | Cell Proliferation (0.677) Inflammation (0.129) | PSPORT1 |
| 38 | 83-142 1244-1318 | Reproductive (0.230) Nervous (0.162) Cardiovascular (0.135) | Cell Proliferation (0.581) Inflammation (0.257) | pINCY |
| 39 | 29-88 758-832 | Nervous (0.281) Reproductive (0.246) | Cell Proliferation (0.491) Inflammation (0.228) | pINCY |
| 40 | 435-494 | Nervous (0.308) Reproductive (0.215) Hematopoietic/Immune (0.108) | Cell Proliferation (0.531) Inflammation (0.315) Neurological (0.100) | pINCY |
| 41 | 1420-1482 | Nervous (0.538) Reproductive (0.231) Urologic (0.077) | Cell Proliferation (0.462) Inflammation (0.346) Neurological (0.115) | PSPORT1 |
| 42 | 866-910 | Reproductive (0.278) Developmental (0.222) Hematopoietic/Immune (0.167) | Cell Proliferation (0.611) Inflammation (0.389) | pINCY |

Table 3 (Cont.)

| Nucleotide SEQ ID NO: | Selected Fragment | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | Vector |
|--------------------------|----------------------|---|--|--------|
| 43 | 948-992 | Reproductive (0.287) Nervous (0.166) Cardiovascular (0.127) Hematopoietic/Immune (0.127) | Cell Proliferation (0.650) Inflammation (0.299) | pINCY |
| 44 | 218-262 | Reproductive (0.510) Gastrointestinal (0.143) Cardiovascular (0.102) Nervous (0.102) | Cell Proliferation (0.714) Inflammation (0.306) | pINCY |
| 45 | 389-496 | Nervous (0.267) Cardiovascular (0.200) Reproductive (0.200) | Cell Proliferation (0.533) Inflammation (0.333) Neurological (0.133) | pINCY |
| 46 | 272-316 | Nervous (0.667) Endocrine (0.167) Gastrointestinal (0.167) | Cell Proliferation (0.333) Inflammation (0.333) | pINCY |
| 47 | 802-894 | Developmental (0.267) Urologic (0.200) Endocrine (0.133) Reproductive (0.133) | Cell Proliferation (0.867) Inflammation (0.267) | pINCY |
| 48 | 219-263 | Reproductive (0.571) Cardiovascular (0.143) Nervous (0.143) Urologic (0.143) | Cell Proliferation (0.571) Inflammation (0.286) | pINCY |

Table 3 (Cont.)

| Nucleotide SEQ ID-NO: | Selected Fragment | Tissue Expression (Fraction Of Total) | Disease or Condition (Fraction of Total) | Vector |
|--------------------------|----------------------|---|--|--------|
| 49 | 280-369 | Nervous (0.885) Cardiovascular (0.038) Developmental (0.038) Endocrine (0.038) | Cell Proliferation (0.308) Inflammation (0.346) Neurological (0.269) | pINCY |
| 50 | 487-531 | Nervous (0.338) Reproductive (0.294) Urologic (0.088) | Cell Proliferation (0.647) Inflammation (0.221) | pINCY |
| 51 | 337-420 | Reproductive (0.250) Gastrointestinal (0.156) Nervous (0.156) | Cell Proliferation (0.500) Inflammation (0.438) | pINCY |
| 52 | 412-474 928-1017 | Reproductive (0.255) Gastrointestinal (0.170) Nervous (0.170) | Cell Proliferation (0.617) Inflammation (0.383) | pINCY |
| 53 | 109-150 | Nervous (1.000) | Inflammation (1.000) | pINCY |
| 54 | 198-242 | Nervous (0.281) Reproductive (0.156) Gastrointestinal (0.138) | Cell Proliferation (0.463) Inflammation (0.394) | pINCY |

Table 4

| Nucleotide SEQ ID NO: | Library | Library Description |
|--------------------------|-----------|--|
| 29 | HNT3AZT01 | Library was prepared from hNT precursor cells (at 80% confluence) treated for three days with 0.35 micromolar 5-aza-2'-deoxycytidine (a demethylating agent) in order to induce transcription of silent genes. |
| 30 | BONTNOT01 | The library was constructed from normal bone connective tissue (periosteum) obtained from a 20-year-old Caucasian male during a hindquarter amputation. Pathology indicated partially necrotic and cystic osteoblastic grade 3 osteosarcoma (post chemotherapy) in the right lower limb. Patient history included osteogenesis imperfecta, bone infection of the lower limb, pathologic closed fracture, and non-union of fracture. Family history included osteogenesis imperfecta and closed fracture and diabetes with hyperosmolarity. |
| 31 | PITUNOT01 | Library was constructed using RNA (Clontech, #6584-2, Lot 35278) obtained from the pituitary glands removed from a pool of 18 male and female Caucasian donors, 16 to 70 years old, who died from trauma. |
| 32 | HYPONOB01 | Library was constructed using RNA (Clontech, #6579-2, Lot 3X843) isolated from the hypothalamus tissues of 51 male and female Caucasian donors, 16 to 75 years old. |
| 33 | PROSTUT04 | Library was constructed using RNA isolated from prostate tumor tissue removed from a 57-year-old Caucasian male during radical prostatectomy, removal of both testes, and excision of regional lymph nodes. Pathology indicated adenocarcinoma (Gleason grade 3+3). Patient history included a benign neoplasm of the large bowel and type I diabetes. Family history included a malignant neoplasm of the prostate and type I diabetes. |

Table 4 (Cont.)

| Nucleotide SEQ ID NO: | Library | Library Description |
|--------------------------|-----------|---|
| 34 | PANCTUT02 | Library was constructed using RNA isolated from pancreatic tumor tissue removed from a 45-year-old Caucasian female during radical pancreaticoduodenectomy. Pathology indicated a grade 4 anaplastic carcinoma. Family history included benign hypertension, hyperlipidemia, and atherosclerotic coronary artery disease. |
| 35 | BLADTUT04 | Library was constructed using RNA isolated from bladder tumor tissue removed from a 60-year-old Caucasian male during a radical cystectomy, prostatectomy, and vasectomy. Pathology indicated grade 3 transitional cell carcinoma in the left bladder wall. Family history included type I diabetes, a malignant neoplasm of the stomach, atherosclerotic coronary artery disease, and an acute myocardial infarction. |
| 36 | PROSTUT10 | Library was constructed using RNA isolated from prostatic tumor tissue removed from a 66-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated an adenocarcinoma (Gleason grade 2+3), and adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Family history included prostate cancer and secondary bone cancer. |
| 37 | LEUKNOT03 | Library was constructed using RNA isolated from white blood cells of a 27-year-old female with blood type A+. |

Table 4 (Cont.)

| | | |
|--------------------------|-----------|---|
| 38 | OVARTUT01 | Library was constructed using RNA isolated from ovarian tumor tissue removed from a 43-year-old Caucasian female during removal of the fallopian tubes and ovaries. Pathology indicated grade 2 mucinous cystadenocarcinoma involving the entire left ovary. Patient history included mitral valve disorder, pneumonia, and viral hepatitis. Family history included atherosclerotic coronary artery disease, pancreatic cancer, stress reaction, cerebrovascular disease, breast cancer, and uterine cancer. |
| Nucleotide SEQ ID NO: | Library | Library Description |
| 39 | LUNGFET04 | Library was constructed using RNA isolated from lung tissue removed from a Caucasian female fetus, who died at 17 weeks' gestation from anencephalus. |
| 40 | PENCNOT02 | Library was constructed using RNA isolated from penis right corpus cavernosum tissue removed from a male. |
| 41 | SPLNNOT12 | Library was constructed using RNA isolated from spleen tissue removed from a 65-year-old female. Pathology indicated the spleen was negative for metastasis, and the associated tumor tissue indicated well-differentiated neuroendocrine carcinoma (islet cell tumor) forming a dominant mass in the distal pancreas. |
| 42 | BRAINOT03 | Library was constructed using RNA isolated from brain tissue removed from a 26-year-old Caucasian male during cranioplasty and excision of a cerebral meningeal lesion. Pathology for the associated tumor tissue indicated a grade 4 oligoastrocytoma in the right fronto-parietal part of the brain. |
| 43 | COLNFET02 | Library was constructed using RNA isolated from the colon tissue of a Caucasian female fetus, who died at 20 weeks' gestation. |

Table 4 (Cont.)

| | | |
|--------------------------|-----------|--|
| 44 | COLNTUT03 | Library was constructed using RNA isolated from colon tumor tissue obtained from the sigmoid colon of a 62-year-old Caucasian male during a sigmoidectomy and permanent colostomy. Pathology indicated invasive grade 2 adenocarcinoma. One lymph node contained metastasis with extranodal extension. Patient history included hyperlipidemia, cataract disorder, and dermatitis. Family history included benign hypertension, atherosclerotic coronary artery disease, hyperlipidemia, breast cancer, and prostate cancer. |
| 45 | SKINBIT01 | Library was constructed using RNA isolated from diseased skin tissue of the left lower leg. Patient history included erythema nodosum of the left lower leg. |
| Nucleotide SEQ ID NO: | Library | Library Description |
| 46 | BRAITUT22 | Library was constructed using RNA isolated from brain tumor tissue removed from the right frontal/parietal lobe of a 76-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a meningioma. Family history included senile dementia. |
| 47 | ADRETUT06 | Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland. |
| 48 | ADRETUT06 | Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland. |
| 49 | ADRETUT06 | Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland. |

Table 4 (Cont.)

| | | |
|----|-----------|--|
| 50 | UTRSNOR01 | Library was constructed using RNA isolated from uterine endometrium tissue removed from a 29-year-old Caucasian female during a vaginal hysterectomy and cystocele repair. Pathology indicated the endometrium was secretory, and the cervix showed mild chronic cervicitis with focal squamous metaplasia. Pathology for the associated tumor tissue indicated intramural uterine leiomyoma. Patient history included hypothyroidism, pelvic floor relaxation, and paraplegia. Family history included benign hypertension, type II diabetes, and hyperlipidemia. |
|----|-----------|--|

Table 4 (Cont.)

| Nucleotide SEQ ID NO: | Library | Library Description |
|--------------------------|-----------|---|
| 51 | BRAINOT20 | Library was constructed using RNA isolated from diseased brain tissue removed from the left temporal lobe of a 27-year-old Caucasian male during a brain lobectomy. Pathology for the left temporal lobe, including the mesial temporal structures, indicated focal, marked pyramidal cell loss and gliosis in hippocampal sector CA1, consistent with mesial temporal sclerosis. The left frontal lobe showed a focal deep white matter lesion, characterized by marked gliosis, calcifications, and hemosiderin-laden macrophages, consistent with a remote perinatal injury. This frontal lobe tissue also showed mild to moderate generalized gliosis, predominantly subpial and subcortical, consistent with chronic seizure disorder. GFAP was positive for astrocytes. Family history included brain cancer. |
| 52 | SEMVN0T04 | Library was constructed using RNA isolated from seminal vesicle tissue removed from a 61-year-old Caucasian male during a radical prostatectomy. Pathology for the associated tumor tissue indicated adenocarcinoma, Gleason grade 3+3. The patient presented with induration, hyperplasia of the prostate, and elevated prostate specific antigen. Patient history included renal failure, osteoarthritis, left renal artery stenosis, thrombocytopenia, hyperlipidemia, and hepatitis C (carrier). Family history included benign hypertension. |
| 53 | SMCCNON03 | This normalized smooth muscle cell library was constructed from 7.56×10^6 independent clones from a smooth muscle tissue library. Starting RNA was made from smooth muscle cell tissue removed from the coronary artery of a 3-year-old Caucasian male. The normalization and hybridization conditions were adapted from Soares et al., (Proc. Natl. Acad. Sci. USA (1994) 91:9228-9232); Swaroop et al., (Nucleic Acids Research (1991) 19:1954-806); and Bonaldo et al., (Genome Research (1996) 6:791-806), using a significantly longer (48 hour) reannealing hybridization period. |

Table 4 (Cont.)

| Nucleotide SEQ ID NO: | Library | Library Description |
|--------------------------|-----------|---|
| 54 | BRSTNOT24 | Library was constructed using RNA isolated from diseased breast tissue removed from a 46-year-old Caucasian female during bilateral subcutaneous mastectomy. Pathology indicated nonproliferative fibrocystic disease bilaterally. Family history included breast cancer, benign hypertension, and atherosclerotic coronary artery disease. |
| 55 | BRADDIR01 | Library was constructed using RNA isolated from diseased choroid plexus tissue of the lateral ventricle, removed from the brain of a 57-year-old Caucasian male, who died from a cerebrovascular accident. Patient history included Huntington's disease and emphysema. |
| 56 | BRAHNOT01 | Library was constructed using RNA isolated from posterior hippocampus tissue removed from a 35-year-old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomenigeal fibrosis and multiple microinfarctions of the cerebral neocortex. Microscopically, the cerebral hemisphere revealed moderate fibrosis of the leptomeninges with focal calcifications. There was evidence of shrunken and slightly eosinophilic pyramidal neurons throughout the cerebral hemispheres. In addition, scattered throughout the cerebral cortex, there were multiple small microscopic areas of cavitation with surrounding gliosis. Patient history included dilated cardiomyopathy, congestive heart failure, cardiomegaly and an enlarged spleen and liver. |

Table 5

| Program | Description | Reference | Parameter Threshold |
|-------------------|---|---|---|
| ABI FACTURA | A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences. | Perkin-Elmer Applied Biosystems, Foster City, CA. | |
| ABI/PARACEL FDF | A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences. | Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA. | Mismatch <50% |
| ABI AutoAssembler | A program that assembles nucleic acid sequences. | Perkin-Elmer Applied Biosystems, Foster City, CA. | |
| BLAST | A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx. | Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402. | ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less |
| FASTA | A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch. | Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489. | ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater |
| BLIMPS | A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions. | Henikoff, S and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424. | Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less |
| HMMER | An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM. | Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322. | Score=10-50 bits for PFAM hits, depending on individual protein families |

Table 5 (cont.)

| Program | Description | Reference | Parameter Threshold |
|-------------|---|--|--|
| ProfileScan | An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite. | Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221. | Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1. |
| Phred | A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability. | Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194. | |
| Phrap | A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences. | Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA. | Score= 120 or greater; Match length= 56 or greater |
| Consed | A graphical tool for viewing and editing Phrap assemblies | Gordon, D. et al. (1998) Genome Res. 8:195-202. | |
| SPScan | A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides. | Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439. | Score=3.5 or greater |
| Motifs | A program that searches amino acid sequences for patterns that matched those defined in Prosite. | Bairoch et al. <i>supra</i> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI. | |

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-27 and fragments thereof.

2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.

3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.

4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.

5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.

6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.

7. A method for detecting a polynucleotide, the method comprising the steps of:
(a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
(b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.

8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.

9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:28-54 and fragments thereof.

10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.

11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.

12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.

5

13. A host cell comprising the expression vector of claim 12.

14. A method for producing a polypeptide, the method comprising the steps of:

10 a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and

b) recovering the polypeptide from the host cell culture.

15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.

15

16. A purified antibody which specifically binds to the polypeptide of claim 1.

17. A purified agonist of the polypeptide of claim 1.

20

18. A purified antagonist of the polypeptide of claim 1.

19. A method for treating or preventing a disorder associated with decreased expression or activity of NEUAP, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.

25

20. A method for treating or preventing a disorder associated with increased expression or activity of NEUAP, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.

1/5

| | | | | | | | |
|-----|-----------|-----------|-----------|------------|-----------|-----------|------------|
| 1 | MA | - - - - - | - - - - - | GSPSRAAGRR | QLP | - - - - - | 2417014 |
| 1 | MEF | SLLPRL | ECNGAIS | AHRN | LR | LP | GI 3002527 |
| 17 | - - - - - | - - - - - | - - - - - | LLCLFL | Q | - - - - - | 2417014 |
| 31 | PAS | ASPVAGIT | GMCTHAR | LILY | FFLV | EMEF | GI 3002527 |
| 24 | - - - - - | - - - - - | - - - - - | - - - - - | - - - - - | VRYNHKT | 2417014 |
| 61 | LHV | GQAGLE | LPTSD | DPVSAS | QSA | RYRTGH | GI 3002527 |
| 41 | DAAL | - - - - - | - - - - - | - - - - - | WH | - - - - - | 2417014 |
| 91 | HARL | CLANFC | GRNRVSL | MCPS | WSP | ELKQST | GI 3002527 |
| 47 | - - - - - | - - - - - | - - - - - | RSNH | SNA | DNFFRY | 2417014 |
| 121 | CLS | LPKCWD | YRRA | AVPGL | FILF | LRHRCP | GI 3002527 |
| 68 | VAA | QAGVQRR | NLGS | LQPS | PPR | - - - - - | 2417014 |
| 151 | LTQ | DEVQW | CDHSS | LQPS | TPE | IKHP | GI 3002527 |
| 88 | - - - - - | - - - - - | - - - - - | - - - - - | - - - - - | SFALVA | 2417014 |
| 181 | VAG | TKDMHH | YTW | LIF | IFIF | NFLRQ | GI 3002527 |

FIGURE 1A

2/5

| | | |
|-----|--|------------|
| 95 | QAGVQWHNLGSPQPPLPPGFKRFSSCLSLSS | 2417014 |
| 211 | QAGVQWRNLGSLQPLPPGFKLFSCPSLLSS | GI 3002527 |
| 125 | WDYS - - - L E S V F P L I A E - - - - - | 2417014 |
| 241 | WDYRRPRLANFFVFLVEMGFTMFARLI I | GI 3002527 |
| 139 | - - - - - G Q R S A T S Q A M H Q L - - - - - | 2417014 |
| 271 | SGPCDLPASASQ S A G I T G V S H H A R L I F N F C | GI 3002527 |
| 154 | LFVTLMFASVGGG - - - - - L G G L - - - - - | 2417014 |
| 301 | LFEMESHSVTQAGVQWPNLGS L Q P L P P G L K | GI 3002527 |
| 173 | KLPFLDSPP - - - - - R L P A - - - - - | 2417014 |
| 331 | RFSCLSLPS SWDYGHLPHPANFC I F I R G G | GI 3002527 |
| 190 | - S S L A G A W R A | 2417014 |
| 361 | V S P Y L S G W S Q T P D L R | GI 3002527 |

FIGURE 1B

3/5

1 MHGSCSFLMLLLPLLLVAT TGPVGALTD 2634931
1 M-----VSFVSNYSH TANI LPDIEN GI 847722

31 EE-KR L M V E L H N L Y R A Q V S P T A S D M L H M R W 2634931
21 E D F I K D C V R I H N K F R S E V K P T A S D M L Y M T W GI 847722

60 D E E L A A F A K A Y A R Q C V W G H N K E R G R R G E N L 2634931
51 D P A L A Q I A K A W A S N C Q F S H N T - R L K P P H K L GI 847722

90 - - - F A I T D E G M - - - D V P L - - - A M E E W H H 2634931
80 H P N F T S L G E N I W T G S V P I F S V S S A I T N W Y D GI 847722

109 E R E H Y N L S A A T C S P G Q M C G H Y T Q V V W A K T E 2634931
110 E I Q D Y N F K T R I C K - - K V C G H Y T Q V V W A D S Y GI 847722

139 R I G C G S H F C E K L Q G V E E - T N I E L L V C N Y E P 2634931
138 K V G C A V Q F C P K V S G F D A L S N G A H F I C N Y G P GI 847722

168 P G N V K G K R P Y Q E G T P C S Q C P S G Y H C K N S L C 2634931
168 G G N Y P T - W P Y K R G A T C S A C P N N D K C L D N L C GI 847722

FIGURE 2A

4/5

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|-----------|-----------|-----------|
| 198 | E | P | I | G | S | P | E | D | A | Q | D | L | P | Y | L | V | T | E | A | P | S | F | R | A | T | E | A | S | D | S | 2634931 | |
| 197 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | V | N | D | S | E | T | GI 847722 |
| 228 | R | K | M | G | T | P | S | S | L | A | T | G | I | P | A | F | L | V | T | E | V | S | G | S | L | A | T | K | A | L | 2634931 | |
| 203 | K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | GI 847722 | |
| 258 | P | A | V | E | T | Q | A | P | T | S | L | A | T | K | D | P | P | S | M | A | T | E | A | P | P | C | V | T | T | E | 2634931 | |
| 204 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | S | N | GI 847722 | |
| 288 | V | P | S | I | L | A | A | H | S | L | P | S | L | D | E | E | P | V | T | F | P | K | S | T | H | V | P | I | P | K | 2634931 | |
| 206 | V | T | M | L | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Y | I | R | L | A | H | I | S | T | GI 847722 | | |
| 318 | S | A | D | K | V | T | D | K | T | K | V | P | S | R | S | P | E | N | S | L | D | P | K | M | S | L | T | G | A | R | 2634931 | |
| 219 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | GI 847722 | |
| 348 | E | L | L | P | H | A | Q | E | E | A | E | A | E | E | L | P | P | S | S | E | V | L | A | S | V | F | P | A | Q | 2634931 | | |
| 219 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | GI 847722 | |

FIGURE 2B

5/5

378 DKPGELQATLDHTGHTSSKSLPNFPNTSAT 2634931
219 GI 847722

408 ANATGGRAALALQSSLPGAEGPDKPSVSGL 2634931
219 GI 847722

438 NSGPGHVWGPPLLGLLLPPLVLAGIF 2634931
219 GI 847722

FIGURE 2C

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.

TANG, Y. Tom

YUE, Henry

BAUGHN, Mariah R.

HILLMAN, Jennifer L.

LAL, Preeti

AU-YOUNG, Janice

YANG, Junming

LU, Dyung Aina M.

AZIMZAI, Yalda

<120> NEURON-ASSOCIATED PROTEINS

<130> PF-0637 PCT

<140> To Be Assigned

<141> Herewith

<150> 09/210,083; unassigned; 60/119,365; 60/124,687

<151> 1998-12-11; 1998-12-11; 1999-02-09; 1999-03-16

<160> 56

<170> PERL Program

<210> 1

<211> 198

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 2417014CD1

<400> 1

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Gly | Ser | Pro | Ser | Arg | Ala | Ala | Gly | Arg | Arg | Leu | Gln | Leu |
| 1 | | | | 5 | | | | | 10 | | | | 15 | |
| Pro | Leu | Leu | Cys | Leu | Phe | Leu | Gln | Gly | Ala | Thr | Ala | Val | Leu | Phe |
| | | | 20 | | | | | | 25 | | | | 30 | |
| Ala | Val | Phe | Val | Arg | Tyr | Asn | His | Lys | Thr | Asp | Ala | Ala | Leu | Trp |
| | | | 35 | | | | | | 40 | | | | 45 | |
| His | Arg | Ser | Asn | His | Ser | Asn | Ala | Asp | Asn | Glu | Phe | Tyr | Phe | Arg |
| | | | 50 | | | | | | 55 | | | | 60 | |
| Tyr | Pro | Lys | Glu | Ser | His | Ser | Val | Ala | Gln | Ala | Gly | Val | Gln | Arg |
| | | | 65 | | | | | | 70 | | | | 75 | |
| Arg | Asn | Leu | Gly | Ser | Leu | Gln | Pro | Ser | Pro | Pro | Arg | Trp | Ser | Phe |
| | | | 80 | | | | | | 85 | | | | 90 | |
| Ala | Leu | Val | Ala | Gln | Ala | Gly | Val | Gln | Trp | His | Asn | Leu | Gly | Ser |
| | | | 95 | | | | | | 100 | | | | 105 | |
| Pro | Gln | Pro | Leu | Pro | Pro | Gly | Phe | Lys | Arg | Phe | Ser | Cys | Leu | Ser |
| | | | 110 | | | | | | 115 | | | | 120 | |
| Leu | Leu | Ser | Ser | Trp | Asp | Tyr | Ser | Leu | Glu | Ser | Val | Phe | Pro | Leu |

| | | | | | |
|---|-----|--|-----|--|-----|
| | 125 | | 130 | | 135 |
| Ile Ala Glu Gly Gln Arg Ser Ala Thr Ser Gln Ala Met His Gln | | | | | |
| | 140 | | 145 | | 150 |
| Leu Phe Gly Leu Phe Val Thr Leu Met Phe Ala Ser Val Gly Gly | | | | | |
| | 155 | | 160 | | 165 |
| Gly Leu Gly Gly Leu Leu Leu Lys Leu Pro Phe Leu Asp Ser Pro | | | | | |
| | 170 | | 175 | | 180 |
| Pro Arg Leu Pro Ala Leu Arg Gly Pro Ser Ser Leu Ala Gly Ala | | | | | |
| | 185 | | 190 | | 195 |
| Trp Arg Ala | | | | | |

<210> 2

<211> 463

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 2634931CD1

<400> 2

| | | | |
|---|--|--|--|
| Met His Gly Ser Cys Ser Phe Leu Met Leu Leu Leu Pro Leu Leu | | | |
| 1 5 10 15 | | | |
| Leu Leu Leu Val Ala Thr Thr Gly Pro Val Gly Ala Leu Thr Asp | | | |
| 20 25 30 | | | |
| Glu Glu Lys Arg Leu Met Val Glu Leu His Asn Leu Tyr Arg Ala | | | |
| 35 40 45 | | | |
| Gln Val Ser Pro Thr Ala Ser Asp Met Leu His Met Arg Trp Asp | | | |
| 50 55 60 | | | |
| Glu Glu Leu Ala Ala Phe Ala Lys Ala Tyr Ala Arg Gln Cys Val | | | |
| 65 70 75 | | | |
| Trp Gly His Asn Lys Glu Arg Gly Arg Arg Gly Glu Asn Leu Phe | | | |
| 80 85 90 | | | |
| Ala Ile Thr Asp Glu Gly Met Asp Val Pro Leu Ala Met Glu Glu | | | |
| 95 100 105 | | | |
| Trp His His Glu Arg Glu His Tyr Asn Leu Ser Ala Ala Thr Cys | | | |
| 110 115 120 | | | |
| Ser Pro Gly Gln Met Cys Gly His Tyr Thr Gln Val Val Trp Ala | | | |
| 125 130 135 | | | |
| Lys Thr Glu Arg Ile Gly Cys Gly Ser His Phe Cys Glu Lys Leu | | | |
| 140 145 150 | | | |
| Gln Gly Val Glu Glu Thr Asn Ile Glu Leu Leu Val Cys Asn Tyr | | | |
| 155 160 165 | | | |
| Glu Pro Pro Gly Asn Val Lys Gly Lys Arg Pro Tyr Gln Glu Gly | | | |
| 170 175 180 | | | |
| Thr Pro Cys Ser Gln Cys Pro Ser Gly Tyr His Cys Lys Asn Ser | | | |
| 185 190 195 | | | |
| Leu Cys Glu Pro Ile Gly Ser Pro Glu Asp Ala Gln Asp Leu Pro | | | |
| 200 205 210 | | | |
| Tyr Leu Val Thr Glu Ala Pro Ser Phe Arg Ala Thr Glu Ala Ser | | | |
| 215 220 225 | | | |
| Asp Ser Arg Lys Met Gly Thr Pro Ser Ser Leu Ala Thr Gly Ile | | | |
| 230 235 240 | | | |
| Pro Ala Phe Leu Val Thr Glu Val Ser Gly Ser Leu Ala Thr Lys | | | |

| | | | |
|-----------------|---------------------|---------------------|-----|
| | 245 | 250 | 255 |
| Ala Leu Pro Ala | Val Glu Thr Gln Ala | Pro Thr Ser Leu Ala | Thr |
| | 260 | 265 | 270 |
| Lys Asp Pro Pro | Ser Met Ala Thr Glu | Ala Pro Pro Cys Val | Thr |
| | 275 | 280 | 285 |
| Thr Glu Val Pro | Ser Ile Leu Ala Ala | His Ser Leu Pro Ser | Leu |
| | 290 | 295 | 300 |
| Asp Glu Glu Pro | Val Thr Phe Pro Lys | Ser Thr His Val Pro | Ile |
| | 305 | 310 | 315 |
| Pro Lys Ser Ala | Asp Lys Val Thr Asp | Lys Thr Lys Val Pro | Ser |
| | 320 | 325 | 330 |
| Arg Ser Pro Glu | Asn Ser Leu Asp Pro | Lys Met Ser Leu Thr | Gly |
| | 335 | 340 | 345 |
| Ala Arg Glu Leu | Leu Pro His Ala Gln | Glu Glu Ala Glu Ala | Glu |
| | 350 | 355 | 360 |
| Ala Glu Leu Pro | Pro Ser Ser Glu Val | Leu Ala Ser Val Phe | Pro |
| | 365 | 370 | 375 |
| Ala Gln Asp Lys | Pro Gly Glu Leu Gln | Ala Thr Leu Asp His | Thr |
| | 380 | 385 | 390 |
| Gly His Thr Ser | Ser Lys Ser Leu Pro | Asn Phe Pro Asn Thr | Ser |
| | 395 | 400 | 405 |
| Ala Thr Ala Asn | Ala Thr Gly Gly Arg | Ala Leu Ala Leu Gln | Ser |
| | 410 | 415 | 420 |
| Ser Leu Pro Gly | Ala Glu Gly Pro Asp | Lys Pro Ser Val Val | Ser |
| | 425 | 430 | 435 |
| Gly Leu Asn Ser | Gly Pro Gly His Val | Trp Gly Pro Leu Leu | Gly |
| | 440 | 445 | 450 |
| Leu Leu Leu Leu | Pro Pro Leu Val Leu | Ala Gly Ile Phe | |
| | 455 | 460 | |

<210> 3

<211> 316

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 110960CD1

<400> 3

| | |
|---|----------|
| Met Thr Gln Gly Lys Leu Ser Val Ala Asn Lys Ala Pro Gly Thr | |
| 1 | 5 10 15 |
| Glu Gly Gln Gln Gln Val His Gly Glu Lys Lys Glu Ala Pro Ala | |
| | 20 25 30 |
| Val Pro Ser Ala Pro Pro Ser Tyr Glu Glu Ala Thr Ser Gly Glu | |
| | 35 40 45 |
| Gly Met Lys Ala Gly Ala Phe Pro Pro Ala Pro Thr Ala Val Pro | |
| | 50 55 60 |
| Leu His Pro Ser Trp Ala Tyr Val Asp Pro Ser Ser Ser Ser Ser | |
| | 65 70 75 |
| Tyr Asp Asn Gly Phe Pro Thr Gly Asp His Glu Leu Phe Thr Thr | |
| | 80 85 90 |
| Phe Ser Trp Asp Asp Gln Lys Val Arg Arg Val Phe Val Arg Lys | |

| | | | | | |
|-----------------|---------------------|---------------------|-----|--|-----|
| | 95 | | 100 | | 105 |
| Val Tyr Thr Ile | Leu Leu Ile Gln Leu | Leu Val Thr Leu Ala | Val | | |
| | 110 | | 115 | | 120 |
| Val Ala Leu Phe | Thr Phe Cys Asp Pro | Val Lys Asp Tyr Val | Gln | | |
| | 125 | | 130 | | 135 |
| Ala Asn Pro Gly | Trp Tyr Trp Ala Ser | Tyr Ala Val Phe Phe | Ala | | |
| | 140 | | 145 | | 150 |
| Thr Tyr Leu Thr | Leu Ala Cys Cys Ser | Gly Pro Arg Arg His | Phe | | |
| | 155 | | 160 | | 165 |
| Pro Trp Asn Leu | Ile Leu Leu Thr Val | Phe Thr Leu Ser Met | Ala | | |
| | 170 | | 175 | | 180 |
| Tyr Leu Thr Gly | Met Leu Ser Ser Tyr | Tyr Asn Thr Thr Ser | Val | | |
| | 185 | | 190 | | 195 |
| Leu Leu Cys Leu | Gly Ile Thr Ala Leu | Val Cys Leu Ser Val | Thr | | |
| | 200 | | 205 | | 210 |
| Val Phe Ser Phe | Gln Thr Lys Phe Asp | Phe Thr Ser Cys Gln | Gly | | |
| | 215 | | 220 | | 225 |
| Val Leu Phe Val | Leu Leu Met Thr Leu | Phe Phe Ser Gly Leu | Ile | | |
| | 230 | | 235 | | 240 |
| Leu Ala Ile Leu | Leu Pro Phe Gln Tyr | Val Pro Trp Leu His | Ala | | |
| | 245 | | 250 | | 255 |
| Val Tyr Ala Ala | Leu Gly Ala Gly Val | Phe Thr Leu Phe Leu | Ala | | |
| | 260 | | 265 | | 270 |
| Leu Asp Thr Gln | Leu Leu Met Gly Asn | Arg Arg His Ser Leu | Ser | | |
| | 275 | | 280 | | 285 |
| Pro Glu Glu Tyr | Ile Phe Gly Ala Leu | Asn Ile Tyr Leu Asp | Ile | | |
| | 290 | | 295 | | 300 |
| Ile Tyr Ile Phe | Thr Phe Phe Leu Gln | Leu Phe Gly Thr Asn | Arg | | |
| | 305 | | 310 | | 315 |
| Glu | | | | | |

<210> 4
 <211> 89
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 380721CD1

<400> 4
 Met Ser Glu Gln Gly Asp Leu Asn Gln Ala Ile Ala Glu Glu Gly
 1 5 10 15
 Gly Thr Glu Gln Glu Thr Ala Thr Pro Glu Asn Gly Ile Val Lys
 20 25 30
 Ser Glu Ser Leu Asp Glu Glu Glu Lys Leu Glu Leu Gln Arg Arg
 35 40 45
 Leu Glu Ala Gln Asn Gln Glu Arg Arg Lys Ser Lys Ser Gly Ala
 50 55 60
 Gly Lys Gly Lys Leu Thr Arg Ser Leu Ala Val Cys Glu Glu Ser
 65 70 75
 Ser Ala Arg Pro Gly Gly Glu Ser Leu Gln Gly Gln Thr Leu
 80 85

<210> 5
 <211> 273
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 829443CD1

<400> 5
 Met Arg Gly Ser Gln Glu Val Leu Leu Met Trp Leu Leu Val Leu
 1 5 10 15
 Ala Val Gly Gly Thr Glu His Ala Tyr Arg Pro Gly Arg Arg Val
 20 25 30
 Cys Ala Val Arg Ala His Gly Asp Pro Val Ser Glu Ser Phe Val
 35 40 45
 Gln Arg Val Tyr Gln Pro Phe Leu Thr Thr Cys Asp Gly His Arg
 50 55 60
 Ala Cys Ser Thr Tyr Arg Thr Ile Tyr Arg Thr Ala Tyr Arg Arg
 65 70 75
 Ser Pro Gly Leu Ala Pro Ala Arg Pro Arg Tyr Ala Cys Cys Pro
 80 85 90
 Gly Trp Lys Arg Thr Ser Gly Leu Pro Gly Ala Cys Gly Ala Ala
 95 100 105
 Ile Cys Gln Pro Pro Cys Arg Asn Gly Gly Ser Cys Val Gln Pro
 110 115 120
 Gly Arg Cys Arg Cys Pro Ala Gly Trp Arg Gly Asp Thr Cys Gln
 125 130 135
 Ser Asp Val Asp Glu Cys Ser Ala Arg Arg Gly Gly Cys Pro Gln
 140 145 150
 Arg Cys Val Asn Thr Ala Gly Ser Tyr Trp Cys Gln Cys Trp Glu
 155 160 165
 Gly His Ser Leu Ser Ala Asp Gly Thr Leu Cys Val Pro Lys Gly
 170 175 180
 Gly Pro Pro Arg Val Ala Pro Asn Pro Thr Gly Val Asp Ser Ala
 185 190 195
 Met Lys Glu Glu Val Gln Arg Leu Gln Ser Arg Val Asp Leu Leu
 200 205 210
 Glu Glu Lys Leu Gln Leu Val Leu Ala Pro Leu His Ser Leu Ala
 215 220 225
 Ser Gln Ala Leu Glu His Gly Leu Pro Asp Pro Gly Ser Leu Leu
 230 235 240
 Val His Ser Phe Gln Gln Leu Gly Arg Ile Asp Ser Leu Ser Glu
 245 250 255
 Gln Ile Ser Phe Leu Glu Glu Gln Leu Gly Ser Cys Ser Cys Lys
 260 265 270
 Lys Asp Ser

<210> 6
 <211> 263
 <212> PRT
 <213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1470058CD1

<400> 6

```

Met Leu Lys Cys His Val Phe Arg Cys Asp Val Pro Ala Lys Ala
 1              5              10              15
Ile Ala Ser Ala Leu His Gly Leu Cys Ala Gln Ile Leu Ser Glu
              20              25              30
Arg Val Glu Val Ser Gly Asp Ala Ser Cys Cys Ser Pro Asp Pro
              35              40              45
Ile Ser Pro Glu Asp Leu Pro Arg Gln Val Glu Leu Leu Asp Ala
              50              55              60
Val Ser Gln Ala Ala Gln Lys Tyr Glu Ala Leu Tyr Met Gly Thr
              65              70              75
Leu Pro Val Thr Lys Ala Met Gly Met Asp Val Leu Asn Glu Ala
              80              85              90
Ile Gly Thr Leu Thr Ala Arg Gly Asp Arg Asn Ala Trp Val Pro
              95              100             105
Thr Met Leu Ser Val Ser Asp Ser Leu Met Thr Ala His Pro Ile
              110             115             120
Gln Ala Glu Ala Ser Thr Glu Glu Glu Pro Leu Trp Gln Cys Pro
              125             130             135
Val Arg Leu Val Thr Phe Ile Gly Val Gly Arg Asp Pro His Thr
              140             145             150
Phe Gly Leu Ile Ala Asp Leu Gly Arg Gln Ser Phe Gln Cys Ala
              155             160             165
Ala Phe Trp Cys Gln Pro His Ala Gly Gly Leu Ser Glu Ala Val
              170             175             180
Gln Ala Ala Cys Met Val Gln Tyr Gln Lys Cys Leu Val Ala Ser
              185             190             195
Ala Ala Arg Gly Lys Ala Trp Gly Ala Gln Ala Arg Ala Arg Leu
              200             205             210
Arg Leu Lys Arg Thr Ser Ser Met Asp Ser Pro Gly Gly Pro Leu
              215             220             225
Pro Leu Pro Leu Leu Lys Gly Gly Val Gly Gly Ala Gly Ala Thr
              230             235             240
Pro Arg Lys Arg Gly Val Phe Ser Phe Leu Asp Ala Phe Arg Leu
              245             250             255
Lys Pro Ser Leu Leu His Met Pro
              260

```

<210> 7

<211> 165

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1554947CD1

<400> 7

```

Met Ala Asp Phe Asp Glu Ile Tyr Glu Glu Glu Glu Asp Glu Glu
 1              5              10              15
Arg Ala Leu Glu Glu Gln Leu Leu Lys Tyr Ser Pro Asp Pro Val

```

| | | | | | |
|---|-----|--|-----|--|-----|
| | 20 | | 25 | | 30 |
| Val Val Arg Gly Ser Gly His Val Thr Val Phe Gly Leu Ser Asn | | | | | |
| | 35 | | 40 | | 45 |
| Lys Phe Glu Ser Glu Phe Pro Ser Ser Leu Thr Gly Lys Val Ala | | | | | |
| | 50 | | 55 | | 60 |
| Pro Glu Glu Phe Lys Ala Ser Ile Asn Arg Val Asn Ser Cys Leu | | | | | |
| | 65 | | 70 | | 75 |
| Lys Lys Asn Leu Pro Val Asn Val Arg Trp Leu Leu Cys Gly Cys | | | | | |
| | 80 | | 85 | | 90 |
| Leu Cys Cys Cys Cys Thr Leu Gly Cys Ser Met Trp Pro Val Ile | | | | | |
| | 95 | | 100 | | 105 |
| Cys Leu Ser Lys Arg Thr Arg Arg Ser Ile Glu Lys Leu Leu Glu | | | | | |
| | 110 | | 115 | | 120 |
| Trp Glu Asn Asn Arg Leu Tyr His Lys Leu Cys Leu His Trp Arg | | | | | |
| | 125 | | 130 | | 135 |
| Leu Ser Lys Arg Lys Cys Glu Thr Asn Asn Met Met Glu Tyr Val | | | | | |
| | 140 | | 145 | | 150 |
| Ile Leu Ile Glu Phe Leu Pro Lys Thr Pro Ile Phe Arg Pro Asp | | | | | |
| | 155 | | 160 | | 165 |

<210> 8

<211> 424

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1690245CD1

<400> 8

| | | | | | |
|---|-----|--|-----|--|-----|
| Met Gln Asn Leu Gly Met Thr Ser Pro Leu Pro Tyr Asp Ser Leu | | | | | |
| 1 | 5 | | 10 | | 15 |
| Gly Tyr Asn Ala Pro His His Pro Phe Ala Gly Tyr Pro Pro Gly | | | | | |
| | 20 | | 25 | | 30 |
| Tyr Pro Met Gln Ala Tyr Val Asp Pro Ser Asn Pro Asn Ala Gly | | | | | |
| | 35 | | 40 | | 45 |
| Lys Val Leu Leu Pro Thr Pro Ser Met Asp Pro Val Cys Ser Pro | | | | | |
| | 50 | | 55 | | 60 |
| Ala Pro Tyr Asp His Ala Gln Pro Leu Val Gly His Ser Thr Glu | | | | | |
| | 65 | | 70 | | 75 |
| Pro Leu Ser Ala Pro Pro Pro Val Pro Val Val Pro His Val Ala | | | | | |
| | 80 | | 85 | | 90 |
| Ala Pro Val Glu Val Ser Ser Ser Gln Tyr Val Ala Gln Ser Asp | | | | | |
| | 95 | | 100 | | 105 |
| Gly Val Val His Gln Asp Ser Ser Val Ala Val Leu Pro Val Pro | | | | | |
| | 110 | | 115 | | 120 |
| Ala Pro Gly Pro Val Gln Gly Gln Asn Tyr Ser Val Trp Asp Ser | | | | | |
| | 125 | | 130 | | 135 |
| Asn Gln Gln Ser Val Ser Val Gln Gln Gln Tyr Ser Pro Ala Gln | | | | | |
| | 140 | | 145 | | 150 |
| Ser Gln Ala Thr Ile Tyr Tyr Gln Gly Gln Thr Cys Pro Thr Val | | | | | |
| | 155 | | 160 | | 165 |
| Tyr Gly Val Thr Ser Pro Tyr Ser Gln Thr Thr Pro Pro Ile Val | | | | | |
| | 170 | | 175 | | 180 |

| | | | | |
|-----------------|---|-----|-----|-----|
| Gln Ser Tyr Ala | Gln Pro Ser Leu Gln Tyr Ile Gln Gly Gln Gln | 185 | 190 | 195 |
| Ile Phe Thr Ala | His Pro Gln Gly Val Val Val Gln Pro Ala Ala | 200 | 205 | 210 |
| Ala Val Thr Thr | Ile Val Ala Pro Gly Gln Pro Gln Pro Leu Gln | 215 | 220 | 225 |
| Pro Ser Glu Met | Val Val Thr Asn Asn Leu Leu Asp Leu Pro Pro | 230 | 235 | 240 |
| Pro Ser Pro Pro | Lys Pro Lys Thr Ile Val Leu Pro Pro Asn Trp | 245 | 250 | 255 |
| Lys Thr Ala Arg | Asp Pro Glu Gly Lys Ile Tyr Tyr Tyr His Val | 260 | 265 | 270 |
| Ile Thr Arg Gln | Thr Gln Trp Asp Pro Pro Thr Trp Glu Ser Pro | 275 | 280 | 285 |
| Gly Asp Asp Ala | Ser Leu Glu His Glu Ala Glu Met Asp Leu Gly | 290 | 295 | 300 |
| Thr Pro Thr Tyr | Asp Glu Asn Pro Met Lys Ala Ser Lys Lys Pro | 305 | 310 | 315 |
| Lys Thr Ala Glu | Ala Asp Thr Ser Ser Glu Leu Ala Lys Lys Ser | 320 | 325 | 330 |
| Lys Glu Val Phe | Arg Lys Glu Met Ser Gln Phe Ile Val Gln Cys | 335 | 340 | 345 |
| Leu Asn Pro Tyr | Arg Lys Pro Asp Cys Lys Val Gly Arg Ile Thr | 350 | 355 | 360 |
| Thr Thr Glu Asp | Phe Lys His Leu Ala Arg Lys Leu Thr His Gly | 365 | 370 | 375 |
| Val Met Asn Lys | Glu Leu Lys Tyr Cys Lys Asn Pro Glu Asp Leu | 380 | 385 | 390 |
| Glu Cys Asn Glu | Asn Val Lys His Lys Thr Lys Glu Tyr Ile Lys | 395 | 400 | 405 |
| Lys Tyr Met Gln | Lys Phe Gly Ala Val Tyr Lys Pro Lys Glu Asp | 410 | 415 | 420 |
| Thr Glu Leu Glu | | | | |

<210> 9
 <211> 164
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1878262CD1

<400> 9
 Met Arg Cys Cys Arg Arg Arg Cys Cys Cys Arg Gln Pro Pro His
 1 5 10 15
 Ala Leu Arg Pro Leu Leu Leu Leu Pro Leu Val Leu Leu Pro Pro
 20 25 30
 Leu Ala Ala Ala Ala Ala Gly Pro Asn Arg Cys Asp Thr Ile Tyr
 35 40 45
 Gln Gly Phe Ala Glu Cys Leu Ile Arg Leu Gly Asp Ser Met Gly
 50 55 60
 Arg Gly Gly Glu Leu Glu Thr Ile Cys Arg Ser Trp Asn Asp Phe

| | | | | | |
|---|-----|--|-----|--|-----|
| | 65 | | 70 | | 75 |
| His Ala Cys Ala Ser Gln Val Leu Ser Gly Cys Pro Glu Glu Ala | | | | | |
| | 80 | | 85 | | 90 |
| Ala Ala Val Trp Glu Ser Leu Gln Gln Glu Ala Arg Gln Ala Pro | | | | | |
| | 95 | | 100 | | 105 |
| Arg Pro Asn Asn Leu His Thr Leu Cys Gly Ala Pro Val His Val | | | | | |
| | 110 | | 115 | | 120 |
| Arg Glu Arg Gly Thr Gly Ser Lys Thr Asn Gln Glu Thr Leu Arg | | | | | |
| | 125 | | 130 | | 135 |
| Ala Thr Ala Pro Ala Leu Pro Met Ala Pro Ala Pro Pro Leu Leu | | | | | |
| | 140 | | 145 | | 150 |
| Ala Ala Ala Leu Ala Leu Ala Tyr Leu Leu Arg Pro Leu Ala | | | | | |
| | 155 | | 160 | | |

<210> 10

<211> 796

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 2253519CD1

<400> 10

| | | | | | |
|---|-----|--|-----|--|-----|
| Met Thr Val Ala Gly Leu Lys Leu Leu Arg Ser Ala Phe Cys Cys | | | | | |
| 1 | 5 | | 10 | | 15 |
| Pro Pro Gln Gln Tyr Leu Thr Leu Ala Phe Thr Val Leu Leu Phe | | | | | |
| | 20 | | 25 | | 30 |
| His Phe Asp Tyr Pro Arg Leu Ser Gln Gly Phe Leu Leu Asp Tyr | | | | | |
| | 35 | | 40 | | 45 |
| Phe Leu Met Ser Leu Leu Cys Ser Lys Leu Trp Asp Leu Leu Tyr | | | | | |
| | 50 | | 55 | | 60 |
| Lys Leu Arg Phe Val Leu Thr Tyr Ile Ala Pro Trp Gln Ile Thr | | | | | |
| | 65 | | 70 | | 75 |
| Trp Gly Ser Ala Phe His Ala Phe Ala Gln Pro Phe Ala Val Pro | | | | | |
| | 80 | | 85 | | 90 |
| His Ser Ala Met Leu Phe Val Gln Ala Leu Leu Ser Gly Leu Phe | | | | | |
| | 95 | | 100 | | 105 |
| Ser Thr Pro Leu Asn Pro Leu Leu Gly Ser Ala Val Phe Ile Met | | | | | |
| | 110 | | 115 | | 120 |
| Ser Tyr Ala Arg Pro Leu Lys Phe Trp Glu Arg Asp Tyr Asn Thr | | | | | |
| | 125 | | 130 | | 135 |
| Lys Arg Val Asp His Ser Asn Thr Arg Leu Val Thr Gln Leu Asp | | | | | |
| | 140 | | 145 | | 150 |
| Arg Asn Pro Gly Ala Asp Asp Asn Asn Leu Asn Ser Ile Phe Tyr | | | | | |
| | 155 | | 160 | | 165 |
| Glu His Leu Thr Arg Ser Leu Gln His Thr Leu Cys Gly Asp Leu | | | | | |
| | 170 | | 175 | | 180 |
| Val Leu Gly Arg Trp Gly Asn Tyr Gly Pro Gly Asp Cys Phe Val | | | | | |
| | 185 | | 190 | | 195 |
| Leu Ala Ser Asp Tyr Leu Asn Ala Leu Val His Leu Ile Glu Val | | | | | |
| | 200 | | 205 | | 210 |
| Gly Asn Gly Leu Val Thr Phe Gln Leu Arg Gly Leu Glu Phe Arg | | | | | |
| | 215 | | 220 | | 225 |

| | | | |
|-----------------|---------------------|-------------------------|-----|
| Gly Thr Tyr Cys | Gln Gln Arg Glu Val | Glu Ala Ile Thr Glu Gly | |
| | 230 | 235 | 240 |
| Val Glu Glu Asp | Glu Gly Cys Cys Cys | Glu Pro Gly His Leu | |
| | 245 | 250 | 255 |
| Pro Arg Val Leu | Ser Phe Asn Ala Ala | Phe Gly Gln Arg Trp Leu | |
| | 260 | 265 | 270 |
| Ala Trp Glu Val | Thr Ala Ser Lys Tyr | Val Leu Glu Gly Tyr Ser | |
| | 275 | 280 | 285 |
| Ile Ser Asp Asn | Asn Ala Ala Ser Met | Leu Gln Val Phe Asp Leu | |
| | 290 | 295 | 300 |
| Arg Lys Ile Leu | Ile Thr Tyr Tyr Val | Lys Ser Ile Ile Tyr Tyr | |
| | 305 | 310 | 315 |
| Val Ser Arg Ser | Pro Lys Leu Glu Val | Trp Leu Ser His Glu Gly | |
| | 320 | 325 | 330 |
| Ile Thr Ala Ala | Leu Arg Pro Val Arg | Val Pro Gly Tyr Ala Asp | |
| | 335 | 340 | 345 |
| Ser Asp Pro Thr | Phe Ser Leu Ser Val | Asp Glu Asp Tyr Asp Leu | |
| | 350 | 355 | 360 |
| Arg Leu Ser Gly | Leu Ser Leu Pro Ser | Phe Cys Ala Val His Leu | |
| | 365 | 370 | 375 |
| Glu Trp Ile Gln | Tyr Cys Ala Ser Arg | Arg Thr Arg Pro Val Asp | |
| | 380 | 385 | 390 |
| Gln Asp Trp Asn | Ser Pro Leu Val Thr | Leu Cys Phe Gly Leu Cys | |
| | 395 | 400 | 405 |
| Val Leu Gly Arg | Arg Ala Leu Gly Thr | Ala Ser His Ser Met Ser | |
| | 410 | 415 | 420 |
| Ala Ser Leu Glu | Pro Phe Leu Tyr Gly | Leu His Ala Leu Phe Lys | |
| | 425 | 430 | 435 |
| Gly Asp Phe Arg | Ile Thr Ser Pro Arg | Asp Glu Trp Val Phe Ala | |
| | 440 | 445 | 450 |
| Asp Met Asp Leu | Leu His Arg Val Val | Ala Pro Gly Val Arg Met | |
| | 455 | 460 | 465 |
| Ala Leu Lys Leu | His Gln Asp His Phe | Thr Ser Pro Asp Glu Tyr | |
| | 470 | 475 | 480 |
| Glu Glu Pro Ala | Ala Leu Tyr Asp Ala | Ile Ala Ala Asn Glu Glu | |
| | 485 | 490 | 495 |
| Arg Leu Val Ile | Ser His Glu Gly Asp | Pro Ala Trp Arg Ser Ala | |
| | 500 | 505 | 510 |
| Ile Leu Ser Asn | Thr Pro Ser Leu Leu | Ala Leu Arg His Val Leu | |
| | 515 | 520 | 525 |
| Asp Asp Ala Ser | Asp Glu Tyr Lys Ile | Ile Met Leu Asn Arg Arg | |
| | 530 | 535 | 540 |
| His Leu Ser Phe | Arg Val Ile Lys Val | Asn Arg Glu Cys Val Arg | |
| | 545 | 550 | 555 |
| Gly Leu Trp Ala | Gly Gln Gln Gln Glu | Leu Val Phe Leu Arg Asn | |
| | 560 | 565 | 570 |
| Arg Asn Pro Glu | Arg Gly Ser Ile Gln | Asn Ala Lys Gln Ala Leu | |
| | 575 | 580 | 585 |
| Arg Asn Met Ile | Asn Ser Ser Cys Asp | Gln Pro Leu Gly Tyr Pro | |
| | 590 | 595 | 600 |
| Ile Tyr Val Ser | Pro Leu Thr Thr Ser | Leu Ala Gly Ser His Pro | |
| | 605 | 610 | 615 |
| Gln Leu Arg Ala | Leu Trp Gly Gly Pro | Ile Ser Leu Gly Ala Ile | |
| | 620 | 625 | 630 |
| Ala His Trp Leu | Leu Arg Thr Trp Glu | Arg Leu His Lys Gly Cys | |

| | | | | | |
|---|-----|--|-----|--|-----|
| | 635 | | 640 | | 645 |
| Gly Ala Gly Cys Asn Ser Gly Gly Asn Val Asp Asp Ser Asp Cys | | | | | |
| | 650 | | 655 | | 660 |
| Ser Gly Gly Gly Gly Leu Thr Ser Leu Ser Asn Asn Pro Pro Val | | | | | |
| | 665 | | 670 | | 675 |
| Ala His Pro Thr Pro Glu Asn Thr Ala Gly Asn Gly Asp Gln Pro | | | | | |
| | 680 | | 685 | | 690 |
| Leu Pro Pro Gly Pro Gly Trp Gly Pro Arg Ser Ser Leu Ser Gly | | | | | |
| | 695 | | 700 | | 705 |
| Ser Gly Asp Gly Arg Pro Pro Pro Leu Leu Gln Trp Pro Pro Pro | | | | | |
| | 710 | | 715 | | 720 |
| Arg Leu Pro Gly Pro Pro Pro Ala Ser Pro Ile Pro Thr Glu Gly | | | | | |
| | 725 | | 730 | | 735 |
| Pro Arg Thr Ser Arg Pro Pro Gly Pro Gly Leu Leu Ser Ser Glu | | | | | |
| | 740 | | 745 | | 750 |
| Gly Pro Ser Gly Lys Trp Ser Leu Gly Gly Arg Lys Gly Leu Gly | | | | | |
| | 755 | | 760 | | 765 |
| Gly Ser Asp Gly Glu Pro Ala Ser Gly Ser Pro Lys Gly Gly Thr | | | | | |
| | 770 | | 775 | | 780 |
| Pro Lys Ser Gln Val Arg His Leu Trp Glu Gly Trp Val Pro Glu | | | | | |
| | 785 | | 790 | | 795 |
| Gly | | | | | |

<210> 11

<211> 854

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 2888437CD1

<400> 11

| | | |
|---|-----|-----|
| Met Lys Cys Leu Tyr Tyr Leu Tyr Ala Ser Leu Asp Pro Asn Ala | | |
| 1 | 5 | 10 |
| Val Lys Ala Leu Asn Glu Met Trp Lys Cys Gln Asn Met Leu Arg | | |
| | 20 | 25 |
| Ile His Val Arg Glu Leu Leu Asp Leu His Lys Gln Pro Thr Ser | | |
| | 35 | 40 |
| Glu Ala Asn Cys Ser Ala Met Phe Gly Lys Leu Met Thr Ile Ala | | |
| | 50 | 55 |
| Lys Asn Leu Pro Asp Pro Gly Lys Ala Gln Asp Phe Val Lys Lys | | |
| | 65 | 70 |
| Phe Asn Gln Val Leu Gly Asp Asp Glu Lys Leu Arg Ser Gln Leu | | |
| | 80 | 85 |
| Glu Leu Leu Ile Ser Pro Thr Cys Ser Cys Lys Gln Ala Asp Ile | | |
| | 95 | 100 |
| Cys Val Arg Glu Ile Ala Arg Lys Leu Ala Asn Pro Lys Gln Pro | | |
| | 110 | 115 |
| Thr Asn Pro Phe Leu Glu Met Val Lys Phe Leu Leu Glu Arg Ile | | |
| | 125 | 130 |
| Ala Pro Val His Ile Asp Ser Glu Ala Ile Ser Ala Leu Val Lys | | |
| | 140 | 145 |
| | | 150 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Met | Asn | Lys | Ser | Ile | Glu | Gly | Thr | Ala | Asp | Asp | Glu | Glu | Glu |
| | | | | 155 | | | | | 160 | | | | | 165 |
| Gly | Val | Ser | Pro | Asp | Thr | Ala | Ile | Arg | Ser | Gly | Leu | Glu | Leu | Leu |
| | | | | 170 | | | | | 175 | | | | | 180 |
| Lys | Val | Leu | Ser | Phe | Thr | His | Pro | Thr | Ser | Phe | His | Ser | Ala | Glu |
| | | | | 185 | | | | | 190 | | | | | 195 |
| Thr | Tyr | Glu | Ser | Leu | Leu | Gln | Cys | Leu | Arg | Met | Glu | Asp | Asp | Lys |
| | | | | 200 | | | | | 205 | | | | | 210 |
| Val | Ala | Glu | Ala | Ala | Ile | Gln | Ile | Phe | Arg | Asn | Thr | Gly | His | Lys |
| | | | | 215 | | | | | 220 | | | | | 225 |
| Ile | Glu | Thr | Asp | Leu | Pro | Gln | Ile | Arg | Ser | Thr | Leu | Ile | Pro | Ile |
| | | | | 230 | | | | | 235 | | | | | 240 |
| Leu | His | Gln | Lys | Ala | Lys | Arg | Gly | Thr | Pro | His | Gln | Ala | Lys | Gln |
| | | | | 245 | | | | | 250 | | | | | 255 |
| Ala | Val | His | Cys | Ile | His | Ala | Ile | Phe | Thr | Asn | Lys | Glu | Val | Gln |
| | | | | 260 | | | | | 265 | | | | | 270 |
| Leu | Ala | Gln | Ile | Phe | Glu | Pro | Leu | Ser | Arg | Ser | Leu | Asn | Ala | Asp |
| | | | | 275 | | | | | 280 | | | | | 285 |
| Val | Pro | Glu | Gln | Leu | Ile | Thr | Pro | Leu | Val | Ser | Leu | Gly | His | Ile |
| | | | | 290 | | | | | 295 | | | | | 300 |
| Ser | Met | Leu | Ala | Pro | Asp | Gln | Phe | Ala | Ser | Pro | Met | Lys | Ser | Val |
| | | | | 305 | | | | | 310 | | | | | 315 |
| Val | Ala | Asn | Phe | Ile | Val | Lys | Asp | Leu | Leu | Met | Asn | Asp | Arg | Ser |
| | | | | 320 | | | | | 325 | | | | | 330 |
| Thr | Gly | Glu | Lys | Asn | Gly | Lys | Leu | Trp | Ser | Pro | Asp | Glu | Glu | Val |
| | | | | 335 | | | | | 340 | | | | | 345 |
| Ser | Pro | Glu | Val | Leu | Ala | Lys | Val | Gln | Ala | Ile | Lys | Leu | Leu | Val |
| | | | | 350 | | | | | 355 | | | | | 360 |
| Arg | Trp | Leu | Leu | Gly | Met | Lys | Asn | Asn | Gln | Ser | Lys | Ser | Ala | Asn |
| | | | | 365 | | | | | 370 | | | | | 375 |
| Ser | Thr | Leu | Arg | Leu | Leu | Ser | Ala | Met | Leu | Val | Ser | Glu | Gly | Asp |
| | | | | 380 | | | | | 385 | | | | | 390 |
| Leu | Thr | Glu | Gln | Lys | Arg | Ile | Ser | Lys | Ser | Asp | Met | Ser | Arg | Leu |
| | | | | 395 | | | | | 400 | | | | | 405 |
| Arg | Leu | Ala | Ala | Gly | Ser | Ala | Ile | Met | Lys | Leu | Ala | Gln | Glu | Pro |
| | | | | 410 | | | | | 415 | | | | | 420 |
| Cys | Tyr | His | Glu | Ile | Ile | Thr | Pro | Glu | Gln | Phe | Gln | Leu | Cys | Ala |
| | | | | 425 | | | | | 430 | | | | | 435 |
| Leu | Val | Ile | Asn | Asp | Glu | Cys | Tyr | Gln | Val | Arg | Gln | Ile | Phe | Ala |
| | | | | 440 | | | | | 445 | | | | | 450 |
| Gln | Lys | Leu | His | Lys | Ala | Leu | Val | Lys | Leu | Leu | Leu | Pro | Leu | Glu |
| | | | | 455 | | | | | 460 | | | | | 465 |
| Tyr | Met | Ala | Ile | Phe | Ala | Leu | Cys | Ala | Lys | Asp | Pro | Val | Lys | Glu |
| | | | | 470 | | | | | 475 | | | | | 480 |
| Arg | Arg | Ala | His | Ala | Arg | Gln | Cys | Leu | Leu | Lys | Asn | Ile | Ser | Ile |
| | | | | 485 | | | | | 490 | | | | | 495 |
| Arg | Arg | Glu | Tyr | Ile | Lys | Gln | Asn | Pro | Met | Ala | Thr | Glu | Lys | Leu |
| | | | | 500 | | | | | 505 | | | | | 510 |
| Leu | Ser | Leu | Leu | Pro | Glu | Tyr | Val | Val | Pro | Tyr | Met | Ile | His | Leu |
| | | | | 515 | | | | | 520 | | | | | 525 |
| Leu | Ala | His | Asp | Pro | Asp | Phe | Thr | Arg | Ser | Gln | Asp | Val | Asp | Gln |
| | | | | 530 | | | | | 535 | | | | | 540 |
| Leu | Arg | Asp | Ile | Lys | Glu | Cys | Leu | Trp | Phe | Met | Leu | Glu | Val | Leu |
| | | | | 545 | | | | | 550 | | | | | 555 |
| Met | Thr | Lys | Asn | Glu | Asn | Asn | Ser | His | Ala | Phe | Met | Lys | Lys | Met |

| | | |
|-------------------------------------|---------------------|-----|
| 560 | 565 | 570 |
| Ala Glu Asn Ile Lys Leu Thr Arg Asp | Ala Gln Ser Pro Asp | Glu |
| 575 | 580 | 585 |
| Ser Lys Thr Asn Glu Lys Leu Tyr Thr | Val Cys Asp Val Ala | Leu |
| 590 | 595 | 600 |
| Cys Val Ile Asn Ser Lys Ser Ala Leu | Cys Asn Ala Asp Ser | Pro |
| 605 | 610 | 615 |
| Lys Asp Pro Val Leu Pro Met Lys Phe | Phe Thr Gln Pro Glu | Lys |
| 620 | 625 | 630 |
| Asp Phe Cys Asn Asp Lys Ser Tyr Ile | Ser Glu Glu Thr Arg | Val |
| 635 | 640 | 645 |
| Leu Leu Leu Thr Gly Lys Pro Lys Pro | Ala Gly Val Leu Gly | Ala |
| 650 | 655 | 660 |
| Val Asn Lys Pro Leu Ser Ala Thr Gly | Arg Lys Pro Tyr Val | Arg |
| 665 | 670 | 675 |
| Ser Thr Gly Thr Glu Thr Gly Ser Asn | Ile Asn Val Asn Ser | Glu |
| 680 | 685 | 690 |
| Leu Asn Pro Ser Thr Gly Asn Arg Ser | Arg Glu Gln Ser Ser | Glu |
| 695 | 700 | 705 |
| Ala Ala Glu Thr Gly Val Ser Glu Asn | Glu Glu Asn Pro Val | Arg |
| 710 | 715 | 720 |
| Ile Ile Ser Val Thr Pro Val Lys Asn | Ile Asp Pro Val Lys | Asn |
| 725 | 730 | 735 |
| Lys Glu Ile Asn Ser Asp Gln Ala Thr | Gln Gly Asn Ile Ser | Ser |
| 740 | 745 | 750 |
| Asp Arg Gly Lys Lys Arg Thr Val Thr | Ala Ala Gly Ala Glu | Asn |
| 755 | 760 | 765 |
| Ile Gln Gln Lys Thr Asp Glu Lys Val | Asp Glu Ser Gly Pro | Pro |
| 770 | 775 | 780 |
| Ala Pro Ser Lys Pro Arg Arg Gly Arg | Arg Pro Lys Ser Glu | Ser |
| 785 | 790 | 795 |
| Gln Gly Asn Ala Thr Lys Asn Asp Asp | Leu Asn Lys Pro Ile | Asn |
| 800 | 805 | 810 |
| Lys Gly Arg Lys Arg Ala Ala Val Gly | Gln Glu Ser Pro Gly | Gly |
| 815 | 820 | 825 |
| Leu Glu Ala Gly Asn Ala Lys Ala Pro | Lys Leu Gln Asp Leu | Ala |
| 830 | 835 | 840 |
| Lys Lys Ala Ala Pro Ala Glu Arg Gln | Ile Asp Leu Gln Arg | |
| 845 | 850 | |

<210> 12

<211> 856

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 3201753CD1

<400> 12

| | |
|---|----------|
| Met Arg Gly Ile Phe Ile Lys His Val Leu Glu Asp Ser Pro Ala | |
| 1 | 5 10 15 |
| Gly Lys Asn Gly Thr Leu Lys Pro Gly Asp Arg Ile Val Glu Val | |
| | 20 25 30 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Gly | Met | Asp | Leu | Arg | Asp | Ala | Ser | His | Glu | Gln | Ala | Val | Glu |
| | | | | 35 | | | | | 40 | | | | | 45 |
| Ala | Ile | Arg | Lys | Ala | Gly | Asn | Pro | Val | Val | Phe | Met | Val | Gln | Ser |
| | | | | 50 | | | | | 55 | | | | | 60 |
| Ile | Ile | Asn | Arg | Pro | Arg | Ala | Pro | Ser | Gln | Ser | Glu | Ser | Glu | Pro |
| | | | | 65 | | | | | 70 | | | | | 75 |
| Glu | Lys | Ala | Pro | Leu | Cys | Ser | Val | Pro | Pro | Pro | Pro | Pro | Ser | Ala |
| | | | | 80 | | | | | 85 | | | | | 90 |
| Phe | Ala | Glu | Met | Gly | Ser | Asp | His | Thr | Gln | Ser | Ser | Ala | Ser | Lys |
| | | | | 95 | | | | | 100 | | | | | 105 |
| Ile | Ser | Gln | Asp | Val | Asp | Lys | Glu | Asp | Glu | Phe | Gly | Tyr | Ser | Trp |
| | | | | 110 | | | | | 115 | | | | | 120 |
| Lys | Asn | Ile | Arg | Glu | Arg | Tyr | Gly | Thr | Leu | Thr | Gly | Glu | Leu | His |
| | | | | 125 | | | | | 130 | | | | | 135 |
| Met | Ile | Glu | Leu | Glu | Lys | Gly | His | Ser | Gly | Leu | Gly | Leu | Ser | Leu |
| | | | | 140 | | | | | 145 | | | | | 150 |
| Ala | Gly | Asn | Lys | Asp | Arg | Ser | Arg | Met | Ser | Val | Phe | Ile | Val | Gly |
| | | | | 155 | | | | | 160 | | | | | 165 |
| Ile | Asp | Pro | Asn | Gly | Ala | Ala | Gly | Lys | Asp | Gly | Arg | Leu | Gln | Ile |
| | | | | 170 | | | | | 175 | | | | | 180 |
| Ala | Asp | Glu | Leu | Leu | Glu | Ile | Asn | Gly | Gln | Ile | Leu | Tyr | Gly | Arg |
| | | | | 185 | | | | | 190 | | | | | 195 |
| Ser | His | Gln | Asn | Ala | Ser | Ser | Ile | Ile | Lys | Cys | Ala | Pro | Ser | Lys |
| | | | | 200 | | | | | 205 | | | | | 210 |
| Val | Lys | Ile | Ile | Phe | Ile | Arg | Asn | Lys | Asp | Ala | Val | Asn | Gln | Met |
| | | | | 215 | | | | | 220 | | | | | 225 |
| Ala | Val | Cys | Pro | Gly | Asn | Ala | Val | Glu | Pro | Leu | Pro | Ser | Asn | Ser |
| | | | | 230 | | | | | 235 | | | | | 240 |
| Glu | Asn | Leu | Gln | Asn | Lys | Glu | Thr | Glu | Pro | Thr | Val | Thr | Thr | Ser |
| | | | | 245 | | | | | 250 | | | | | 255 |
| Asp | Ala | Ala | Val | Asp | Leu | Ser | Ser | Phe | Lys | Asn | Val | Gln | His | Leu |
| | | | | 260 | | | | | 265 | | | | | 270 |
| Glu | Leu | Pro | Lys | Asp | Gln | Gly | Gly | Leu | Gly | Ile | Ala | Ile | Ser | Glu |
| | | | | 275 | | | | | 280 | | | | | 285 |
| Glu | Asp | Thr | Leu | Ser | Gly | Val | Ile | Ile | Lys | Ser | Leu | Thr | Glu | His |
| | | | | 290 | | | | | 295 | | | | | 300 |
| Gly | Val | Ala | Ala | Thr | Asp | Gly | Arg | Leu | Lys | Val | Gly | Asp | Gln | Ile |
| | | | | 305 | | | | | 310 | | | | | 315 |
| Leu | Ala | Val | Asp | Asp | Glu | Ile | Val | Val | Gly | Tyr | Pro | Ile | Glu | Lys |
| | | | | 320 | | | | | 325 | | | | | 330 |
| Phe | Ile | Ser | Leu | Leu | Lys | Thr | Ala | Lys | Met | Thr | Val | Lys | Leu | Thr |
| | | | | 335 | | | | | 340 | | | | | 345 |
| Ile | His | Ala | Glu | Asn | Pro | Asp | Ser | Gln | Ala | Val | Pro | Ser | Ala | Ala |
| | | | | 350 | | | | | 355 | | | | | 360 |
| Gly | Ala | Ala | Ser | Gly | Glu | Lys | Lys | Asn | Ser | Ser | Gln | Ser | Leu | Met |
| | | | | 365 | | | | | 370 | | | | | 375 |
| Val | Pro | Gln | Ser | Gly | Ser | Pro | Glu | Pro | Glu | Ser | Ile | Arg | Asn | Thr |
| | | | | 380 | | | | | 385 | | | | | 390 |
| Ser | Arg | Ser | Ser | Thr | Pro | Ala | Ile | Phe | Ala | Ser | Asp | Pro | Ala | Thr |
| | | | | 395 | | | | | 400 | | | | | 405 |
| Cys | Pro | Ile | Ile | Pro | Gly | Cys | Glu | Thr | Thr | Ile | Glu | Ile | Ser | Lys |
| | | | | 410 | | | | | 415 | | | | | 420 |
| Gly | Arg | Thr | Gly | Leu | Gly | Leu | Ser | Ile | Val | Gly | Gly | Ser | Asp | Thr |
| | | | | 425 | | | | | 430 | | | | | 435 |
| Leu | Leu | Gly | Ala | Ile | Ile | Ile | His | Glu | Val | Tyr | Glu | Glu | Gly | Ala |

| | | | | | |
|-----------------|-----|-----------------|-----|-----------------------------|-----|
| Ala Cys Lys Asp | 440 | Gly Arg Leu Trp | 445 | Ala Gly Asp Gln Ile Leu Glu | 450 |
| | 455 | | 460 | | 465 |
| Val Asn Gly Ile | 470 | Asp Leu Arg Lys | 475 | Ala Thr His Asp Glu Ala Ile | 480 |
| Asn Val Leu Arg | 485 | Gln Thr Pro Gln | 490 | Arg Val Arg Leu Thr Leu Tyr | 495 |
| Arg Asp Glu Ala | 500 | Pro Tyr Lys Glu | 505 | Glu Val Cys Asp Thr Leu | 510 |
| Thr Ile Glu Leu | 515 | Gln Lys Lys Pro | 520 | Gly Lys Gly Leu Gly Leu Ser | 525 |
| Ile Val Gly Lys | 530 | Arg Asn Asp Thr | 535 | Gly Val Phe Val Ser Asp Ile | 540 |
| Val Lys Gly Gly | 545 | Ile Ala Asp Ala | 550 | Asp Gly Arg Leu Met Gln Gly | 555 |
| Asp Gln Ile Leu | 560 | Met Val Asn Gly | 565 | Glu Asp Val Arg Asn Ala Thr | 570 |
| Gln Glu Ala Val | 575 | Ala Ala Leu Leu | 580 | Lys Cys Ser Leu Gly Thr Val | 585 |
| Thr Leu Glu Val | 590 | Gly Arg Ile Lys | 595 | Ala Gly Pro Phe His Ser Glu | 600 |
| Arg Arg Pro Ser | 605 | Gln Ser Ser Gln | 610 | Val Ser Glu Gly Ser Leu Ser | 615 |
| Ser Phe Thr Phe | 620 | Pro Leu Ser Gly | 625 | Ser Ser Thr Ser Glu Ser Leu | 630 |
| Glu Ser Ser Ser | 635 | Lys Lys Asn Ala | 640 | Leu Ala Ser Glu Ile Gln Gly | 645 |
| Leu Arg Thr Val | 650 | Glu Met Lys Lys | 655 | Gly Pro Thr Asp Ser Leu Gly | 660 |
| Ile Ser Ile Ala | 665 | Gly Gly Val Gly | 670 | Ser Pro Leu Gly Asp Val Pro | 675 |
| Ile Phe Ile Ala | 680 | Met Met His Pro | 685 | Thr Gly Val Ala Ala Gln Thr | 690 |
| Gln Lys Leu Arg | 695 | Val Gly Asp Arg | 700 | Ile Val Thr Ile Cys Gly Thr | 705 |
| Ser Thr Glu Gly | 710 | Met Thr His Thr | 715 | Gln Ala Val Asn Leu Leu Lys | 720 |
| Asn Ala Ser Gly | 725 | Ser Ile Glu Met | 730 | Gln Val Val Ala Gly Gly Asp | 735 |
| Val Ser Val Val | 740 | Thr Gly His Gln | 745 | Gln Glu Pro Ala Ser Ser Ser | 750 |
| Leu Ser Phe Thr | 755 | Gly Leu Thr Ser | 760 | Ser Ser Ile Phe Gln Asp Asp | 765 |
| Leu Gly Pro Pro | 770 | Gln Cys Lys Ser | 775 | Ile Thr Leu Glu Arg Gly Pro | 780 |
| Asp Gly Leu Gly | 785 | Phe Ser Ile Val | 790 | Gly Gly Tyr Gly Ser Pro His | 795 |
| Gly Asp Leu Pro | 800 | Ile Tyr Val Lys | 805 | Thr Val Phe Ala Lys Gly Ala | 810 |
| Ala Ser Glu Asp | 815 | Gly Arg Leu Lys | 820 | Arg Gly Asp Gln Ile Ile Ala | 825 |
| Val Asn Gly Gln | 830 | Ser Leu Glu Gly | 835 | Val Thr His Glu Glu Ala Val | 840 |

Ala Ile Leu Lys Arg Thr Lys Gly Thr Val Thr Leu Met Val Leu
 845 850 855
 Ser

<210> 13

<211> 361

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 3800639CD1

<400> 13

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Thr | Gly | Ala | Ala | Glu | Leu | Tyr | Asp | Gln | Ala | Leu | Leu | Gly |
| 1 | | | 5 | | | | | | 10 | | | | | 15 |
| Ile | Leu | Gln | His | Val | Gly | Asn | Val | Gln | Asp | Phe | Leu | Arg | Val | Leu |
| | | | 20 | | | | | | 25 | | | | | 30 |
| Phe | Gly | Phe | Leu | Tyr | Arg | Lys | Thr | Asp | Phe | Tyr | Arg | Leu | Leu | Arg |
| | | | 35 | | | | | | 40 | | | | | 45 |
| His | Pro | Ser | Asp | Arg | Met | Gly | Phe | Pro | Pro | Gly | Ala | Ala | Gln | Ala |
| | | | 50 | | | | | | 55 | | | | | 60 |
| Leu | Val | Leu | Gln | Val | Phe | Lys | Thr | Phe | Asp | His | Met | Ala | Arg | Gln |
| | | | 65 | | | | | | 70 | | | | | 75 |
| Asp | Asp | Glu | Lys | Arg | Arg | Gln | Glu | Leu | Glu | Glu | Lys | Ile | Arg | Arg |
| | | | 80 | | | | | | 85 | | | | | 90 |
| Lys | Glu | Glu | Glu | Glu | Ala | Lys | Thr | Val | Ser | Ala | Ala | Ala | Ala | Glu |
| | | | 95 | | | | | | 100 | | | | | 105 |
| Lys | Glu | Pro | Val | Pro | Val | Pro | Val | Gln | Glu | Ile | Glu | Ile | Asp | Ser |
| | | | 110 | | | | | | 115 | | | | | 120 |
| Thr | Thr | Glu | Leu | Asp | Gly | His | Gln | Glu | Val | Glu | Lys | Val | Gln | Pro |
| | | | 125 | | | | | | 130 | | | | | 135 |
| Pro | Gly | Pro | Val | Lys | Glu | Met | Ala | His | Gly | Ser | Gln | Glu | Ala | Glu |
| | | | 140 | | | | | | 145 | | | | | 150 |
| Ala | Pro | Gly | Ala | Val | Ala | Gly | Ala | Ala | Glu | Val | Pro | Arg | Glu | Pro |
| | | | 155 | | | | | | 160 | | | | | 165 |
| Pro | Ile | Leu | Pro | Arg | Ile | Gln | Glu | Gln | Phe | Gln | Lys | Asn | Pro | Asp |
| | | | 170 | | | | | | 175 | | | | | 180 |
| Ser | Tyr | Asn | Gly | Ala | Val | Arg | Glu | Asn | Tyr | Thr | Trp | Ser | Gln | Asp |
| | | | 185 | | | | | | 190 | | | | | 195 |
| Tyr | Thr | Asp | Leu | Glu | Val | Arg | Val | Pro | Val | Pro | Lys | His | Val | Val |
| | | | 200 | | | | | | 205 | | | | | 210 |
| Lys | Gly | Lys | Gln | Val | Ser | Val | Ala | Leu | Ser | Ser | Ser | Ser | Ile | Arg |
| | | | 215 | | | | | | 220 | | | | | 225 |
| Val | Ala | Met | Leu | Glu | Glu | Asn | Gly | Glu | Arg | Val | Leu | Met | Glu | Gly |
| | | | 230 | | | | | | 235 | | | | | 240 |
| Lys | Leu | Thr | His | Lys | Ile | Asn | Thr | Glu | Ser | Ser | Leu | Trp | Ser | Leu |
| | | | 245 | | | | | | 250 | | | | | 255 |
| Glu | Pro | Gly | Lys | Cys | Val | Leu | Val | Asn | Leu | Ser | Lys | Val | Gly | Glu |
| | | | 260 | | | | | | 265 | | | | | 270 |
| Tyr | Trp | Trp | Asn | Ala | Ile | Leu | Glu | Gly | Glu | Glu | Pro | Ile | Asp | Ile |
| | | | 275 | | | | | | 280 | | | | | 285 |
| Asp | Lys | Ile | Asn | Lys | Glu | Arg | Ser | Met | Ala | Thr | Val | Asp | Glu | Glu |
| | | | 290 | | | | | | 295 | | | | | 300 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Gln | Ala | Val | Leu | Asp | Arg | Leu | Thr | Phe | Asp | Tyr | His | Gln | Lys |
| | | | | 305 | | | | | 310 | | | | | 315 |
| Leu | Gln | Gly | Lys | Pro | Gln | Ser | His | Glu | Leu | Lys | Val | His | Glu | Met |
| | | | | 320 | | | | | 325 | | | | | 330 |
| Leu | Lys | Lys | Gly | Trp | Asp | Ala | Glu | Gly | Ser | Pro | Phe | Arg | Gly | Gln |
| | | | | 335 | | | | | 340 | | | | | 345 |
| Arg | Phe | Asp | Pro | Ala | Met | Phe | Asn | Ile | Ser | Pro | Gly | Ala | Val | Gln |
| | | | | 350 | | | | | 355 | | | | | 360 |
| Phe | | | | | | | | | | | | | | |

<210> 14

<211> 632

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 533825CD1

<400> 14

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Lys | Ala | Leu | Leu | Leu | Leu | Val | Leu | Pro | Trp | Leu | Ser | Pro | Ala |
| 1 | | | 5 | | | | | | 10 | | | | | 15 |
| Asn | Tyr | Ile | Asp | Asn | Val | Gly | Asn | Leu | His | Phe | Leu | Tyr | Ser | Glu |
| | | | 20 | | | | | | 25 | | | | | 30 |
| Leu | Cys | Lys | Gly | Ala | Ser | His | Tyr | Gly | Leu | Thr | Lys | Asp | Arg | Lys |
| | | | 35 | | | | | | 40 | | | | | 45 |
| Arg | Arg | Ser | Gln | Asp | Gly | Cys | Pro | Asp | Gly | Cys | Ala | Ser | Leu | Thr |
| | | | 50 | | | | | | 55 | | | | | 60 |
| Ala | Thr | Ala | Pro | Ser | Pro | Glu | Val | Ser | Ala | Ala | Ala | Thr | Ile | Ser |
| | | | 65 | | | | | | 70 | | | | | 75 |
| Leu | Met | Thr | Asp | Glu | Pro | Gly | Leu | Asp | Asn | Pro | Ala | Tyr | Val | Ser |
| | | | 80 | | | | | | 85 | | | | | 90 |
| Ser | Ala | Glu | Asp | Gly | Gln | Pro | Ala | Ile | Ser | Pro | Val | Asp | Ser | Gly |
| | | | 95 | | | | | | 100 | | | | | 105 |
| Arg | Ser | Asn | Arg | Thr | Arg | Ala | Arg | Pro | Phe | Glu | Arg | Ser | Thr | Ile |
| | | | 110 | | | | | | 115 | | | | | 120 |
| Arg | Ser | Arg | Ser | Phe | Lys | Lys | Ile | Asn | Arg | Ala | Leu | Ser | Val | Leu |
| | | | 125 | | | | | | 130 | | | | | 135 |
| Arg | Arg | Thr | Lys | Ser | Gly | Ser | Ala | Val | Ala | Asn | His | Ala | Asp | Gln |
| | | | 140 | | | | | | 145 | | | | | 150 |
| Gly | Arg | Glu | Asn | Ser | Glu | Asn | Ile | Thr | Ala | Pro | Glu | Val | Phe | Pro |
| | | | 155 | | | | | | 160 | | | | | 165 |
| Arg | Leu | Tyr | His | Leu | Ile | Pro | Asp | Gly | Glu | Ile | Thr | Ser | Ile | Lys |
| | | | 170 | | | | | | 175 | | | | | 180 |
| Ile | Asn | Arg | Val | Asp | Pro | Ser | Glu | Ser | Leu | Ser | Ile | Arg | Leu | Val |
| | | | 185 | | | | | | 190 | | | | | 195 |
| Gly | Gly | Ser | Glu | Thr | Pro | Leu | Val | His | Ile | Ile | Ile | Gln | His | Ile |
| | | | 200 | | | | | | 205 | | | | | 210 |
| Tyr | Arg | Asp | Gly | Val | Ile | Ala | Arg | Asp | Gly | Arg | Leu | Leu | Pro | Gly |
| | | | 215 | | | | | | 220 | | | | | 225 |
| Asp | Ile | Ile | Leu | Lys | Val | Asn | Gly | Met | Asp | Ile | Ser | Asn | Val | Pro |
| | | | 230 | | | | | | 235 | | | | | 240 |
| His | Asn | Tyr | Ala | Val | Arg | Leu | Leu | Arg | Gln | Pro | Cys | Gln | Val | Leu |
| | | | 245 | | | | | | 250 | | | | | 255 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Trp | Leu | Thr | Val | Met | Arg | Glu | Gln | Lys | Phe | Arg | Ser | Arg | Asn | Asn | |
| | | | | 260 | | | | | 265 | | | | | 270 | |
| Gly | Gln | Ala | Pro | Asp | Ala | Tyr | Arg | Pro | Arg | Asp | Asp | Ser | Phe | His | |
| | | | | 275 | | | | | 280 | | | | | 285 | |
| Val | Ile | Leu | Asn | Lys | Ser | Ser | Pro | Glu | Glu | Gln | Leu | Gly | Ile | Lys | |
| | | | | 290 | | | | | 295 | | | | | 300 | |
| Leu | Val | Arg | Lys | Val | Asp | Glu | Pro | Gly | Val | Phe | Ile | Phe | Asn | Val | |
| | | | | 305 | | | | | 310 | | | | | 315 | |
| Leu | Asp | Gly | Gly | Val | Ala | Tyr | Arg | His | Gly | Gln | Leu | Glu | Glu | Asn | |
| | | | | 320 | | | | | 325 | | | | | 330 | |
| Asp | Arg | Val | Leu | Ala | Ile | Asn | Gly | His | Asp | Leu | Arg | Tyr | Gly | Ser | |
| | | | | 335 | | | | | 340 | | | | | 345 | |
| Pro | Glu | Ser | Ala | Ala | His | Leu | Ile | Gln | Ala | Ser | Glu | Arg | Arg | Val | |
| | | | | 350 | | | | | 355 | | | | | 360 | |
| His | Leu | Val | Val | Ser | Arg | Gln | Val | Arg | Gln | Arg | Ser | Pro | Asp | Ile | |
| | | | | 365 | | | | | 370 | | | | | 375 | |
| Phe | Gln | Glu | Ala | Gly | Trp | Asn | Ser | Asn | Gly | Ser | Trp | Ser | Pro | Gly | |
| | | | | 380 | | | | | 385 | | | | | 390 | |
| Pro | Gly | Glu | Arg | Ser | Asn | Thr | Pro | Lys | Pro | Leu | His | Pro | Thr | Ile | |
| | | | | 395 | | | | | 400 | | | | | 405 | |
| Thr | Cys | His | Glu | Lys | Val | Val | Asn | Ile | Gln | Lys | Asp | Pro | Gly | Glu | |
| | | | | 410 | | | | | 415 | | | | | 420 | |
| Ser | Leu | Gly | Met | Ala | Val | Ala | Gly | Gly | Ala | Ser | His | Arg | Glu | Trp | |
| | | | | 425 | | | | | 430 | | | | | 435 | |
| Asp | Leu | Pro | Ile | Tyr | Val | Ile | Ser | Val | Glu | Pro | Gly | Gly | Val | Ile | |
| | | | | 440 | | | | | 445 | | | | | 450 | |
| Ser | Arg | Asp | Gly | Arg | Ile | Lys | Thr | Gly | Asp | Ile | Leu | Leu | Asn | Val | |
| | | | | 455 | | | | | 460 | | | | | 465 | |
| Asp | Gly | Val | Glu | Leu | Thr | Glu | Val | Ser | Arg | Ser | Glu | Ala | Val | Ala | |
| | | | | 470 | | | | | 475 | | | | | 480 | |
| Leu | Leu | Lys | Arg | Thr | Ser | Ser | Ser | Ile | Val | Leu | Lys | Ala | Leu | Glu | |
| | | | | 485 | | | | | 490 | | | | | 495 | |
| Val | Lys | Glu | Tyr | Glu | Pro | Gln | Glu | Asp | Cys | Ser | Ser | Pro | Ala | Ala | |
| | | | | 500 | | | | | 505 | | | | | 510 | |
| Leu | Asp | Ser | Asn | His | Asn | Met | Ala | Pro | Pro | Ser | Asp | Trp | Ser | Pro | |
| | | | | 515 | | | | | 520 | | | | | 525 | |
| Ser | Trp | Val | Met | Trp | Leu | Glu | Leu | Pro | Arg | Cys | Leu | Tyr | Asn | Cys | |
| | | | | 530 | | | | | 535 | | | | | 540 | |
| Lys | Asp | Ile | Val | Leu | Arg | Arg | Asn | Thr | Ala | Gly | Ser | Leu | Gly | Phe | |
| | | | | 545 | | | | | 550 | | | | | 555 | |
| Cys | Ile | Val | Gly | Gly | Tyr | Glu | Glu | Tyr | Asn | Gly | Asn | Lys | Pro | Phe | |
| | | | | 560 | | | | | 565 | | | | | 570 | |
| Phe | Ile | Lys | Ser | Ile | Val | Glu | Gly | Thr | Pro | Ala | Tyr | Asn | Asp | Gly | |
| | | | | 575 | | | | | 580 | | | | | 585 | |
| Arg | Ile | Arg | Cys | Gly | Asp | Ile | Leu | Leu | Ala | Val | Asn | Gly | Arg | Ser | |
| | | | | 590 | | | | | 595 | | | | | 600 | |
| Thr | Ser | Gly | Met | Ile | His | Ala | Cys | Leu | Ala | Arg | Leu | Leu | Lys | Glu | |
| | | | | 605 | | | | | 610 | | | | | 615 | |
| Leu | Lys | Gly | Arg | Ile | Thr | Leu | Thr | Ile | Val | Ser | Trp | Pro | Gly | Thr | |
| | | | | 620 | | | | | 625 | | | | | 630 | |
| Phe | Leu | | | | | | | | | | | | | | |

<210> 15
 <211> 391
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1311833CD1

<400> 15
 Met Lys Met Lys Ile Gln Lys Lys Glu Lys Gln Leu Ser Asn Leu
 1 5 10 15
 Lys Val Leu Asn His Ser Pro Met Ser Asp Ala Ser Val Asn Phe
 20 25 30
 Asp Tyr Lys Ser Pro Ser Pro Phe Asp Cys Ser Thr Asp Gln Glu
 35 40 45
 Glu Lys Ile Glu Asp Val Ala Ser His Cys Leu Pro Gln Lys Asp
 50 55 60
 Leu Tyr Thr Ala Glu Glu Glu Ala Ala Thr Leu Phe Pro Arg Lys
 65 70 75
 Met Thr Ser His Asn Gly Met Glu Asp Ser Gly Gly Gly Gly Thr
 80 85 90
 Gly Val Lys Lys Lys Arg Lys Lys Lys Glu Pro Gly Asp Gln Glu
 95 100 105
 Gly Ala Ala Lys Gly Ser Lys Asp Arg Glu Pro Lys Pro Lys Arg
 110 115 120
 Lys Arg Glu Pro Lys Glu Pro Lys Glu Pro Arg Lys Ala Lys Glu
 125 130 135
 Pro Lys Lys Ala Lys Glu His Lys Glu Pro Lys Gln Lys Asp Gly
 140 145 150
 Ala Lys Lys Ala Arg Lys Pro Arg Glu Ala Ser Gly Thr Lys Glu
 155 160 165
 Ala Lys Glu Lys Arg Ser Cys Thr Asp Ser Ala Ala Arg Thr Lys
 170 175 180
 Ser Arg Lys Ala Ser Lys Glu Gln Gly Pro Thr Pro Val Glu Lys
 185 190 195
 Lys Lys Lys Gly Lys Arg Lys Ser Glu Thr Thr Val Glu Ser Leu
 200 205 210
 Glu Leu Asp Gln Gly Leu Thr Asn Pro Ser Leu Arg Ser Pro Glu
 215 220 225
 Glu Ser Thr Glu Ser Thr Asp Ser Gln Lys Arg Arg Ser Gly Arg
 230 235 240
 Gln Val Lys Arg Arg Lys Tyr Asn Glu Asp Leu Asp Phe Lys Val
 245 250 255
 Val Asp Asp Asp Gly Glu Thr Ile Ala Val Leu Gly Ala Gly Arg
 260 265 270
 Thr Ser Ala Leu Ser Ala Ser Thr Leu Ala Trp Gln Ala Glu Glu
 275 280 285
 Pro Pro Glu Asp Asp Ala Asn Ile Ile Glu Lys Ile Leu Ala Ser
 290 295 300
 Lys Thr Val Gln Glu Val His Pro Gly Glu Pro Pro Phe Asp Leu
 305 310 315
 Glu Leu Phe Tyr Val Lys Tyr Arg Asn Phe Ser Tyr Leu His Cys
 320 325 330
 Lys Trp Ala Thr Met Glu Glu Leu Glu Lys Asp Pro Arg Ile Ala

| | | | | | |
|-------------------------------------|-----|-------------------------|-----|--|-----|
| | 335 | | 340 | | 345 |
| Gln Lys Ile Lys Arg Phe Arg Asn Lys | | Gln Ala Gln Met Lys His | | | |
| | 350 | | 355 | | 360 |
| Ile Phe Thr Glu Val Lys Gln Tyr Leu | | Leu Thr His Leu Thr Ala | | | |
| | 365 | | 370 | | 375 |
| Ala Phe Leu Ala Ala Val Asn Thr Val | | Phe Thr Phe Leu Ser Pro | | | |
| | 380 | | 385 | | 390 |
| Ser | | | | | |

<210> 16

<211> 490

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1342819CD1

<400> 16

| | | | |
|---|-----|-----|-----|
| Met Glu Asp Ser Ala Ser Ala Ser Leu Ser Ser Ala Ala Ala Thr | | | |
| 1 | 5 | 10 | 15 |
| Gly Thr Ser Thr Ser Thr Pro Ala Ala Pro Thr Ala Arg Lys Gln | | | |
| | 20 | 25 | 30 |
| Leu Asp Lys Glu Gln Val Arg Lys Ala Val Asp Ala Leu Leu Thr | | | |
| | 35 | 40 | 45 |
| His Cys Lys Ser Arg Lys Asn Asn Tyr Gly Leu Leu Leu Asn Glu | | | |
| | 50 | 55 | 60 |
| Asn Glu Ser Leu Phe Leu Met Val Val Leu Trp Lys Ile Pro Ser | | | |
| | 65 | 70 | 75 |
| Lys Glu Leu Arg Val Arg Leu Thr Leu Pro His Ser Ile Arg Ser | | | |
| | 80 | 85 | 90 |
| Asp Ser Glu Asp Ile Cys Leu Phe Thr Lys Asp Glu Pro Asn Ser | | | |
| | 95 | 100 | 105 |
| Thr Pro Glu Lys Thr Glu Gln Phe Tyr Arg Lys Leu Leu Asn Lys | | | |
| | 110 | 115 | 120 |
| His Gly Ile Lys Thr Val Ser Gln Ile Ile Ser Leu Gln Thr Leu | | | |
| | 125 | 130 | 135 |
| Lys Lys Glu Tyr Lys Ser Tyr Glu Ala Lys Leu Arg Leu Leu Ser | | | |
| | 140 | 145 | 150 |
| Ser Phe Asp Phe Phe Leu Thr Asp Ala Arg Ile Arg Arg Leu Leu | | | |
| | 155 | 160 | 165 |
| Pro Ser Leu Ile Gly Arg His Phe Tyr Gln Arg Lys Lys Val Pro | | | |
| | 170 | 175 | 180 |
| Val Ser Val Asn Leu Leu Ser Lys Asn Leu Ser Arg Glu Ile Asn | | | |
| | 185 | 190 | 195 |
| Asp Cys Ile Gly Gly Thr Val Leu Asn Ile Ser Lys Ser Gly Ser | | | |
| | 200 | 205 | 210 |
| Cys Ser Ala Ile Arg Ile Gly His Val Gly Met Gln Ile Glu His | | | |
| | 215 | 220 | 225 |
| Ile Ile Glu Asn Ile Val Ala Val Thr Lys Gly Leu Ser Glu Lys | | | |
| | 230 | 235 | 240 |
| Leu Pro Glu Lys Trp Glu Ser Val Lys Leu Leu Phe Val Lys Thr | | | |
| | 245 | 250 | 255 |
| Glu Lys Ser Ala Ala Leu Pro Ile Phe Ser Ser Phe Val Ser Asn | | | |

| | | |
|-------------------------------------|-------------------------|-----|
| 260 | 265 | 270 |
| Trp Asp Glu Ala Thr Lys Arg Ser Leu | Leu Asn Lys Lys Lys Lys | |
| 275 | 280 | 285 |
| Glu Ala Arg Arg Lys Arg Arg Glu Arg | Asn Phe Glu Lys Gln Lys | |
| 290 | 295 | 300 |
| Glu Arg Lys Lys Lys Arg Gln Gln Ala | Arg Lys Thr Ala Ser Val | |
| 305 | 310 | 315 |
| Leu Ser Lys Asp Asp Val Ala Pro Glu | Ser Gly Asp Thr Thr Val | |
| 320 | 325 | 330 |
| Lys Lys Pro Glu Ser Lys Lys Glu Gln | Thr Pro Glu His Gly Lys | |
| 335 | 340 | 345 |
| Lys Lys Arg Gly Arg Gly Lys Ala Gln | Val Lys Ala Thr Asn Glu | |
| 350 | 355 | 360 |
| Ser Glu Asp Glu Ile Pro Gln Leu Val | Pro Ile Gly Lys Lys Thr | |
| 365 | 370 | 375 |
| Pro Ala Asn Glu Lys Val Glu Ile Gln | Lys His Ala Thr Gly Lys | |
| 380 | 385 | 390 |
| Lys Ser Pro Ala Lys Ser Pro Asn Pro | Ser Thr Pro Arg Gly Lys | |
| 395 | 400 | 405 |
| Lys Arg Lys Ala Leu Pro Ala Ser Glu | Thr Pro Lys Ala Ala Glu | |
| 410 | 415 | 420 |
| Ser Glu Thr Pro Gly Lys Ser Pro Glu | Lys Lys Pro Lys Ile Lys | |
| 425 | 430 | 435 |
| Glu Glu Ala Val Lys Glu Lys Ser Pro | Ser Leu Gly Lys Lys Asp | |
| 440 | 445 | 450 |
| Ala Arg Gln Thr Pro Lys Lys Pro Glu | Ala Lys Phe Phe Thr Thr | |
| 455 | 460 | 465 |
| Pro Ser Lys Ser Val Arg Lys Ala Ser | His Thr Pro Lys Lys Trp | |
| 470 | 475 | 480 |
| Pro Lys Lys Pro Lys Val Pro Gln Ser | Thr | |
| 485 | 490 | |

<210> 17

<211> 252

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1871288CD1

<400> 17

| | |
|-------------------------------------|-------------------------|
| Met Ala Glu Leu Glu Phe Val Gln Ile | Ile Ile Ile Val Val Val |
| 1 | 5 10 15 |
| Met Met Val Met Val Val Val Ile Thr | Cys Leu Leu Ser His Tyr |
| 20 | 25 30 |
| Lys Leu Ser Ala Arg Ser Phe Ile Ser | Arg His Ser Gln Gly Arg |
| 35 | 40 45 |
| Arg Arg Glu Asp Ala Leu Ser Ser Glu | Gly Cys Leu Trp Pro Ser |
| 50 | 55 60 |
| Glu Ser Thr Val Ser Gly Asn Gly Ile | Pro Glu Pro Gln Val Tyr |
| 65 | 70 75 |
| Ala Pro Pro Arg Pro Thr Asp Arg Leu | Ala Val Pro Pro Phe Ala |
| 80 | 85 90 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Arg | Glu | Arg | Phe | His | Arg | Phe | Gln | Pro | Thr | Tyr | Pro | Tyr | Leu |
| | | | | 95 | | | | | 100 | | | | | 105 |
| Gln | His | Glu | Ile | Asp | Leu | Pro | Pro | Thr | Ile | Ser | Leu | Ser | Asp | Gly |
| | | | | 110 | | | | | 115 | | | | | 120 |
| Glu | Glu | Pro | Pro | Pro | Tyr | Gln | Gly | Pro | Cys | Thr | Leu | Gln | Leu | Arg |
| | | | | 125 | | | | | 130 | | | | | 135 |
| Asp | Pro | Glu | Gln | Gln | Leu | Glu | Leu | Asn | Arg | Glu | Ser | Val | Arg | Ala |
| | | | | 140 | | | | | 145 | | | | | 150 |
| Pro | Pro | Asn | Arg | Thr | Ile | Phe | Asp | Ser | Asp | Leu | Met | Asp | Ser | Ala |
| | | | | 155 | | | | | 160 | | | | | 165 |
| Arg | Leu | Gly | Gly | Pro | Cys | Pro | Pro | Ser | Ser | Asn | Ser | Gly | Ile | Ser |
| | | | | 170 | | | | | 175 | | | | | 180 |
| Ala | Thr | Cys | Tyr | Gly | Ser | Gly | Gly | Arg | Met | Glu | Gly | Pro | Pro | Pro |
| | | | | 185 | | | | | 190 | | | | | 195 |
| Thr | Tyr | Ser | Glu | Val | Ile | Gly | His | Tyr | Pro | Gly | Ser | Ser | Phe | Gln |
| | | | | 200 | | | | | 205 | | | | | 210 |
| His | Gln | Gln | Ser | Ser | Gly | Pro | Pro | Ser | Leu | Leu | Glu | Gly | Thr | Arg |
| | | | | 215 | | | | | 220 | | | | | 225 |
| Leu | His | His | Thr | His | Ile | Ala | Pro | Leu | Glu | Ser | Ala | Ala | Ile | Trp |
| | | | | 230 | | | | | 235 | | | | | 240 |
| Ser | Lys | Glu | Lys | Asp | Lys | Gln | Lys | Gly | His | Pro | Leu | | | |
| | | | | 245 | | | | | 250 | | | | | |

```
<210> 18
<211> 142
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> misc_feature  
<223> Incyte ID No.: 2587338CD1
```

[illegible]

<210> 19
 <211> 67
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 2821211CD1

<400> 19
 Met Glu Ile Ile Glu Asn Ser Phe His Ile Asn Gly Leu Lys Ile
 1 5 10 15
 Asn Gln Arg Thr Leu Cys Val His Val Cys Ile Ser Ala His Arg
 20 25 30
 Asn Ile Tyr Thr Tyr Val Asp Tyr Ile His Val Cys Ile Tyr Val
 35 40 45
 Tyr Ile Tyr Ile His Leu Tyr Lys Cys Ile Tyr Thr Tyr Thr Tyr
 50 55 60
 Asn Val Cys Met Cys Ile Tyr
 65

<210> 20
 <211> 455
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 2824832CD1

<400> 20
 Met Phe Gln Phe His Ala Gly Ser Trp Glu Ser Trp Cys Cys Cys
 1 5 10 15
 Cys Leu Ile Pro Ala Asp Arg Pro Trp Asp Arg Gly Gln His Trp
 20 25 30
 Gln Leu Glu Met Ala Asp Thr Arg Ser Val His Glu Thr Arg Phe
 35 40 45
 Glu Ala Ala Val Lys Val Ile Gln Ser Leu Pro Lys Asn Gly Ser
 50 55 60
 Phe Gln Pro Thr Asn Glu Met Met Leu Lys Phe Tyr Ser Phe Tyr
 65 70 75
 Lys Gln Ala Thr Glu Gly Pro Cys Lys Leu Ser Arg Pro Gly Phe
 80 85 90
 Trp Asp Pro Ile Gly Arg Tyr Lys Trp Asp Ala Trp Ser Ser Leu
 95 100 105
 Gly Asp Met Thr Lys Glu Glu Ala Met Ile Ala Tyr Val Glu Glu
 110 115 120
 Met Lys Lys Ile Ile Glu Thr Met Pro Met Thr Glu Lys Val Glu
 125 130 135
 Glu Leu Leu Arg Val Ile Gly Pro Phe Tyr Glu Ile Val Glu Asp
 140 145 150
 Lys Lys Ser Gly Arg Ser Ser Asp Ile Thr Ser Asp Leu Gly Asn

```

<210> 21
<211> 252
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No.: 3070147CD1

<400> 21
Met Gln Leu Thr Arg Cys Cys Phe
  1                               5

```

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Tyr | Leu | Val | Ile | Cys | Gly | Gln | Asp | Asp | Gly | Pro | Pro | Gly | Ser |
| | | | | 20 | | | | | | 25 | | | | 30 |
| Glu | Asp | Pro | Glu | Arg | Asp | Asp | His | Glu | Gly | Gln | Pro | Arg | Pro | Arg |
| | | | | 35 | | | | | | 40 | | | | 45 |
| Val | Pro | Arg | Lys | Arg | Gly | His | Ile | Ser | Pro | Lys | Ser | Arg | Pro | Met |
| | | | | 50 | | | | | | 55 | | | | 60 |
| Ala | Asn | Ser | Thr | Leu | Leu | Gly | Leu | Leu | Ala | Pro | Thr | Gly | Glu | Ala |
| | | | | 65 | | | | | | 70 | | | | 75 |
| Trp | Gly | Ile | Leu | Gly | Gln | Pro | Pro | Asn | Arg | Pro | Asn | His | Ser | Pro |
| | | | | 80 | | | | | | 85 | | | | 90 |
| Pro | Pro | Ser | Ala | Lys | Val | Lys | Lys | Ile | Phe | Gly | Trp | Gly | Asp | Phe |
| | | | | 95 | | | | | | 100 | | | | 105 |
| Tyr | Ser | Asn | Ile | Lys | Thr | Val | Ala | Leu | Asn | Leu | Leu | Val | Thr | Gly |
| | | | | 110 | | | | | | 115 | | | | 120 |
| Lys | Ile | Val | Asp | His | Gly | Asn | Gly | Thr | Phe | Ser | Val | His | Phe | Gln |
| | | | | 125 | | | | | | 130 | | | | 135 |
| His | Asn | Ala | Thr | Gly | Gln | Gly | Asn | Ile | Ser | Ile | Ser | Leu | Val | Pro |
| | | | | 140 | | | | | | 145 | | | | 150 |
| Pro | Ser | Lys | Ala | Val | Glu | Phe | His | Gln | Glu | Gln | Gln | Ile | Phe | Ile |
| | | | | 155 | | | | | | 160 | | | | 165 |
| Glu | Ala | Lys | Ala | Ser | Lys | Ile | Phe | Asn | Cys | Arg | Met | Glu | Trp | Glu |
| | | | | 170 | | | | | | 175 | | | | 180 |
| Lys | Val | Glu | Arg | Gly | Arg | Arg | Thr | Ser | Leu | Cys | Thr | His | Asp | Pro |
| | | | | 185 | | | | | | 190 | | | | 195 |
| Ala | Lys | Ile | Cys | Ser | Arg | Asp | His | Ala | Gln | Ser | Ser | Ala | Thr | Trp |
| | | | | 200 | | | | | | 205 | | | | 210 |
| Ser | Cys | Ser | Gln | Pro | Phe | Lys | Val | Val | Cys | Val | Tyr | Ile | Ala | Phe |
| | | | | 215 | | | | | | 220 | | | | 225 |
| Tyr | Ser | Thr | Asp | Tyr | Arg | Leu | Val | Gln | Lys | Val | Cys | Pro | Asp | Tyr |
| | | | | 230 | | | | | | 235 | | | | 240 |
| Asn | Tyr | His | Ser | Asp | Thr | Pro | Tyr | Tyr | Pro | Ser | Gly | | | |
| | | | | 245 | | | | | | 250 | | | | |

<210> 22

<211> 149

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 3271841CD1

<400> 22

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Ser | Arg | Gly | Lys | Ser | Ala | Ser | Ser | Pro | Lys | Pro | Asp | Thr |
| | | | | 5 | | | | | | 10 | | | | 15 |
| Lys | Val | Pro | Gln | Val | Thr | Thr | Glu | Ala | Lys | Val | Pro | Pro | Ala | Ala |
| | | | | 20 | | | | | | 25 | | | | 30 |
| Asp | Gly | Lys | Ala | Pro | Leu | Thr | Lys | Pro | Ser | Lys | Lys | Glu | Ala | Pro |
| | | | | 35 | | | | | | 40 | | | | 45 |
| Ala | Glu | Lys | Gln | Gln | Pro | Pro | Ala | Ala | Pro | Thr | Thr | Ala | Pro | Ala |
| | | | | 50 | | | | | | 55 | | | | 60 |
| Lys | Lys | Thr | Ser | Ala | Lys | Ala | Asp | Pro | Ala | Leu | Leu | Asn | Asn | His |
| | | | | 65 | | | | | | 70 | | | | 75 |
| Ser | Asn | Leu | Lys | Pro | Ala | Pro | Thr | Val | Pro | Ser | Ser | Pro | Asp | Ala |

```
<210> 24
<211> 367
<212> PRT
<213> Homo sapiens
```


<220>

<221> misc_feature

<223> Incyte ID No.: 3729267CD1

<400> 24

```

Met Ala Ser Glu Leu Cys Lys Thr Ile Ser Val Ala Arg Leu Glu
 1          5          10          15
Lys His Lys Asn Leu Phe Leu Asn Tyr Arg Asn Leu His His Phe
          20          25          30
Pro Leu Glu Leu Leu Lys Asp Glu Gly Leu Gln Tyr Leu Glu Arg
          35          40          45
Leu Tyr Met Lys Arg Asn Ser Leu Thr Ser Leu Pro Glu Asn Leu
          50          55          60
Ala Gln Lys Leu Pro Asn Leu Val Glu Leu Tyr Leu His Ser Asn
          65          70          75
Asn Ile Val Val Val Pro Glu Ala Ile Gly Ser Leu Val Lys Leu
          80          85          90
Gln Cys Leu Asp Leu Ser Asp Asn Ala Leu Glu Ile Val Cys Pro
          95          100          105
Glu Ile Gly Arg Leu Arg Ala Leu Arg His Leu Arg Leu Ala Asn
          110          115          120
Asn Gln Leu Gln Phe Leu Pro Pro Glu Val Gly Asp Leu Lys Glu
          125          130          135
Leu Gln Thr Leu Asp Ile Ser Thr Asn Arg Leu Leu Thr Leu Pro
          140          145          150
Glu Arg Leu His Met Cys Leu Ser Leu Gln Tyr Leu Thr Val Asp
          155          160          165
Arg Asn Arg Leu Trp Tyr Val Pro Arg His Leu Cys Gln Leu Pro
          170          175          180
Ser Leu Asn Glu Leu Ser Met Ala Gly Asn Arg Leu Ala Phe Leu
          185          190          195
Pro Leu Asp Leu Gly Arg Ser Arg Glu Leu Gln Tyr Val Tyr Val
          200          205          210
Asp Asn Asn Ile His Leu Lys Gly Leu Pro Ser Tyr Leu Tyr Asn
          215          220          225
Lys Val Ile Gly Cys Ser Gly Cys Gly Ala Pro Ile Gln Val Ser
          230          235          240
Glu Val Lys Leu Leu Ser Phe Ser Ser Gly Gln Arg Thr Val Phe
          245          250          255
Leu Pro Ala Glu Val Lys Ala Ile Gly Thr Glu His Asp His Val
          260          265          270
Leu Pro Leu Gln Glu Leu Ala Met Arg Gly Leu Tyr His Thr Tyr
          275          280          285
His Ser Leu Leu Lys Asp Leu Asn Phe Leu Ser Pro Ile Ser Leu
          290          295          300
Pro Arg Ser Leu Leu Glu Leu Leu His Cys Pro Leu Gly His Cys
          305          310          315
His Arg Cys Ser Glu Pro Met Phe Thr Ile Val Tyr Pro Lys Leu
          320          325          330
Phe Pro Leu Arg Glu Thr Pro Met Ala Gly Leu His Gln Trp Lys
          335          340          345
Thr Thr Val Ser Phe Val Ala Tyr Cys Cys Ser Thr Gln Cys Leu
          350          355          360
Gln Thr Phe Asp Leu Leu Ser
          365

```

<210> 25
 <211> 681
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 3768771CD1

<400> 25
 Met Cys Thr Tyr Ile Asn Met Glu Asn Phe Thr Leu Ala Arg Asp
 1 5 10 15
 Glu Lys Gly Asn Val Leu Leu Glu Asp Gly Lys Gly Arg Cys Pro
 20 25 30
 Phe Asp Pro Asn Phe Lys Ser Thr Ala Leu Val Val Asp Gly Glu
 35 40 45
 Leu Tyr Thr Gly Thr Val Ser Ser Phe Gln Gly Asn Asp Pro Ala
 50 55 60
 Ile Ser Arg Ser Gln Ser Leu Arg Pro Thr Lys Thr Glu Ser Ser
 65 70 75
 Leu Asn Trp Leu Gln Asp Pro Ala Phe Val Ala Ser Ala Tyr Ile
 80 85 90
 Pro Glu Ser Leu Gly Ser Leu Gln Gly Asp Asp Asp Lys Ile Tyr
 95 100 105
 Phe Phe Phe Ser Glu Thr Gly Gln Glu Phe Glu Phe Phe Glu Asn
 110 115 120
 Thr Ile Val Ser Arg Ile Ala Arg Ile Cys Lys Gly Asp Glu Gly
 125 130 135
 Gly Glu Arg Val Leu Gln Gln Arg Trp Thr Ser Phe Leu Lys Ala
 140 145 150
 Gln Leu Leu Cys Ser Arg Pro Asp Asp Gly Phe Pro Phe Asn Val
 155 160 165
 Leu Gln Asp Val Phe Thr Leu Ser Pro Ser Pro Gln Asp Trp Arg
 170 175 180
 Asp Thr Leu Phe Tyr Gly Val Phe Thr Ser Gln Trp His Arg Gly
 185 190 195
 Thr Thr Glu Gly Ser Ala Val Cys Val Phe Thr Met Lys Asp Val
 200 205 210
 Gln Arg Val Phe Ser Gly Leu Tyr Lys Glu Val Asn Arg Glu Thr
 215 220 225
 Gln Gln Trp Tyr Thr Val Thr His Pro Val Pro Thr Pro Arg Pro
 230 235 240
 Gly Ala Cys Ile Thr Asn Ser Ala Arg Glu Arg Lys Ile Asn Ser
 245 250 255
 Ser Leu Gln Leu Pro Asp Arg Val Leu Asn Phe Leu Lys Asp His
 260 265 270
 Phe Leu Met Asp Gly Gln Val Arg Ser Arg Met Leu Leu Leu Gln
 275 280 285
 Pro Gln Ala Arg Tyr Gln Arg Val Ala Val His Arg Val Pro Gly
 290 295 300
 Leu His His Thr Tyr Asp Val Leu Phe Leu Gly Thr Gly Asp Gly
 305 310 315

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Leu | His | Lys | Ala | Val | Ser | Val | Gly | Pro | Arg | Val | His | Ile | Ile |
| | | | | 320 | | | | | 325 | | | | | 330 |
| Glu | Glu | Leu | Gln | Ile | Phe | Ser | Ser | Gly | Gln | Pro | Val | Gln | Asn | Leu |
| | | | | 335 | | | | | 340 | | | | | 345 |
| Leu | Leu | Asp | Thr | His | Arg | Gly | Leu | Leu | Tyr | Ala | Ala | Ser | His | Ser |
| | | | | 350 | | | | | 355 | | | | | 360 |
| Gly | Val | Val | Gln | Val | Pro | Met | Ala | Asn | Cys | Ser | Leu | Tyr | Arg | Ser |
| | | | | 365 | | | | | 370 | | | | | 375 |
| Cys | Gly | Asp | Cys | Leu | Leu | Ala | Arg | Asp | Pro | Tyr | Cys | Ala | Trp | Ser |
| | | | | 380 | | | | | 385 | | | | | 390 |
| Gly | Ser | Ser | Cys | Lys | His | Val | Ser | Leu | Tyr | Gln | Pro | Gln | Leu | Ala |
| | | | | 395 | | | | | 400 | | | | | 405 |
| Thr | Arg | Pro | Trp | Ile | Gln | Asp | Ile | Glu | Gly | Ala | Ser | Ala | Lys | Asp |
| | | | | 410 | | | | | 415 | | | | | 420 |
| Leu | Cys | Ser | Ala | Ser | Ser | Val | Val | Ser | Pro | Ser | Phe | Val | Pro | Thr |
| | | | | 425 | | | | | 430 | | | | | 435 |
| Gly | Glu | Lys | Pro | Cys | Glu | Gln | Val | Gln | Phe | Gln | Pro | Asn | Thr | Val |
| | | | | 440 | | | | | 445 | | | | | 450 |
| Asn | Thr | Leu | Ala | Cys | Pro | Leu | Leu | Ser | Asn | Leu | Ala | Thr | Arg | Leu |
| | | | | 455 | | | | | 460 | | | | | 465 |
| Trp | Leu | Arg | Asn | Gly | Ala | Pro | Val | Asn | Ala | Ser | Ala | Ser | Cys | His |
| | | | | 470 | | | | | 475 | | | | | 480 |
| Val | Leu | Pro | Thr | Gly | Asp | Leu | Leu | Leu | Val | Gly | Thr | Gln | Gln | Leu |
| | | | | 485 | | | | | 490 | | | | | 495 |
| Gly | Glu | Phe | Gln | Cys | Trp | Ser | Leu | Glu | Glu | Gly | Phe | Gln | Gln | Leu |
| | | | | 500 | | | | | 505 | | | | | 510 |
| Val | Ala | Ser | Tyr | Cys | Pro | Glu | Val | Val | Glu | Asp | Gly | Val | Ala | Asp |
| | | | | 515 | | | | | 520 | | | | | 525 |
| Gln | Thr | Asp | Glu | Gly | Gly | Ser | Val | Pro | Val | Ile | Ile | Ser | Thr | Ser |
| | | | | 530 | | | | | 535 | | | | | 540 |
| Arg | Val | Ser | Ala | Pro | Ala | Gly | Gly | Lys | Ala | Ser | Trp | Gly | Ala | Asp |
| | | | | 545 | | | | | 550 | | | | | 555 |
| Arg | Ser | Tyr | Trp | Lys | Glu | Phe | Leu | Val | Met | Cys | Thr | Leu | Phe | Val |
| | | | | 560 | | | | | 565 | | | | | 570 |
| Leu | Ala | Val | Leu | Leu | Pro | Val | Leu | Phe | Leu | Leu | Tyr | Arg | His | Arg |
| | | | | 575 | | | | | 580 | | | | | 585 |
| Asn | Ser | Met | Lys | Val | Phe | Leu | Lys | Gln | Gly | Glu | Cys | Ala | Ser | Val |
| | | | | 590 | | | | | 595 | | | | | 600 |
| His | Pro | Lys | Thr | Cys | Pro | Val | Val | Leu | Pro | Pro | Glu | Thr | Arg | Pro |
| | | | | 605 | | | | | 610 | | | | | 615 |
| Leu | Asn | Gly | Leu | Gly | Pro | Pro | Ser | Thr | Pro | Leu | Asp | His | Arg | Gly |
| | | | | 620 | | | | | 625 | | | | | 630 |
| Tyr | Gln | Ser | Leu | Ser | Asp | Ser | Pro | Pro | Gly | Ser | Arg | Val | Phe | Thr |
| | | | | 635 | | | | | 640 | | | | | 645 |
| Glu | Ser | Glu | Lys | Arg | Pro | Leu | Ser | Ile | Gln | Asp | Ser | Phe | Val | Glu |
| | | | | 650 | | | | | 655 | | | | | 660 |
| Val | Ser | Pro | Val | Cys | Pro | Arg | Pro | Arg | Val | Arg | Leu | Gly | Ser | Glu |
| | | | | 665 | | | | | 670 | | | | | 675 |
| Ile | Arg | Asp | Ser | Val | Val | | | | | | | | | |
| | | | | 680 | | | | | | | | | | |

<210> 26
 <211> 137
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 4248993CD1

<400> 26
 Met Gly Arg Lys Leu Asp Leu Ser Gly Leu Thr Asp Asp Glu Thr
 1 5 10 15
 Glu His Val Leu Gln Val Val Gln Arg Asp Phe Asn Leu Arg Lys
 20 25 30
 Lys Glu Glu Glu Arg Leu Ser Glu Leu Lys Gln Lys Leu Asp Glu
 35 40 45
 Glu Gly Ser Lys Cys Ser Ile Leu Ser Lys His Gln Gln Phe Val
 50 55 60
 Glu His Cys Cys Met Arg Cys Cys Ser Pro Phe Thr Phe Leu Val
 65 70 75
 Asn Thr Lys Arg Gln Cys Gly Asp Cys Lys Phe Asn Val Cys Lys
 80 85 90
 Ser Cys Cys Ser Tyr Gln Lys His Glu Lys Ala Trp Val Cys Cys
 95 100 105
 Val Cys Gln Gln Ala Arg Leu Leu Arg Ala Gln Ser Leu Glu Trp
 110 115 120
 Phe Tyr Asn Asn Val Lys Ser Arg Phe Lys Arg Phe Gly Ser Ala
 125 130 135
 Arg Phe

<210> 27
 <211> 117
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 5402418CD1

<400> 27
 Met Lys Phe Gln Tyr Lys Glu Asp His Pro Phe Glu Tyr Arg Lys
 1 5 10 15
 Lys Glu Gly Glu Lys Ile Arg Lys Lys Tyr Pro Asp Arg Val Pro
 20 25 30
 Val Ile Val Glu Lys Ala Pro Lys Ala Arg Val Pro Asp Leu Asp
 35 40 45
 Lys Arg Lys Tyr Leu Val Pro Ser Asp Leu Thr Val Gly Gln Phe
 50 55 60
 Tyr Phe Leu Ile Arg Lys Arg Ile His Leu Arg Pro Glu Asp Ala
 65 70 75
 Leu Phe Phe Phe Val Asn Asn Thr Ile Pro Pro Thr Ser Ala Thr
 80 85 90

```
<210> 28
<211> 1058
<212> DNA
<213> Homo sapiens
```

```
<220>  
<221> misc_feature  
<223> Incyte ID No.: 2417014CB1
```

```
<210> 29
<211> 2235
<212> DNA
<213> Homo sapiens
```

```
<220>  
<221> misc_feature  
<223> Incyte ID No.: 2634931CB1
```

| <400> 29 | | | | | | | |
|------------|------------|-------------|------------|------------|-------------|--|-----|
| cgccaccgcg | tccgaccaca | ccaggggaac | tgtagtgcc | gtgcctggt | ccaccgggg | | 60 |
| ggcatctgag | aactgtgtcc | ttccattcct | gagtcagca | ctcccaggc | caggaactca | | 120 |
| cacagctttt | ggcctgagcc | ccggttacca | agagaaagga | ggtttttgcc | aaggactcca | | 180 |
| aggggagtg | acttgatgct | ggtcgggacc | caaagcacc | agccctccct | gagacattgt | | 240 |
| gtgagtcggg | ctgggcctca | aacacggccc | ccactgcccc | accccagcca | gggtgggtgct | | 300 |
| tgtgtgggta | ggactttaaa | tccagctgcc | agacccctgg | acgggagaag | gagagacggc | | 360 |
| tggccaccat | gcacggctcc | tgcagtttcc | tgatgcttct | gctgccgcta | ctgctactgc | | 420 |
| tggtgccac | cacaggcccc | gttgagagccc | tcacagatga | ggagaaacgt | ttgatgggtgg | | 480 |
| agctgcacaa | cctctaccgg | gccaggtat | ccccgacggc | ctcagacatg | ctgcacatga | | 540 |

```

gatgggacga ggagctggcc gccttcgcca aggcctacgc acggcagtg cgtgtggggcc 600
acaacaagga ggcgggcgcg cgcggcgaga atctgttcgc catcacagac gagggcatgg 660
acgtgccgct ggccatggag gagtggcacc acgagcgtga gcactacaac ctgagcgccg 720
ccacctgcag cccaggccag atgtgcggcc actacacgca ggtggtatgg gccaaagacag 780
agaggatcgg ctgtggttcc cacttctgtg agaagctcca ggtgtttgag gagaccaaca 840
tcgaattact ggtgtgcaac tatgagcctc cggggaacgt gaaggggaaa cggccctacc 900
aggaggggac tccgtgctcc caatgtccct ctggctacca ctgcaagaac tccctctgtg 960
aaccatcgg aagcccggaa gatgctcagg atttgcccta cctggtaact gagggcccat 1020
ccttccgggc gactgaagca tcagactcta ggaaaatggg tactccttct tccctagcaa 1080
cggggattcc ggctttcttg gtaacagagg tctcaggctc cctggcaacc aaggctctgc 1140
ctgctgtgga aaccaggcc ccaacttcct tagcaacgaa agaccgccc tccatggcaa 1200
cagaggctcc acctgctga acaactgagg tcccttccat tttggcagct cacagcctgc 1260
cctccttgga tgaggagcca gttaccttcc ccaaactgac ccatgttctt atcccaaaat 1320
cagcagacaa agtgacagac aaaacaaaag tgccctctag gagccagag aactctctgg 1380
acccaagat gtccctgaca ggggcaaggg agctcctacc ccatgcccag gaggaggtg 1440
aggctgaggc tgagtgcct ccttccagtg aggtcttggc ctgagttttt ccagcccagg 1500
acaagccagg tgagctgcag gccacactgg accacacggg gcacacctcc tccaagtccc 1560
tgcccaattt ccccaatacc tctgccaccg ctaatgccac ggggtggcggt gccctggctc 1620
tgagtcgtc cttgccaggt gcagagggcc ctgacaagcc tagcgtcgtg tcagggtctga 1680
actcggggcc tggatcatgt tggggccctc tcctgggact actgctcctg cctcctctgg 1740
tgttggtgg aatcttctga aggggatacc actcaaaggg tgaagaggtc agctgtcctc 1800
ctgtcatctt cccacacctg tcccagccc ctaaacaaga tacttcttgg ttaaggcctt 1860
ccggaaggga aaggctacgg ggcattgtgc tcatcacacc atccatcctg gaggcacaag 1920
gcctggctgg ctgcgagctc agggggccgc ctgaggactg cacaccgggc ccacacctct 1980
cctgccccct cctcctgagt cctgggggtg ggaggatttg agggagctca ctgcctacct 2040
ggcctggggc tgtctgcca cacagcatgt gcgctctccc tgagtgcctg tgtagctggg 2100
gatggggatt ctaggggca gatgaaggac aagccccact ggagtggggt tctttgagt 2160
ggggaggcag ggacgagga aggaaagcaa ctctgactc tccaataaaa acctgtccaa 2220
cctgtgaaaa aaaaaa

```

<210> 30

<211> 1559

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 110960CB1

<400> 30

```

cccaggcccc gccctctcct cccccgcgc cgatggtacg cgccggctcg cctggccccg 60
ctgcagtggg tgttgctgga acccagcgg aggaaggaa agacgcaggc aggtgcgggt 120
tacccaagcg gccaccggg cctcaggggac cccttcccc agagacggca ccatgacca 180
gggaaagctc tccgtggcta acaaggcccc tgggaccgag gggcagcagc aggtgcatgg 240
cgagaagaag gaggtccag cagtgcctc agccccacc tcctatgagg aagccacctc 300
tggggagggg atgaaggcag gggccttccc cccagcccc acagcgggtg ctctccacc 360
tagctgggcc tatgtggacc ccagcagcag ctccagctat gacaacgggt tccccaccgg 420
agaccatgag ctcttcacca ctttcagctg ggatgaccag aaagtctcgt gagtctttgt 480
cagaaagggtc tacaccatcc tgctgattca gctgctggtg accttggctg tcgtggctct 540
ctttactttt tgtgaccctg tcaaggacta tgtccaggcc aaccagggt ggtactgggc 600
atcctatgct gtgttctttg caacctacct gacctgggt tgctgttctg gaccaggag 660
gcatttcccc tggaacctga ttctcctgac cgtctttacc ctgtccatgg cctacctcac 720
tgggatgctg tcagctact acaacaccac ctccgtgctg ctgtgcctgg gcatcacggc 780
ccttgtctgc ctctcagtca cgtcttcag cttccagacc aagttcgact tcacctcctg 840

```

```

ccagggcgctg ctcttcgtgc ttctcatgac tcttttcttc agcggactca tcctggccat 900
cctcctaccc ttccaatatg tgccctggct ccatgcagtt tatgcagcac tgggagcggg 960
tgtatttaca ttgttcctgg cacttgacac ccagttgctg atgggtaacc gacgccactc 1020
gctgagccct gaggagtata tttttggagc cctcaacatt tacctagaca tcctctatat 1080
cttcaccttc ttctgcagc tttttggcac taaccgagaa tgaggagccc tcctgcccc 1140
accgtcctcc agagaatgcg cccctcctgg ttccctgtcc ctccctgcg ctectgcgag 1200
accagatata aaactagctg ccaaccagc ctgtggccag gtcactgtct accccagccc 1260
agcccagccc tctgccgctt gtacatacgc catggggacc ctgaggaact gaggccacgt 1320
caatccctgt gccgccccat tcgcccgtta catcttccaa actgggacgg tcaaggctga 1380
aggctcctct gggtttgagg gtccaaggga caaggagag aagcctagca ggatttcaga 1440
tgcaggagag agaccaggg aagcccggca gagccctgag cccactgca attctcctag 1500
ggctgcacat catgtggctt agggacactg tctgcatcca gtctgtgtct cctgtcttc 1559

```

<210> 31

<211> 876

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 380721CB1

<400> 31

```

cccacgcgtc cgccccacgcg tccgattttt catctttttt caggttgacg atgtgtcaca 60
ctgtgtaagg gaatcgcatg gagatgggca ttccgaactg ttaatgggga catgggactc 120
cagttgtctc tgatcacttg tgtggatttt cctggcgtag aacgacagaa gccgctagta 180
agtcgccaag acctacagca ggaattctgc accaaagggc ataaaatctt gttattttta 240
tttgcactct ggagaatgtc tgagcaagga gacctgaatc aggcaatagc agaggaagga 300
gggactgagc aggagacggc cactccagag aacggcattg ttaaatcaga aagtctggat 360
gaagaggaga aactggaact gcagaggcgg ctggaggctc agaatacaga aagaagaaaa 420
tccaagtcag gagcaggaaa aggtaaaactg actcgcagtc ttgctgtctg tgaggaatct 480
tctgccagac caggagggtga aagtcttcag ggtcagactc tctgaaaact gcaaatngga 540
agggatttca aaagggtttag gttaaaaagt aaattaaaag taggnacagt agtctgaat 600
tttccctcaa ggctctcttt tgataaggct gaaccaaata taatcccaag aatactctct 660
ccttccttgt tggagatgtc ttacctctca gtcccccaaa atgcacttgc ctataagaaa 720
cacaattgct ggttcatata aacttaggaa atagtgaata aggtgcattt aactttggag 780
aaatactttt atggcttttg tggagatttc tcaatactgc caaagttgtc cagaaatcga 840
tctgagctga tggctgcttt tagttcatat tatcat 876

```

<210> 32

<211> 1521

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 829443CB1

<400> 32

```

caagctggcc ctgcacggct gcaagggagg ctcctgtgga caggccaggc aggtgggcct 60
caggagggtg ctccaggcgg ccagtgggcc tgaggcccca gcaagggcta ggggtccatct 120
ccagtcccag gacacagcag cggccaccat ggccacgcct gggctccagc agcatcagca 180
gccccagga ccggggaggc acaggtggcc cccaccacc gaggagcag ctctgcccc 240

```

```

tgccggggg atgactgatt ctccctccgc aggccaccca gaggagaagg ccaccccgcc 300
tggaggcaca ggccatgagg ggctctcagg aggtgctgct gatgtggctt ctggtgttgg 360
cagtgggagg cacagagcac gcctaccggc ccggccgtag ggtgtgtgct gtccgggctc 420
acggggaccc tgtctccgag tcgttcgtgc agcgtgtgta ccagcccttc ctcaccacct 480
gcgacgggca ccgggcctgc agcacctacc gaaccatcta taggaccgac taccgcccga 540
gccctgggct ggccctgccc aggcctcgct acgcgtgctg ccccggtggt aagaggacca 600
gcgggcttcc tggggcctgt ggagcagcaa tatgccagcc gccatgcccg aacggaggga 660
gctgtgtcca gcctggccgc tgccgctgcc ctgcaggatg gcggggtgac acttgccagt 720
cagatgtgga tgaatgcagt gctaggaggg gcggctgtcc ccagcgctgc gtcaacaccg 780
ccggcagtta ctggtgccag tgttgggagg ggcacagcct gtctgcagac ggtacactct 840
gtgtgcccac gggaggggcc cccagggtgg ccccaacccc gacaggagtg gacagtgcaa 900
tgaaggaaga agtgacagag ctgcagcca gggaggacct gctggaggag aagctgcagc 960
tgggtgctggc cccactgcac agcctggcct cgcaggcact ggagcatggg ctcccggacc 1020
ccggcagcct cctggtgcac tccttcacag agctcggccg catcgactcc ctgagcgagc 1080
agatttcctt cctggaggag cagctggggt cctgctcctg caagaaagac tcgtgactgc 1140
ccagcgcctc aggcctggag gagccctca cgcgcctg cagcccccac gccctgccc 1200
aacatgctgg gggtcagaa gccacctcgg ggtgactgag cggaaggcca ggcagggcct 1260
tcctctctt ctctctcccc tcctcggga ggctccccag accctggcat gggatgggct 1320
gggatcttct ctgtgaatcc acccctggct acccccaccc tggctacccc aacggcatcc 1380
caaggccagg tgggcccctca gctgaggga ggtacgagct ccctgctgga gcctgggacc 1440
catggcacag gccaggcagc ccggaggctg ggtggggcct cagtgggggc tgctgcctga 1500
ccccagcac aataaaaatg t 1521

```

<210> 33

<211> 1349

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1470058CB1

<400> 33

```

aggctgggct gattcccttc tgtgctccca catgcttccg gaacagtgac aggtgagtga 60
aaaccaggta tcctgagccc catccctgat gtccctactc catccctgct atatccctag 120
cctgactttc cagcctcctg caggetcctg cctctaacca gcttctaccc cagccccatc 180
tctgcccctg ctagggactt cgcttttgtg gcaagtgaca aagatagctg tatgctcaag 240
tgccatgtgt ttccgtgtga tgcctctgcc aaggccattg ccagtgcctt acatgggctt 300
tgtgcccaga tcttgtcaga gcgagttag gtcagtggg atgcctcttg ctgctcccca 360
gaccccatct ctccgaaga cctgccacgg caagtggagc tgctggatgc ggtaagccaa 420
gctgctcaga agtacgaggc actgtatatg gggacactgc cagtcaccaa ggccatgggc 480
atggatgtgc tgaacgaggc cattggtacc ctcaccgcca ggggggaccg gaatgcctgg 540
gtccccacca tgctcagtgt gtctgactct ctcactgactg cacatcccat tcaggcagag 600
gccagtacag agggaggagc attgtggcag tgccctgtgc gccttgtgac atttattggg 660
gttggccgag acccacacac ctttggcctc atcgctgacc tgggcccgtc gagcttccag 720
tgcgagcct tctggtgcca gcccctatgca gggggactct ctgaagctgt gcaggctgcc 780
tgtatgggtt agtaccagaa gtgtcttgtg gcctctgcag ctcgaggcaa ggcctggggg 840
gccaggggcc gtgcccgcct gcggctcaag cggaccagct ccatggattc ccaggagggt 900
cccctgcccc tccccctgct caaaggaggg gttggcggtg caggggcaac ccctcgaaag 960
cgggggtgtc tctcttttct tgatgccttc cggtgaaac cctctctgct ccatatgccc 1020
taaacttata tgggaaggct ggggaagtag gctctgggtc catgcctaac tctgtaccgt 1080
tttattcctc aaggcctata gcctgtcact ccttgaagcc ttctctgcct gtccctccga 1140
tccttgtcca cgtctattt attgcccatt ttattgttta tacggatgac tgggaggcac 1200
tgaccacaa cgtaggagccc tggctcccct ttccttgggt ccttgtgttc cttgcccctg 1260

```


tccaacctg gacagttggc tctacctcag taacacttta tagcaaaatc agtgcaaata 1320
 aaaatccctc agtgacctca aaaaaaaaaa 1349

<210> 34
 <211> 1338
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1554947CB1

<400> 34
 ggctgttgc gtggtttcct gagttgctgc tgctgcggcg gcggcagcgg cgtctgtgct 60
 tgtggaggtg tgggcctctg ggcggatgtt gacattgtgt tgttggttatt gctgatggta 120
 atggcggcgg cgggtggcggc gacgggtccag accccatccc ctctgtagcc ggagccgaga 180
 cagccgacag cgaactccgc ggcctcggag ccggcggcag cggcgactcc cctcagcctc 240
 cgccgcctcg ccgcgcggta ccccgggcgc aaccccgggg gtcaggccct ttgggcaggg 300
 gagctcggag gctcaggatg gcggatttctg acgaaatcta tgaggaagag gaggacgagg 360
 agcgggcccct ggaggagcag ctgctcaagt actcgccgga cccggtggtc gtcgcgggct 420
 ccggtcacgt caccgtatct ggactgagca acaaatttga atctgaattc ccttcttcat 480
 taactggaaa agtagctcct gaagaattta aagccagcat caacagagtt aacagttgtc 540
 ttaagaagaa ccttcctgtt aatgtacgtt ggctactttg tggtgcctt tgttgctgct 600
 gcacattagg ttgcagtatg tggccagtta tttgcctcag taaaagaaca cgaagatcga 660
 ttgagaagtt attagaatgg gaaaacaata gggtatacca caagctgtgc ttgcattgga 720
 gactgagcaa aaggaaatgt gaaacgaata acatgatgga atatgtcatc ctcatagaat 780
 ttttaccaaa gacaccgatt tttcgaccag attagcattt actttattta tagagacttt 840
 ccaagtatgt tgtctttcca atgggtgcctt gcttggtgct ctccctgggtg tgacataaca 900
 ttggtttctac agaatcgtgt ggtgtttttt ttgtttttgt tttttttttt tttttaaata 960
 accgcatgtt ctaagtgtgc atttttgtca atctttgcaa cagttatttc atacagatgt 1020
 ttaatactta agttattgtg ctcttttctg ttatgtattc tgattttcaa ggattacttt 1080
 tttgtattat caaaaaata catttgaaact tagcataaaa agtggccagc cttttttatt 1140
 ttgtcaccaa ggtacacaca gtcctttatt tataaattcc ttaacagaga aaaacacctt 1200
 tgtaaggctc aacttaccta ttccagcaag cacacttttt ctgtcatttt ttctttcttt 1260
 tcaaatttga tattgtcatt attttaaaat agtaagtgtt ctttaatagt cttttgggac 1320
 ctaacatacc ctttctca 1338

<210> 35
 <211> 2120
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 1690245CB1

<400> 35
 tccctctcac caccctcttc tgcctatgag cggggaacaa aaaggccaga tgacagatat 60
 gatacaccaa cttctaaaaa gaaagtacga attaaagacc gcaataaaact ttctacagag 120
 gaacgccgga agttggttga gcaagaggtg gctcaacggg aggttcagaa acaacagcaa 180
 cagatgcaga acctgggaat gacatcacca ctgccctatg actctcttgg ttataatgcc 240
 ccgcatcatc cctttgctgg ttaccaccca ggttatccca tgcaggccta tgtggatccc 300
 agcaacccta atgctggaaa ggtgctcctg cccacaccca gcatggaccc agtgtgttct 360

```

cctgctcctt atgatcatgc tcagcccttg gtgggacatt ctacagaacc cctttctgcc 420
cctccaccag taccagtggg gccacatgtg gcagctcctg tggaggtttc cagttcccag 480
tatgtggccc agagtgatgg tgtagtacac caagactcca gcgttgctgt cttgccagt 540
ccggcccccg gccagttca gggacagaat tatagtgttt gggattcaaa ccaacagtct 600
gtcagtgtac agcagcagta ctctcctgca cagtctcaag caaccatata ttatcaagga 660
cagacatgtc caacagtcta tgggtgtgaca tcaccttatt cacagacaac tccaccaatt 720
gtacagagtt atgcccagcc aagtcttcag tatatccagg ggcaacagat tttcacagct 780
catccacaag gagtgggtgg acagccagcc gcagcagtga ctacaatagt tgcaccaggg 840
cagcctcagc ccttgccagcc atctgaaatg gttgtgacaa ataatctctt ggatctgccg 900
ccccctctc ctcccaaacc aaaaaccatt gtcttacctc ccaactggaa gacagctcga 960
gatccagaag ggaagattta ttactaccat gtgatcaciaa ggcagactca gtgggacctt 1020
cctacttggg aaagcccagg agatgatgcc agccttgagc atgaagctga gatggacctg 1080
ggaactccaa catatgatga aaaccccatg aaggcctcga aaaagcccaa gacagcagaa 1140
gcagacacct ccagtgaact agcaaagaaa agcaaagaag tattcagaaa agagatgtcc 1200
cagttcatcg tccagtgcct gaacccttac cggaaacctg actgcaaagt gggaagaatt 1260
accacaactg agacttttaa acatctggct cgcaagctga ctacggtgt tatgaataag 1320
gagctgaagt actgtaaaga tcctgaggac ctggagtgca atgagaatgt gaaacacaaa 1380
accaaggagt atattaagaa gtacatgcag aagtttgggg ctgtttacaa acccaaagag 1440
gacactgaat tagagtgaact gttgggcccag gttgggagga tgggtggtca ggtaaagacag 1500
actctagggg gaggaaatcc tgtgggcctt tctgtccac ccctgtcagc actgtgctac 1560
tgatgataca tcacctggg gaattcaacc ctgcagatgt caactgaagg ccacaaaaat 1620
gaactccatc tacaagtgat tacctagttg tgagctgttg gcatgtggtt agaagccatc 1680
agaggtgcaa gggcttagaa aagaccctgg ccagacctga ctccactctt aaacctgggt 1740
cttctccttg gcggtgctgt cagcgcacag acccatgcgc atccccacc acaacccttt 1800
accctgatga tctgtattat attttaatgt atatgtgaat atattgaaaa taatttgttt 1860
tttctcgtgt tttgtttggt tttcgttttg ctttttagcct ctacatgcta ggatcacagg 1920
aagactttgt aaggacagtt taagttctcc tgcaaggttt aatttgttat catgtaaata 1980
ttccaaagca ggctgccttg tggttttggc cagccttggt ctatgttgat aagattgatt 2040
tactgcttaa aatcacttta ctttatccaa tttttactga actttttatg taaaaaata 2100
aatcaatta aagaaaaaaa 2120

```

<210> 36

<211> 642

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1878262CB1

<400> 36

```

ctcctgcact aggtcttcag ccagggatga tgcgctgctg ccgcccgcgc tgctgctgcc 60
ggcaaccacc ccatgccctg aggcggttgc tgttgetgcc cctcgctcct ttacctcccc 120
tggcagcagc tgcagcgggc ccaaaccgat gtgacaccat ataccagggc ttcgccagt 180
gtctcatccg cttggggggac agcatgggccc gcggaggcga gctggagacc atctgcaggt 240
cttggaatga cttccatgcc tgtgcctctc aggtcctgtc aggtgtctcg gaggaggcag 300
ctgcagtgtg ggaatcacta cagcaagaag ctgcgcaggc ccccgctccg aataacttgc 360
acactctgtg cgggtgcccc gtgcatgttc gggagcgcgg cacaggctcc aaaaccaacc 420
aggagacgct gcggggtaca gcgcctgcac tccccatggc ccctgcgccc ccactgctgg 480
cggctgctct ggctctggcc tacctcctga ggcctctggc ctagcttgtt gggttgggt 540
gcagcgcggc tacctccagc cctgctctgg cgggtggtgt ccaggctctg cagagcgcgag 600
cagggtttt cattaaaggt atttatattt gtaaaaaaaa aa 642

```

<210> 37
 <211> 2536
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No.: 2253519CB1

<400> 37
 gccgtggtgc tcaacgccct caagggtggac gccacacag tcgtcagcca cccggacaag 60
 tactgttctt actgccgggc gctgctgatg accgtggctg ggctgaagct gctgcgtca 120
 gccttctgct gccccccaca gcagtacctg acgttggcct tcaccgtcct gctcttccac 180
 tttgactacc cgcgcctctc ccagggtctt ctgcttgact acttcctcat gtccctgctt 240
 tgcagcaagc tgtgggactt gctgtacaag ctgcgtttcg tgctgaccta catcgcgccc 300
 tggcagatca cctggggctc ggctttccac gcttttgccc agccgtttgc cgtgccacac 360
 tcggccatgc tgttcgtcca ggccctgctc tcggggctct tctccacgcc tctcaaccca 420
 ctgctaggca gtgccgtctt catcatgtcc tacgctcggc ccctcaagtt ctgggagcgc 480
 gactacaaca ctaaactgtg ggatcattcc aacacccgcc tggtcacaca gctggacagg 540
 aacctggcg ctgatgacaa caacctcaac tccatcttct atgagcactt gacacgttcg 600
 ctgcagcaca cactgtgtgg ggacctggtg ctgggcccgt ggggcaacta tggccctggt 660
 gactgcttgc tcctggcctc tgactacctc aacgccctgg tgcacctcat cgaggttggc 720
 aatggcctcg tcaccttcca gctgcgtggc cttgagttcc ggggcaacta ctgccagcag 780
 cgcgaggtgg aggttatcac cgagggtgtg gaggaggacg agggctgttg ctgctgtgaa 840
 cctggccacc tgccacgggt cctgtccttc aatgctgcct ttgggcagcg ctggctggct 900
 tgggaggtaa cagccagcaa gtacgtgctg gagggtcata gcattagtga caataatgct 960
 gcctccatgc tgcaggtttt cgacctccgc aagatcctca tcacctacta tgtcaagagc 1020
 atcatctact acgtgagccg ctacccaaag ctggaggtgt ggctcagcca tgagggcac 1080
 acggcagccc tgaggcctgt gcgggtgccc ggctatgccg actcggatcc cacttctcgc 1140
 ctgagtgtgg atgaggacta tgacctccgc ctgtctggcc tctcgtgcc ctcttttgt 1200
 gctgtgcacc tcgagtggat ccagtaactgc gcctcccggc gcaccaggcc cgtggaccag 1260
 gattggaact ccccgctggt cacgctgtgt tttggcctgt gtgtgctggg ccgcccggcc 1320
 ctggggacag cctctcacag catgtctgca agcctggagc ccttcctcta cggcctgcac 1380
 gccctgttca agggggattt tcgcatcacc tccccacgtg acgagtgggt ctttgccgac 1440
 atggacctgc ttcaccgcgt tgtgggcctt ggggttcgca tggccctcaa gttcaccag 1500
 gaccacttca cgtccccaga tgaatatgag gagccagcag ccctatacga tgccattgct 1560
 gccaacgagg agcggctggt catctcacat gagggtgacc cagcatggcg cagcgccatc 1620
 ctacgcaaca cgccctccct gctggcgctg cgccatgtcc tggatgatgc ctccgacgag 1680
 tacaagatca tcatgctcaa ccggcgccac ctacgcttcc gagtcacaa ggtgaaccgg 1740
 gagtgcgtgc gcggcctgtg ggccgggcag cagcaggagc tgggtgttctt ggcgaaccgc 1800
 aaccccgagc gtggcagcat ccagaacgcc aagcaggcgc ttcgcaacat gatcaactcc 1860
 tcctgtgacc agccgctggg ctaccccatc tacgtgtcgc ctctcaccac ctcgctggct 1920
 ggcagccacc cccagctacg ggcactgtgg ggtggcccca tcagcctggg tgccattgcc 1980
 cactggctcc tgcgcacctg ggagaggctt cacaagggtg gtggcgccgg ctgcaatagt 2040
 ggcggaacg tggatgattc agactgtagt gggggcggtg gcctgacctc cctcagcaat 2100
 aacccccccg tggcacaccc cacacctgag aacacggcag gcaatgggtga ccaacccctc 2160
 ccaccaggcc ctggctgggg gccgcgggtc tccctgagtg gctctgggtg tgggcggccc 2220
 ccacctctgc tgcaagtggc tccccctcgg ctccctggac cccccctgc atcgctatc 2280
 cccacagagg gtccccggac ctacaggccc cctggcccgg gtctcctcag tctgagggc 2340
 cccagtggaa agtggagcct gggggggcgg aaggggctgg gaggatctga cggggagcca 2400
 gcctcagggg gccccaaagg aggtaccccc aaatctcagg taaggcacct gtgggagggc 2460
 tgggtcccag aaggctaagg cctgctcacc cgccaacctc tccccctcc ccaggcgcc 2520
 tctagacctc agcctc 2536

<210> 38
 <211> 3957
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 2888437CB1

<400> 38
 ggaagctgca gagaaagtca gctggataaa ggacaaactt ctgcatatattt attatcagaa 60
 cagcattgac gacaaactgt tggtagagaa aatccttctg cagtatcttg tccccacaa 120
 cctggaaaca gaagagagaa tgaaatgctt atattactta tatgctagtt tggatccaaa 180
 tgctgtaaaa gctctcaacg aaatgtggaa gtgtcagaac atgcttcgga tccatgtacg 240
 cgaactattg gatttgacac agcagcctac atcagaggct aactgttctg ccatgttttg 300
 aaaactgatg accatagcaa agaatttgcc tgaccccgga aaagcacaag attttgtgaa 360
 gaaatttaac caggttctcg gcgatgatga gaaacttcgg tctcagttgg agttattaat 420
 tagccaacc tgttcttgca aacaagcaga tatttgtgtg agagaaatag cccggaaact 480
 tgcaaatcct aagcaaccaa caaatccttt tctagagatg gtcaaatttc tgttgaaaag 540
 aatcgcacct gtgcacattg attcagaagc cataagtgc ctagtgaaat tgatgaataa 600
 gtcaatagag gggacagcag atgatgaaga ggaggtgtga agtccagata cagctatccg 660
 ttcaggactt gaacttctta aggttctgtc ttttacacat cctacctcgt tccactctgc 720
 agagacatat gagtcttctg tacagtgcct aagaatggag gatgacaagg tagcagaagc 780
 tgctattcaa attttttagaa atacagggtc caaaatagaa acagaccttc cccagatacg 840
 atcgacctta attcccattt tacatcaaaa agcaaaaggg ggtactccac accaagcaaa 900
 acaggctgtg cactgtatac acgccatatt cacaataaaa gaagtccagc ttgcacagat 960
 ttttgagcca cttagtagga gtctgaatgc tgatgtgcca gaacaactta taactccatt 1020
 agtttcattg ggccacattt ctatgttagc accagatcag tttgcttccc caatgaaatc 1080
 tgtagtagca aatttttattg tgaaagatct gctaataaat gacaggtcaa caggtgaaaa 1140
 gaatggaaaa ctgtggtctc cagatgaaga ggtttccctt gaagtactag caaaggtaca 1200
 ggcaattaaa cttctggtaa ggtggctgtt gggtaggaaa acaaccagt ctaaatctgc 1260
 caattcaacc cttcggttat tatcagcgat gttgggttagt gaggggtgacc tgacagagca 1320
 aaagaggatc agtaaatctg atatgtctcg cttgcgatta gctgctggta gtgccataat 1380
 gaagcttgct caggaacctt gttaccatga aattattacc ccagaacagt ttcagctctg 1440
 tgcacttggt attaatgatg agtggtacca agtaaggcag atatttgctc agaagctgca 1500
 taaggcactt gtgaagttac tgctcccatg ggagtatatg gcgatctttg ccttgtgtgc 1560
 caaagatcct gtgaaggaga gaagagcaca cgcacgacaa tgtttactga aaaatatcag 1620
 tatacgagag gaatacatta agcagaatcc tatggctact gagaaattat tatcactgtt 1680
 gcctgaatat gtagttccat acatgattca cctgctagcc catgatccag atttttacaag 1740
 atcacaagat gttgatcagc ttcgtgatat caaagagtgc ctatggttca tgcttgaagt 1800
 tttaatgaca aagaatgaaa acaatagcca tgcttttatg aagaagatgg cagagaacat 1860
 caagttaacc agagatgccc agtctccaga tgaatccaag acaaatgaaa aactgtatac 1920
 agtatgtgat gtggctctct gtgttataaa tagtaaaagt gctttgtgca atgcagattc 1980
 accaaaggac ccagtcctcc caatgaaatt ttttacacaa cctgaaaagg acttctgtaa 2040
 cgataagagt tatatttcag aagagacaag agtacttctg ttaacaggaa agccaaagcc 2100
 tgctggagta ctagggtgag taaataagcc tttatcagca acgggaagga aaccctatgt 2160
 tagaagcact ggcactgaga ctggaagcaa tattaatgta aattcagagc tgaaccttc 2220
 aaccggaat cgatcaaggg aacagagtgc agaggcagca gaaactggag ttagtgaaaa 2280
 tgaagagAAC cctgtgagga ttatttcagt cacacctgta aagaatattg acccagtaaa 2340
 gaataaggaa attaattctg atcaggctac ccagggaac atcagcagtg accgaggaaa 2400
 gaaaagaaca gtaacagcag ctggtgcaga gaatatccaa caaaaaacag atgagaaagt 2460
 agatgaatcg ggacctcccg ccccttccaa acccaggaga ggacgtcgac ccaagtctga 2520
 atctcagggc aatgctacca aaaatgatga tctaaataaa cctattaaca agggaaggaa 2580
 gagagctgca gtgggtcagg agagccctgg ggggttgga gcaggtaatg ccaaagcacc 2640
 caaactgcaa gatttagcca aaaaggcagc accagcagaa agacaaattg acttacaaag 2700

```

gtaaaaatgc atttgcaaag ggagaaaatg aaggccaaac agaagcagge tccagcttct 2760
gcaaaaactt ggattcacaa atgtccctga acagaaaatg aagetcaacg cagaccgtgt 2820
gtgttctgaa gtgagcttca gaacacacac tctctgcctt gaaaactaaa gagactatta 2880
cttccttttc acatgaccac aagtcctctg atggaaatgt acagcagaaa ctcttgagag 2940
agaggctaaa agcaactctg ttctccccct tcccctagac ttttcttacg aaaagtcaat 3000
aattaagcaa attgcttaac acttggttcc agttcctgcc tatctggagt ttaaattgct 3060
aatacaccat taatttccac gctgcagttt ttattttaaa gaaagtaaca agatgtcttt 3120
acactgacac tgaaaattca tccatttttag agccaggaat tcccatgtta cacaggaaaa 3180
aatagaagtc tactgaatta attttttaaa agaaaagaga tcagattaaa tatttctttg 3240
tttttctttt tggaaaacttt tatgtataat tctttctgcc tgcctacttt tctgcaaaaa 3300
tgagatgtac agatttctggg tccctgctat gaaaagtgat gtggtagcaa ttttataaat 3360
gttgctttct gatttttatc agagttagaa aattaaatt attgatttgc aagtagtaaa 3420
cagttcatat tttgatttcc cctcatttta gttaaataa atttgcaata aatgtacata 3480
ttgttgtttg tttcataaag catatcactt taaaatgggt tttactcctg tgattatgtt 3540
ggaatatttg gaattttaaa ggagtaaaga ctgtccagca tttggtttta taatgtttgt 3600
caccagattt ttattaatgt aaaaaaaatc aattttttaa aaatagttgg actttggcag 3660
cttttaagga aagttggagg tgttttagga ttgctatcaa ttttcagcat tgtgctatct 3720
ggaaataagt gttttgcttt tgtctgatgg tctgggctca tttttatgtt tatttttagaa 3780
aactgttgca tcaatatatt atgtttcttg gcattgttca gcataggtaa tgtgtgcact 3840
ttatgtgtac acataatcat atttaagttt tttgcataaa ataaatgctt ctagatgtca 3900
tggcagtcct tttaatcttt ttatcatatg ctttcttggt aattttttca tgttaa 3957

```

<210> 39

<211> 3188

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 3201753CB1

<400> 39

```

ggggagtcgg ctaagcaatg gagaagtgat gaggggcatt ttcacaaac atgttctgga 60
agatagtcca gctggcaaaa atggaacctt gaaacctgga gatagaatcg tagagggtgga 120
tggaatggac ctgagagatg caagccatga acaagctgtg gaagccattc ggaaagcagg 180
caaccctgta gtcttttatgg tacagagcat tataaacaga ccaagggcac ccagtcagtc 240
agagtcagag ccagagaagg ctccattgtg cagtgtgccc ccacccctc cttcagcctt 300
tgccgaaatg ggtagtgatc acacacagtc atctgcaagc aaaatctcac aagatgtgga 360
caaagaggat gagtttggtt acagctggaa aaatatcaga gagcgttatg gaaccctaac 420
aggcgagctg catatgattg aactggagaa aggtcatagt ggtttgggccc taagtcttgc 480
tggaacaaa gaccgatcca ggatgagtg ctcatagtg gggattgatc caaatggagc 540
tgcaggaaaa gatggtcgat tgcaaatgac agatgagctt ctgagatca atgggtcagat 600
tttatatgga agaagtcac acaatgcctc atcaatcatt aaatgtgccc ctctctaaagt 660
gaaaataatt tttatcagaa ataaagatgc agtgaatcag atggccgtat gtcctggaaa 720
tgcagtagaa cctttgcctt ctaactcaga aaatcttcaa aataaggaga cagagccaac 780
tgttactact tctgatgcag ctgtggacct cagttcattt aaaaatgtgc aacatctgga 840
gcttcccaag gatcaggggg gtttgggtat tgctatcagc gaagaagata cactcagttg 900
agtcataata aagagcttaa cagagcatgg ggtagcagcc acggatggac gactcaaagt 960
cggagatcag atactggctg tagatgatga aattgttgtt ggttacccta ttgaaaagtt 1020
tattagcctt ctgaagacag caaagatgac agtaaaactt accatccatg ctgagaatcc 1080
agattcccag gctgttcctt cagcagctgg tgcagccagt ggagaaaaaa agaacagctc 1140
ccagtcctct atggtcccac agtctggctc ccagaaccg gagtccatcc gaaatacaag 1200
cagatcatca acaccagcaa tttttgcttc tgatcctgca acctgcccc tttatccctg 1260
ctgcgaaaca accatcgaga tttccaaagg gcgaacaggg ctgggcctga gdatcgttgg 1320

```

```

gggttcagac acgctgctgg gtgccattat tatccatgaa gtttatgaag aaggagcagc 1380
atgtaaagat ggaagactct gggctggaga tcagatctta gaggtgaatg gaattgactt 1440
gagaaaggcc acacatgatg aagcaatcaa tgtcctgaga cagacgccac agagagtgcg 1500
cctgacactc tacagagatg aggcccata caaagaggag gaagtgtgtg acaccctcac 1560
tattgagctg cagaagaagc cgggaaaagg cctaggatta agtattgttg gtaaaagaaa 1620
cgatactgga gtatttgtgt cagacattgt caaaggagga attgcagatg ccgatggaag 1680
actgatgcag ggagaccaga tattaatggg gaatggggaa gacgttcgta atgccacca 1740
agaagcgggt gccgctttgc taaagtgttc cctaggcaca gtaaccttgg aagttggaag 1800
aatcaaagct ggtccattcc attcagagag gaggccatct caaagcagcc aggtgagtga 1860
aggcagcctg tcatctttca cttttccact ctctggatcc agtacatctg agtcaactgga 1920
aagtagctca aagaagaatg cattggcatc tgaaatacag ggattaagaa cagtcaaat 1980
gaaaaagggc cctactgact cactgggaat cagcatcgct ggaggagtag gcagcccact 2040
tggtgatgtg cctatattta ttgcaatgat gcaccaact ggagttgcag cacagacca 2100
aaaactcaga gttggggata ggattgtcac catctgtggc acatccactg agggcatgac 2160
tcacacccaa gcagttaacc tactgaaaaa tgcactctggc tccattgaaa tgcaggtggg 2220
tgctggagga gacgtgagtg tggtcacagg tcatcagcag gacctgcaa gttccagtct 2280
ttctttcact gggctgacgt caagcagtat atttcaggat gatthagga ctcctcaatg 2340
taagtctatt acactagagc gaggaccaga tggcttaggc ttcagtatag ttggaggata 2400
tggcagccct catggagact taccatttta gttaaaaca gtgtttgcaa agggagcagc 2460
ctctgaagac ggacgtctga aaaggggcga tcagatcatt gctgtcaatg ggcagagtct 2520
agaaggagtc acccatgaag aagctgttgc catccttaaa cggacaaaag gcactgtcac 2580
tttgatgggt ctctcttgaa ttggctgcca gaattgaacc aacccaaccc ctagctcacc 2640
tcctactgtā aagagaatgc actggtcctg acaattttta tgctgtgttc agccgggtct 2700
tcaaaactgt aggggggaaa taacacttaa gtttcttttt ctcatctaga aatgctttcc 2760
ttactgacaa cctaacatca ttttctttt cttcttgcac tttgtgaact taaagagaag 2820
gaatatattgt gtaggtgaat ctctgtttta tttgtggaga tatctaattg tttgtagtca 2880
catgggcaag aattattaca tgctaagctg gttagtataa agaaagataa ttctaaagct 2940
aaccaaagaa aatggcttca gtaagttagg atgaaaaatg aaaaataaaa ataaagaaga 3000
aaatctcggg gagtttaaaa aaaatgcctc aatttggcaa tctacctcct ctccccaccc 3060
caaaactaaaa aaagaaaaaa aggttttcta atgaaaatct ttaaaaatac tgtcagtatt 3120
ttaaaatttt caacagtatt ataaaaacat tgcactctcc cacctctaatt atgcatatat 3180
atttttcc 3188

```

<210> 40

<211> 3551

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 3800639CB1

<400> 40

```

tgtctgaggg ggcgctgtgt gtgtgaagcg tacctagggc gggaggcgac atggagacag 60
gggcggccga gctgtatgac caggcccttt tgggcatcct gcagcacgtg ggcaacgtcc 120
aggatttcct gcgcgtttct tttggcttcc tctaccgcaa gacagacttc tatcgcttgc 180
tgcgccaccc atcggaccgc atgggcttcc cgcccggggc cgcgcaggcc ttggtgctgc 240
aggatttcaa aacctttgac cacatggccc gtcaggatga tgagaagaga aggcaggaac 300
ttgaagagaa aatcagaaga aaggaagagg aagaggccaa gactgtgtca gctgctgcag 360
ctgagaagga gccagtccca gttccagtcc aggaaataga gattgactcc accacagaat 420
tggtatgggca tcaggaagta gagaaagtgc agcctccagg ccctgtgaag gaaatggccc 480
atggttcaca ggaggcagaa gctccaggag cagttgctgg tgctgctgaa gtccctaggg 540
aaccaccaat tcttccagag attcaggagc agttccagaa aaatcccagc agttacaatg 600
tgctgtgccg agagaactac acctggtcac aggactatac tgacctggag gtcagggtgc 660

```

```

cagtacccaa gcacgtggtg aagggaaagc aggtctcagt ggcccttagc agcagctcca 720
ttcgtgtggc catgctggag gaaaatgggg agcgcgtcct catggaaggg aagctcacc 780
acaagatcaa cactgagagt tctctctgga gtctcgagcc cgggaagtgc gtttttggtga 840
acctgagcaa ggtgggagag tattggtgga acgccatcct ggagggagaa gagcccatcg 900
acattgacaa gatcaacaag gacgcgtcca tggccaccgt ggatgaggag gaacaggcgg 960
tgttgacag gcttaccttt gactaccacc agaagctgca gggcaagcca cagagccatg 1020
agctgaaagt ccatgagatg ctgaagaagg ggtgggatgc tgaaggttct cccttccgag 1080
gccagcgatt cgaccctgcc atgttcaaca tctccccggg ggctgtgcag ttttaatgac 1140
cagaaggaaa ggaaaccctc gccggtgggg aggcagagcc ttatcctcgg ctgcccttct 1200
tggctccctg cattccaggg acttgctcgt ctgttttacc cctagccatc ctttctttca 1260
aggggtgaacc aggccttcca ccctgacctt gcctctccag actgttccag agaagggtgcg 1320
gggccagctg ctatgtggtg gccgctgtgg ctgacactga gtgaagggtg tggaaatgca 1380
ggagaggata tcccagcaaa ttgggatcac atgcttttgt ctccacagca accagccact 1440
gcaggcagca tgtctttcct ccctgctct ctgcttgctg ttgttttgac gctattctgc 1500
ttgcatgtct tctgggtggg atgtggagtt gttgctggac tctcaggcga actgaagtca 1560
ttgaagtgtg tgaagctctg tgcttgcctg agggcaagca aggaatggct gtgcctgagg 1620
ctgctctggg aaactccttg cccttgacc tcttttgaga gcattcacgt ggtcctcttg 1680
ctcatccctt tataaatgtg ctttgctgc ctcagcctca tggtcagagc agtggagact 1740
ggagccctgt ttgcacgttc tagttgttcg gagaaagcct aggttctggg ctccaggtcca 1800
gatgcagcgg ggattctgtt ctctgactgt ggcgaccttg ctttggttct tgttgaagtg 1860
aaccaagccc ggccaccacg catggcatgc tgtgcttggc tccccataag adgtcctctt 1920
tgggtgcacg gtgtcaaagt gtgggcagga gtggagagct ggtgccctca ggaggagacc 1980
acagcatgtc ctgggagagg aggaatttct gcctggggcg tgaaggcaca ctgtcccacc 2100
acaactgaac cagaagagag tgaagactcc cctcttccca tctctgtgc cagggtgccag 2160
actgtgctcc ttggaactta tggcccaatc ttacctgttc tccagggact ggtcactgcc 2220
tcaggacccc caagcctatg ccctgagcca tggctgctga ctgactccag ccaagggtgca 2280
aagacgagat tatgagacag gtccctcaggc ctgtgttcca agtactcaca ggggctctgg 2340
gtgcccacg cgggagtat ggttcagctg ccaccggcac tgtccatttg cctgtctgtc 2400
aagctcagag catggataag ccacacagca gggcagtgca ccctggcacc atgcacggcc 2460
agcaagaatc aaggcccgca gatgctaaga gggcctattg tcaggggaag gtccccgctc 2520
ctgcacactc tctatggata cttgggttgt gggggctctc ttggagagta agtttgtggt 2580
ttgtttctgg tttacagtgg tggctgacac cccttgtaag aaagcattcc tgggaagtct 2640
tctgtgggtc caaacatgtt gctccgatca tcacaggaga gcaaaaggcc ctagataccc 2700
cctttggaat gtgagagtct tgttgtctga tatttgccac tgagctggtg aagcccctct 2760
aaagagatct cgaccctggg gagcagaatt cttgtcatct atgaggggtc ctgagaaaga 2820
cttgtcattt ttttctctgg agttcttccc attgaggtcc taggatttgc adaccactgt 2880
cccacaagag ctttctctgcc taatgaaagg aggtcttgtg gtgtgtgtct cctctcttct 2940
ctatagttcc cgagttggcc cccttgagc ccccaccct gtgggtagtc tccagaagt 3000
gatgcagtgg tgtgagatgc cctacacctt gttatttggg agactttgag agtcattcac 3060
ttccatgggt actagtgtt gttttgcctg attttatatt ctgtgttgca tttctcccca 3120
ctccctgccc tgctttaata aacagcaaac caatatctag gaagaatgac tgagggatag 3180
tattgggtat tggcccatg gcaggaacag ccacttgcct ctggtcccgg tgccacactg 3240
cgggtgcttg tgtggttgtg gagcctgtcc ctgcgcgcct tgctcccgtt gagccacgct 3300
gtctgggtgg tgattctctg ccctgagcca ccaccctgga ctggcccagt ctccagagct 3360
ggcacaccct gcctgttttc tctttttaga cacaacagcc gcagtttggc cagccactaa 3420
gtcccaccag ctgaggtccg aggaaagcgg ggtgactcat tteccctgtc cagggcccga 3480
ggagagtgg gtgtccagcc tgcaaagcta ttccagctcc ttggtgttgg tttgcaataa 3540
attggtattt a 3551

```

<210> 41

<211> 2308

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 533825CB1

<400> 41

```
cgccaaccgt ggtggctcct tgcgttccta catcctctca tctgagaatc agagagcata 60
atcttcttac gggcccgatga tttattaacg tggcttaatc tgaaggttct cagtcaaatt 120
ctttgtgatc tactgattgt gggggcatgg caaggtttgc ttaaaggagc ttggctggtt 180
tgggcccttg tagctgacag aaggtggcca gggagaaggc agcacactgc tcggagaatg 240
aaggcgcttc tgttgcctgg cttgccttgg ctcagtcctg ctaactacat tgacaatgtg 300
ggcaacctgc acttcctgta ttcagaactc tgtaaagggtg cctccacta cggcctgacc 360
aaagatagga agaggcgctc acaagatggc tgtccagacg gctgtgagag cctcacagcc 420
acggctccct cccagaggtt ttctgcagct gccaccatct ccttaatgac agacgagcct 480
ggcctagaca accctgccta cgtgtcctcg gcagaggacg ggcagccagc aatcagccca 540
gtggactctg gccggagcaa ccgaactagg gcacggccct ttgagagatc cactattaga 600
agcagatcat ttaaaaaaat aaatcgagct ttgagtgttc ttcgaaggac aaagagcggg 660
agtgcagttg ccaaccatgc cgaccagggc agggaaaatt ctgaaaacat cactgcccct 720
gaagtctttc caaggttgta ccacctgatt ccagatgggtg aaattaccag catcaagatc 780
aatcgagtag atcccagtg aagcctctct attaggtctg tgggaggtag cgaaacccca 840
ctggtccata tcattatcca acacatttat cgtgatgggg tgatcgccag agacggccgg 900
ctactgccag gagacatcat tctaaaggtc aacgggatgg acatcagcaa tgtccctcac 960
aactacgctg tgcgtctcct gcggcagccc tgccaggtgc tgtggctgac tgtgatgcgt 1020
gaacagaagt tccgcagcag gaacaatgga caggcccgag atgcctacag accccgagat 1080
gacagctttc atgtgattct caacaaaagt agccccgagg agcagcttgg aataaaaactg 1140
gtcgcgaagg tggatgagcc tggggttttc atcttcaatg tgctggatgg cgggtgtggca 1200
tatcgacatg gtcagcttga ggagaatgac cgtgtgttag ccatcaatgg acatgatctt 1260
cgatatggca gcccgaaaag tgcggctcat ctgattcagg ccagtgaag acgtgttcac 1320
ctcgtcgtgt cccgccaggt tcggcagcgg agccctgaca tctttcagga agccggctgg 1380
aacagcaatg gcagctggtc cccagggcca ggggagagga gcaacactcc caagcccctc 1440
catctacaa ttacttgta tgagaagggtg gtaaatatcc aaaaggaccc cgggtgaatct 1500
ctcggcatgg ccgtcgcagg gggagcatca catagagaat gggatttgcc tatctatgtc 1560
atcagtgttg agcccgagg agtcataagc agagatggaa gaataaaaac aggtgacatt 1620
ttgttgaatg tggatggggc cgaactgaca gaggtcagcc ggagtgaggc agtggcatta 1680
ttgaaaagaa catcatctc gatagtactc aaagctttgg aagtcaaaga gtatgagccc 1740
caggaagact gcagcagccc agcagccctg gactccaacc acaacatggc cccaccagat 1800
gactggctcc catcctgggt catgtggctg gaattaccac ggtgcttgta taactgtaaa 1860
gatattgtat tacgaagaaa cacagctgga agtctgggct tctgcattgt aggaggttat 1920
gaagaatata atggaacaa accttttttc atcaaatcca ttgttgaagg aacaccagca 1980
tacaatgatg gaagaattag atgtggtgat attcttcttg ctgtcaatgg tagaagtaca 2040
tcaggaatga tacatgcttg cttggcaaga ctgctgaaag aacttaaagg aagaattact 2100
ctaactattg tttcttggcc tggcactttt ttatagaatc aatgatgggt cagaggaaaa 2160
cagaaaaatc acaaatatag gctaagaagt tgaaacacta tatttatctt gtccagtttt 2220
atattttaaag aaagaatata ttgtaaaaat gtcaggaaaa gtatgatcat ctaatgaaag 2280
ccagttacac ctcagaaaat atgattcc 2308
```

<210> 42

<211> 1881

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1311833CB1


```

<400> 42
ccacactgcg ccttgcaagc aagcttgaaa tgggcttctg tctgagcggc accgggatga 60
ccaatgggtc tgtgttttgg accggcgaac caatggcgcg acaggggaagg cgggcccagag 120
atgggttagg gtgtccttgc aggggtgtctg agctaaactt caccaaataa tagctgtttg 180
tattttggct gctgcaggag ccatttttaga aataaatatc ttccttcaat agatgaaaaat 240
gaaaatacag aaaaaagaga agcagttgtc aaatttaaaa gttttgaatc acccccaat 300
gtctgatgcc tctgtcaatt ttgactacaa atctccatcc ccatttgact gcagcactga 360
tcaagaagag aaaattgaag atgttgctag tcaactgtctg cctcagaagg acctgtatac 420
tgctgaagag gaagctgcta ccctttttcc taggaaaatg acatcccata atgggatgga 480
ggacagtgga ggaggaggta ctggagtga gaagaaacgg aagaaaaagg agccaggaga 540
ccaagagggg gcagcaaagg gaagcaagga cagagagccc aagccaaaga ggaaacgaga 600
accgaaagag ccaaaggaac ccagaaaggc caaggagccg aagaaggcca aggagcacia 660
ggagccgaag caaaaagatg gggcaaagaa ggacgggaag ccccgaggag cctcgggcac 720
caaggaggcc aaagagaaga ggagctgcac tgactctgca gccaggacga agtccaggaa 780
ggccagcaag gagcaaggac caaccccagt ggagaaaaag aagaaaggaa aaaggaaaag 840
tgaaactaca gtggagagtt tagagctgga tcagggcctg acgaaccat ctctgcggag 900
tcctgaggag tccactgagt ctacagacag ccagaaacga cgctcgggaa ggcaagtaaa 960
gcgcagaaaa tacaatgagg acctggactt caaagtgggt gatgatgatg gggaaacaat 1020
tgctgttctt ggagctggtc gaacatctgc actctcagcc tctacactgg cctggcaggc 1080
ggaggagcct ccagaagatg atgcaaacat cattgagaag atcctggcat ctaagactgt 1140
ccaggagggt caccaggag aacctccgtt cgacttgagg ctgttctacg ttaagtatag 1200
aaatttttcc tacttacatt gtaaattgggc cacaatggaa gagctcgaaa agbatcctcg 1260
catcgcacag aagatcaagc gatttaggaa taaacaagcc cagatgaagc acatttttac 1320
ggaggtgaag caatatttac tgactcattt gactgctgct tttcttgca cagtaaatat 1380
tgtgtttacg tttctaagtc caagttaaat tcctatacag atctgttgct caagtcaaat 1440
tgataaatgt gtgctgattt gcaacaaaac tagtctagat tcaagtcaaa gaaaactatc 1500
caccaaagtt aaggatcaaa ccttataaac tgacaactca taacggcgtg catcttggtc 1560
tgaatactaa taaatagcta gactgagagg aatacgaca caattctttt gtccctgctc 1620
cctcaaccca ctgcaaccca aaaaggacat ttcagaaggt cctaaagttt gaatgtaaaa 1680
aacaaaacaa atctaaaagt gagagaaagt aaacaaataa ataattttat ttatgtaaac 1740
ttgggaattt ctaagtattg tacctatagc aagaggaagg actgatggat tttaattatta 1800
aacaaatcta taatgctata tatcagaaaa tgccacaaac cttaacctta atgtgttatt 1860
cttgaataaa agactaaacc a 1881

```

```

<210> 43
<211> 1974
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No.: 1342819CB1

```

```

<400> 43
ccagaagcca gcagtggggt tgcacacgcg cctcttcacg aggtggaaac aagatggagg 60
attcggcctc ggcctcgctg tcttctgcag ccgctactgg aacctccacc tcgactccag 120
cggccccgac agcacggaag cagctggata aagaacaggt tagaaaggca gtggacgctc 180
tcttgacgca ttgcaagtc aggaaaaaca attatgggtt gcttttgaat gagaatgaaa 240
gtttattttt aatgggtggtt ttatggaaaa ttccaagtaa agaactgagg gtccagattga 300
ccttgccctca tagtattcga tcagattcag aagatatctg tttatttacg aaggatgaac 360
ccaattcaac tcctgaaaag acagaacagt tttatagaaa gcttttaaac aagcatggaa 420
ttaaaaccgt ttctcagatt atctccctcc aaactctaaa gaaggaatat aaatcctatg 480
aagccaagct ccgccttctg agcagttttg atttcttcc tactgatgcc agaattaggc 540
ggctcttacc ctcaactcatt gggagacatt tctatcaaag aaagaaagtt ccagtatctg 600

```

```

taaaccttct gtccaagaat ttatcaagag agatcaatga ctgtataggt ggaacggtct 660
taaacatttc taaaagtggg tcttgacgtg ctatacgtat tgggtcacgtt ggaatgcaaa 720
ttgagcacat cattgaaaac attgttgctg tcaccaaagg actttcagaa aaattgccag 780
agaagtggga gagcgtgaaa ctctgtttg tgaaaactga gaaatcggct gcacttccca 840
tcttttcttc gtttgtcagc aattgggatg aagccacca aagatctttg cttaataaga 900
agaaaaaaga ggcaaggaga aaacgaagag aaagaaattt tgaaaaacaa aaggagagga 960
agaagaagag gcagcaggct aggaagactg catcagttct tagtaaagat gatgtggcac 1020
ctgaaagtgg tgatactaca gtgaagaaac ctgaatcaaa gaaggaaacag accccagagc 1080
atgggaagaa aaaacgtggc agaggaaaag cccaagttaa agcaacaaat gaatccgaag 1140
acgaaatccc acagctggta ccaataggaa agaagactcc agctaataa aaagtagaga 1200
ttcaaaaaaca tgccacagga aagaagtctc cagcaaagag tcctaataccc agcacacctc 1260
gtgggaagaa aagaaaggct ttgccagcat ctgagacccc aaaagctgca gagtctgaga 1320
ccccagggaa aagccagag aagaagccaa aaatcaaaga agaggcagtg aaggaaaaaa 1380
gtccttcgct ggggaaaaaa gatgcgagac agactccaaa aaagccagag gccaaagttt 1440
tcaccactcc tagtaaatct gtgagaaaag cttccacac ccccaaaaaa tggcccaaaa 1500
aacccaaagt accccagtcg acctaaagtc agtgattcaa ctggaaggaa acctcaatgc 1560
tgccctccaga gcttttttga aatactcaga tcctggccgc ctttgttaacc ttctctaaac 1620
gtcaggcctg gacttaaaag attttttaaa acctccataa gtagtccagg ggcggtggct 1680
cacgcctgta atcccagcac tttgggaggg cgaggcaggg ggatcacaag gtcaacgaga 1740
tcgagaccat cctggccaac atggtgaaac cctgtctgta ccaaaaatac aaaaattaat 1800
tgggcatggg ggtggacacc tgtaatccca gctactaggg aggctgaggc aggagaaattg 1860
cttgaacctg ggaggcggag gttgcagtga gccactgcac tccagcctga tgacagagca 1920
agactcagtc tcaaaaataa ataaaaataa taaaacctca aaaaaaaaaa aaaa 1974

```

<210> 44

<211> 1061

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 1871288CB1

<400> 44

```

tcctccttgg gttcgggtga aagcgcttgg gggttcagtg gggcatgac cccgagctgc 60
tggagaactg aaggcggagc gtctcctgcg aaaccaggca atggcggagt tggactttgt 120
tcagatcatc atcatcgtgg tggatgatg ggtgatggg gtggatgaca cctcctgct 180
gagccactac aagctgtctg cagcgtcctt catcagccgg cacagccagg ggcggaggag 240
agaagatgac ctgtcctcag aaggatgct gtggccctcg gagagcacag tgcaggcaa 300
cggaatccca gagcgcgagg tctacgcccc gcctcggccc accgacggcc tggcgtgcc 360
gcccttcgcc cagcggggagc gcttcacccg cttccagccc acctatccgt acctgcagca 420
cgagatcgac ctgcccggca ccatctcgct gtcagacggg gaggagcccc cactctacca 480
gggccccctg accctccagc ttccgggaccc cgagcagcag ctggaactga accgagctc 540
ggtgpcgcca ccccaaaaca gaaccatctt cgacagtgc ctgatggata gtcgaggct 600
gggcgggccc tgccccccca gcagtaactc gggcatcagc gccacgtgct acgacggcgg 660
cgggcgcctg gaggggccgc cgcccaccta cagcagggtc atcggccact accggggctc 720
ctccttcagc caccagcaga gcagtgggtc gctcctctg ctggaggagg ccgggtcca 780
ccacacacac atcgcgcccc tagagagcgc agccatctgg agcaaaagaa aggaataaca 840
gaaaggagac cctctctagg gtcccaggg gggcggggct ggggctgcgt aggtgaaaaa 900
gcagaacact ccgcgcttct tagaagagga gtgagaggaa ggcggggggc gcagcaacgc 960
atcgtgtggc cctccccctc cacctccttg tgtataaata tttacatgtg atgtctggct 1020
tgaatgcaca agctaagaga gcttgcaaaa aaaaaaaaaa a 1061

```

<210> 45
 <211> 505
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 2587338CB1

<400> 45
 ggagcctgga ggagcccacg cagtctgttc ccggcaccgc gtgcgtgtga agggacttga 60
 gggcagcgag atggaatcag caagagaaaa catcgacctt caacctggaa gctccgaccc 120
 caggagccag cccatcaacc tgaaccatta cgccaccaag aagagcgtgg cggagagcat 180
 gctggacgtg gccctgttca tgtccaacgc catgcggctg aaggcgggtg tggagcaggg 240
 accatcctct cactactaca ccaccctggt caccctcatc agcctctctc tgctcctgca 300
 ggtggtcatc ggtgtcctgc tctgtgtcat tgcacggctg aacctgaatg aggtagaaaa 360
 gcagtggcga ctcaaccagc tcaacaacgg cagccacatc ttggtcttct tctactgtgt 420
 catcaatggt ttcattacag gcttcggggc acataaaaaca agggctcctg cctgccagga 480
 ctccaggaat cctctctgaa tggag 505

<210> 46
 <211> 1099
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No.: 2821211CB1

<400> 46
 gaaatgcttt gtcttcagcc tctccaggca ccatctccct tcctgtggga gcagagagct 60
 tagcctggag cacctttcct tcaagccagc aacacagagc actagggttca attccctgaa 120
 ggtggccact ttaagagaga aatctgaaaa ccccatcttc tttcttttct cccatattgg 180
 catggatttc tgtcttctct aacaccttgt gaccttctct atatcatgct ttaaagtgtg 240
 ataatatgat tttttaaaag aaatttatta cttgttgcaa aggtcttttt aaaccagttt 300
 agattttcaag aaaaaataaa tggaaatcat cgaaaattca tttcacatta atggtctaaa 360
 aataaaccac aggacattat gtgtgcatgt gtgtataagt gcacacagaa atatatatac 420
 atatgtagac tatatacatg tgtgtatata tgtgtatata tacatacact tgtataaatg 480
 tatatacaca tatacctata atgtgtgtat gtgtatttat tgaagaaaca gataccatac 540
 tcattttctaa aagaatattc agagaatata aagatgattc tggctgaaaa aggccagtgg 600
 aaattcaggt gaaaatgttc atcaattccc attgcatcac ctctgtaatt ttcagctctc 660
 ctgtataaac attaaatgtc ttatatagca gcaaaaatat aaaatagttg tccatatttt 720
 cacagggtgtg gtgtaattta taaaattaga aagcaactta tcagctactt aagagaaatg 780
 gcaagttttg atatgagtat acaatatata aaaatatata tagtgctata tatataaata 840
 tttggtctct atttcatatt ttgcatcagt attaatacta aaatatgtct cgctagtgtg 900
 gtttttatga tatccctgat cctaactgaa gagacagtta tttatagtca tttattttta 960
 aaaatgaaaa taagtgaata ataattaggt taacattggt gctccctgtg acaaaatttt 1020
 ataagcaaat ttcaaaagac atgttgtaaa ttaggagggt caacaataaa acattatgct 1080
 ccagaaaaaa aaaaaaaaaa 1099

<210> 47
 <211> 1727
 <212> DNA
 <213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 2824832CB1

<400> 47

```

gttgatccgc ggctgcgctc catgttccag tttcatgcag gctcttgga aagctgggtgc 60
tgctgctgcc tgattcccgc cgacagacct tgggaccggg gccaacactg gcagctggag 120
atggcggaca cgagatccgt gcacgagact aggtttgagg cggccgtgaa ggtgatccag 180
agtttgccga agaattggtt attccagcca acaaatgaaa tgatgcttaa attttatagc 240
ttctataagc aggcaactga aggacctgt aaactttcaa ggcctggatt ttgggatcct 300
attggaagat ataaatggga tgcttgaggt tctctgggtg atatgaccaa agaggaagcc 360
atgattgcat atgttgaaga aatgaaaaag attattgaaa ctatgccaat gactgagaaa 420
gttgagaagt tgctgcgtgt cataggtcca ttttatgaaa ttgtcgagga caaaaagagt 480
ggcaggagtt ctgatataac ctcatatctt ggtaatgttc tcaacttctac tccgaacgcc 540
aaaaccgtta atggttaaagc tgaaagcagt gacagtggag ccgagtctga ggaagaagag 600
gccaagaag aagtgaagg agcagaacaa agtgataatg atataaatga tgatcatgtt 660
gaagatgtta caggaattca gcatttgaca agcagttcag acagtgaagt ttactgtgat 720
tctatggaac aatttggaac agaagagtct ttagacagct ttacgtccaa caatggacca 780
tttcagtatt acttgggtgg tcattccagt caacctatgg aaaattctgg atttcgtgaa 840
gatattcaag tacctcctgg aaatggcaac attgggaata tgcaggtggg tgcagttgaa 900
ggaaaagggt aagtcaagca tggaggagaa gatggcagga ataacagcgg agcaccacac 960
cgggagaagc gaggcggaga aactgacgaa ttctctaata ttagaagagg aagaggacat 1020
aggatgcâac acttgagcga aggaaccaag ggccggcagg tgggaagtgg aggtgatggg 1080
gagcgtggg gctccgacag aggggtcccga ggcgcctca atgagcagat cgcctcgtg 1140
ctgatgagac tgcaggagga catgcagaat gtccttcaga gactgcagaa actggaaacg 1200
ctgactgctt tgcaggcaaa atcatcaaca tcaacattgc agactgctcc tcagcccacc 1260
tcacagagac catcttggtg gcccttcgag atgtctcctg gtgtgctaac gtttgccatc 1320
atatggcctt ttattgcaca gtggttggtg tatttatact atcaaagaag gagaagaaaa 1380
ctgaactgag gaaaatggtg ttttcctcaa gaagactact ggaactggat gacctcagaa 1440
tgaactggat tgtggtgttc acaagaaaat cttagtttgt gatgattaca ttgctttttg 1500
ttgtccagta gtttagtttg tgtacatata tacacatata tattttgcac tacacaaacg 1560
ataacatttt aaggactaat attgctgata cttgaataat caatctctac taggttataa 1620
gtagtataca cagatttacc ctgcccttga acttgaagga cattaaatta ttaatgatca 1680
tttggtâaca tgtttacctg attatcttcc atagagtaac ataaggg 1727

```

<210> 48

<211> 951

<212> DNA

<213> Homo sapiens

<220>

<221> misc_Feature

<223> Incyte ID No.: 3070147CB1

<400> 48

```

ggggactgga gcatgggacg gcgcgcctga aggagcagga aggggaagga ggcctgggac 60
cccgaââaga gaaggggaga gcgaggggac gagagcggag gaggaagatg caactgactc 120
gctgctgctt cgtgttctct gtgcagggtg gcctctatct ggtcatctgt ggccaggatg 180
atggctctcc cggctcagag gacctgagc gtgatgacca cgagggccag ccccgccccc 240
gggtgcctcg gaagcggggc cacatctcac ctaagtcccg ccccatggcc aattccactc 300
tctagggtct gctggccccg actggggagg cttggggcat tcttgggcag cccccaacc 360
gcccgaacca cagcccccca ccctcagcca aggtgaagaa aatctttggc tggggcgact 420
tctactccaa catcaagacg gtggccctga acctgctcgt cacagggaag attgtggacc 480
atggcaatgg gaccttcagc gtccacttcc aacacaatgc cacaggccag ggaaacatct 540

```

```

ccatcagcct cgtgcccccc agtaaagctg tagagtcca ccaggaacag cagatcttca 600
tcgaagccaa ggcctccaaa atcttcaact gccggatgga gtgggagaag gtagaacggg 660
gccgccggac ctgcgtttgc acccacgacc cagccaagat ctgctcccga gaccacgctc 720
agagctcagc cacttgagc tgctcccagc ccttcaaagt cgtctgtgtc tacatcgctt 780
tctacagcac ggactatcgg ctgggtccaga aggtgtgccc agattacaac taccatagtg 840
atacccccta ctacccatct ggggtgacct gggcaggcca cagaggccag gccaggggctg 900
gaaggacagg cctgcccctg caggagacca tctggacacc gggcaggggaa g 951

```

<210> 49

<211> 1624

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 3271841CB1

<400> 49

```

ctcctccgcg ttccgagccg ccgtcatccc gcggaggagc gcgcacgccc ggggaggccg 60
gaggacgcgc ccatagaatg cccaggggcg acaaactgtc ctgagcccct ctgggtgcagc 120
cacctgcctg tcccatagc cccgcccacc atggagtcca gagggaaagt agccagcagc 180
cccaagcccc acaccaaggt gcccaggtc accaccgagg ccaaggtacc cccggcagcc 240
gatgggaaag cccccttgac caagccctcg aagaaggagg ccccgccga gaagcagcag 300
ccgcccagcag cccccaccac ggcacctgcc aagaagacct cggccaaggc cgacctgtcc 360
cttctcaaca accacagcaa cctgaagcca gccccacgg tccccagcag tcccgatgca 420
accccgagc ccaaggggtc tggggacggg gcggaggaa atgaggctgc cagtgggggg 480
cctggggggc gaggtccctg gtcctgtgag aacttcaacc ccctgctggt ggctgggggt 540
gtggccgtgg cagccatagc cctgattctc ggtgtggcct tcctggtccg gaaaaataa 600
tacctggggg ccaggcgggg ggcacggagc cacttctgt acagaccga ggaagccagt 660
gcatgcagag ttcacctta cctattcgta cacacgcaca ttcattacac acctacatat 720
gcccccaaca cagcgcacg gtgaagagga cgcgcagacc caccctgtct gaccaggac 780
ttcccccaacc tccagggcag aaagagccca ggctccgggg tccacagcac aggatgtggg 840
gcgagggcac agctggggaa cggcaagaaa ggaatggacc ctgtgtgtgg cccccccacc 900
cctggcggtt ggggtgatcct gggccccccag ggctggtctg agtgcagggt ggggtgcccg 960
gatgggttgg gcctggggcc ggccctcgtg gggacattaa agggcgcggt ggctccactc 1020
gccccatttc tgctctttgc gtaccccccg ggggtctgcc tgggcgaatg cagtgggacg 1080
gacctggggg gggcactcac ctccagcagag cctcaatgcc acctccccac accaccaag 1140
cctagctggg tgggaagacg gagccctgaa gcctgcgtgt ggaggggggt ctgcccgaag 1200
gtcgccttcc ccagcttgtg ctccagggga gcccgcagc cggcggggag gcagggatgt 1260
cgagggcccc tcacagctgt gcccgccctg ccccgctaga ctgcccctcc agcttgcacc 1320
cagcaccacc tgagtctaac cagcgtataa tgcaataaca ggtagagtag aactgctttt 1380
ggcggcgacc gtcacacact gtcctcagcc cactgcacct ggggaagccc ctctgtcagc 1440
ccctccttag cacatccagt cccagcgtgg cccttggcgc gcagcagcag gcgaactccc 1500
agaaggtggg ggtgggcact gtgagaacgt ggctgcctc cactggccag tggccacagg 1560
aaccgccggc ctgagtgagg gctgagctct aaataaactc tgtcgtctga aaaaaaaaaa 1620
aaaa 1624

```

<210> 50

<211> 2080

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 3537827CB1

<400> 50

```
gtcaaggtca ccttcctctt ccagtagcag caggactgag tgattccatc tatttgaggt 60
cgcggaagcg gtgaattgga ggggaggagc tgaccagat gaggaactg agaccagaa 120
aggtggaagc a'cttgtctaa ggtagcgct ccaggaagca gtgtgtccac gactccagtc 180
caagtgggtca gggtccagag cccacagtcc caggggtcca tgatgccgag ctgcaatcgt 240
tcctgcagct gcagccgagg cccacagctg gaggatggca agtgggtatgg ggtccgctcc 300
tacctgcacc tcttctatga ggactgtgca ggcactgtct tcagcgacga cctgagggga 360
cctccggtcc tgtgcccccg ccggccttg ccctcactgt gttggaagat cagcctgtcc 420
tcggggaccc tgcttctgct gctgggtgtg gcggctctga ccactggcta tgcagtgcc 480
cccaagctgg agggcatcgg tgaggggtgag ttcctggtgt tggatcagcg ggcagccgac 540
tacaaccagg ccctgggcac ctgtcgcctg gcaggcacag cgctctgtgt ggcagctgga 600
gttctgctcg ccatctgcct cttctgggccc atgataggct ggctgagcca ggacaccaag 660
gcagagccct tggaccccgga agccgacagc cacgtggagg tcttcgggga tgagccagag 720
cagcagttgt caccattttt ccgcaatgcc agtggccagt catgggtctc gccaccgcc 780
agcccccttg ggcaatcttc tgtgcagact atccagccca agagggactc ctgagctgcc 840
cacatggcct aagatgtggg tccctggatcc tcccccttc tcaccataac cccctctcag 900
tggttcccca acttctccct tttagcaggg tccctttaga gcccaactcc aggtcaaactc 960
tgagagctcaa atcccagtc tccctcccca ggagtggggc cccaactctt ccaagatacc 1020
agcattcctc aagtcctccc aaaacttcct acccacaccc tcttcccaag gccctcaggg 1080
gcagaaaaca tctccttcaa cccgtcccca ctcttctctc tgcattgacct tgggcaaacc 1140
cttgcccttt caagccatca gctcctgcct ctctgccatg agggcttttg atcagattcc 1200
tcttctcgcc aggatgagga cagcactgc cctccataga cacagatgaa ggggtggggg 1260
tcattcagct cgaatgggtc ccagatgctc acttggcctt tccctgcagg atgagtgaag 1320
acgtttgcct ctacagtggt gtcttctacc tgcatttttg catcagagcc cccagccca 1380
cccaccacag gcaattacta gccctagtgt ataggtgagg tgggtgaaga aggctggagg 1440
tgacatgtcc gaggtcacac aacaaagcag catgcaggaa ctagaaacac atcttcagcc 1500
tcctcctggg ccagctcttg tgctacaggt ggggcggagc cagccctca ccttctggt 1560
tccttgaggg tctcaggggt ggaggacagg tttggccag aaagactagc cagaggcctg 1620
atgggtccag gtggctctgg atatactttg gatattgatt taaatggtct ctaagagccg 1680
ggggtagggg gcaggaaaag tgggtgtgtt ttgcccctca aagtccacct acctagaaac 1740
caagcccacg gtcttgccg tgaccctgat aataaatggg ctctctcaga ggcgccagcc 1800
cctccctccc cagccggagg cgtcatctct cttctgtacc actagagggg gctctgatgc 1860
agctggagag cagcgtcaa ggctctcgcc cctccctcc ctaaccctta ccttcagtct 1920
ccaccagcct gaagggcctc ctaggggatc ctcaggcggc cccaccagg gcacacctta 1980
ctgtccttgt gcctcacgcc cctcctcat cctgcacccc tcccatccca ccttcccttt 2040
caataaacag ctgggatgga tactgaaaaa aaaaaaaaaa 2080
```

<210> 51

<211> 1420

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 3729267CB1

<400> 51

```
cttcacagcg cgcttgcgct ccggagcgct ggctctgctg gcgctgagaa atggaccaat 60
tttgacaaga tatagtgtg cagcgtgcct gatgggatat attcagtcac ggcgtccgaa 120
ctttgtaaga cgatctctgt ggcaaggcta gaaaagcaca agaatttgtt cttaaattat 180
```

```

aggaatctgc accatthttcc attggagtta ctgaaagatg agggactgca gtacttggag 240
agactctata tgaaaaggaa ctccctgaca tccttgccag aaaaccttgc tcagaagctt 300
ccaaaccttg tggaactata cctgcaactca aataacatag ttgtgggttcc ggaagccatt 360
gggtctcttg taaaactcca atgtctggat cttagtgaaca atgccttaga aattgtttgc 420
ccagaaattg gtcgtctgag agctttacgt catcttcgat tagctaataa ccaactgcaa 480
ttcctacctc cagagggttg cgattttgaag gagctgcaga cactagacat ttctaccaat 540
cgtttgctaa ctttaccgga gaggtttcac atgtgccttt ctctgcagta cctcaatgag 600
gaccgaaatc gtctatggta tgtgcgcgcgc catctctgcc agctgcccag cctcaatgag 660
ctctccatgg ctggaaccg tcttgcatth ttgccacttg atttaggtcg atctcgagaa 720
ctacagtatg tatacgtgga taacaacatt cacctgaaag gcttgccatc ttatctgtac 780
aataaagtca tcgggtgcag tggctgtggt gctcccatc aagtttccga ggtgaagctg 840
ctttcctttt catcagggca gcgaaccgtt ttccctccag ctgagggtgaa ggccataggg 900
acggagcatg atcacgtcct cctctgcag gaattggcta tgagagggtc gtatcatacc 960
taccacagct tgctgaaaga tttgaacttt ctgtctccaa tctcattacc cagaagcttc 1020
ctagagctgc tgcactgcc tctggggcac tgtcatcggt gtagtgagcc tatgtttacc 1080
atcgtctacc ccaagctctt tcccttgaga gagacgcaa tggcaggggt gcaccagtgg 1140
aagacaactg ttagttttgt ggcttactgc tgctccaccc agtgtctgca gacttttgac 1200
ctgctgagtt gataaacact caagaacctc agggagcgtg ccagcttgac actgggggaat 1260
ccagccagtc cagcacactc ttccatcctg tcctgtccaa tgcgggggca ctgcagaact 1320
ctctagaaat gtcattgatt agcttcagag ctaaaatgcc ttcacccttc cccaagttg 1380
gaatatatcc tcccccaaat taaggaaaaa aaaaaaaaaa 1420

```

<210> 52

<211> 2703

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 3768771CB1

<400> 52

```

gctgattacc ttccctttaa ccagtcacatc taaagggttg tgtaagagg cttcccatgg 60
gaggggtggc cccaggtaat acccatcttc ctctcccccag gctctgaaga gcggccatc 120
ctcagattcg aagctgaaca catctccaac tacacagccc ttctgctgag cagggatggc 180
aggaccctgt acgtgggtgc tcgagaggcc ctctttgcac tcagtagcaa cctcagcttc 240
ctgccaggcg gggagtacca ggagctgctt tgggggtgcag acgcagagaa gaaacagcag 300
tcgagcttca agggcaagga cccacagcgc gactgtcaaa actacatcaa gatcctcctg 360
ccgctcagcg cagntcacct gttcacctgt ggcacagcag ccttcagccc catgtgtacc 420
tacatcaaca tggagaactt caccctggca agggacgaga aggggaatgt cctcctggaa 480
gatggcaagg gccgttgtcc cttcgacccg aatttcaagt ccaactgccct ggtggttgat 540
ggcgagctct aactggaac agtcagcagc ttccaaggga atgaccgggc catctcgcg 600
agccaaagcc ttgcgccac caagaccgag agctccctca actggctgca agaccagct 660
tttgtggcct cagcctacat tcctgagagc ctgggcagct tgcaaggcga tgatgacaag 720
atctactttt tcttcagcga gactggccag gaatttgagt tctttgagaa caccattgtg 780
tcccgcattg cccgcactcg caaggcgat gaggggtggag agcgggtgct acagcagcgc 840
tggacctcct tcctcaaggc ccagctgctg tgctcacggc ccgacgatgg cttcccttc 900
aacgtgctgc aggatgtctt cacgctgagc cccagccccc aggactggcg tgacaccctt 960
ttctatgggg tcttcacttc ccagtggcac aggggaacta cagaaggctc tgccgtctgt 1020
gtcttcacaa tgaaggatgt gcagagagtc ttcagcgcc tctacaagga ggtgaaccgt 1080
gagacacagc agtggtacac cgtgaccac cgggtgcccc caccggggc tggagcgtgc 1140
atcaccaaca gtgcccggga aaggaagatc aactcatccc tgcagctccc agaccgctg 1200
ctgaactttc tcaaggacca cttcctgatg gacgggcagg tccgaagccg catgctgctg 1260
ctgcagcccc aggtcgctc ccagcgcgctg gctgtacacc gcgtccctgg cctgcaccac 1320

```

```

acctacgatg tcctcttctt gggcactggg gacggccggc tccacaaggc agtgagcgtg 1380
ggccccggg tgcacatcat tgaggagctg cagatcttct catcgggaca gcccgtgcag 1440
aatctgctcc tggacaccca cagggggctg ctgtatgcgg cctcacactc gggcgtagtc 1500
caggtgcccc tggccaactg cagcctgtac cggagctgtg gggactgcct cctcgcccgg 1560
gaccctact gtgcttgag cggctccagc tgcaagcacg tcagcctcta ccagcctcag 1620
ctggccacca ggccgtggat ccaggacatc gagggagcca gcgccaagga cctttgcagc 1680
gcgtcttcgg ttgtgtcccc gtcttttcta ccaacagggg agaagccatg tgagcaagtc 1740
cagttccagc ccaacacagt gaacactttg gcctgcccgc tcctctccaa cctggcgacc 1800
cgactctggc tacgcaacgg ggcéccccgc aatgcctcgg cctcctgcca cgtgctaccc 1860
actggggacc tgcctgctggg gggcacccaa cagctggggg agttccagtg ctggctacta 1920
gaggagggct tcacgcagct ggtagccagc tactgcccag aggtgggtgga ggacgggggtg 1980
gcagaccaaa cagatgaggg tggcagtgtg cccgtcatta tcagcacatc gcgtgtgagt 2040
gcaccagctg gtggcaaggc cagctggggg gcagacaggt cctactggaa ggagttcctg 2100
gtgatgtgca cgtcttttgt gctggccgtg ctgctccag ttttattctt gctctaccgg 2160
caccggaaca gcatgaaagt cttcctgaag cagggggaat gtgccagcgt gcaccccaag 2220
acctgccctg tgggtgctgcc ccctgagacc cgcccactca acggcctagg gccccttagc 2280
accccgctcg atcaccgagg gtaccagtc cgtgcagaca gccccccggg gtcccagtc 2340
ttcactgagt cagagaagag gccactcagc atccaagaca gcttcgtgga ggtatcccca 2400
gtgtgcccc ggccccgggt ccgccttggc tcggagatcc gtgactctgt ggtgtgagag 2460
ctgacttcca gaggacgctg ccctggcttc aggggctgtg aatgctcgga gaggtcaac 2520
tggacctccc ctccgctctg ctcttcgtgg aacacgaccg tgggtgcccgg cccttgggag 2580
ccttggagcc agctggcctg ctgctctcca gtcaagtagc gaactcctac caccagaca 2640
cccaaacagc cgtggcccca gaggtcctgg ccaaatatgg gggcctgcct aggttgggtg 2700
aaa

```

<210> 53

<211> 571

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 4248993CB1

<400> 53

```

ctgtgttgag taaccatggg gaggaagctg gacctgtctg gtttgactga tgatgaaaca 60
gagcatgttc ttcaggtggg tcaaagagac ttcaatcttc gaaaaaaga agaagaacga 120
ctaagtgagc tgaagcagaa gctggatgag gaaggcagca agtgcagcat cctctcgaag 180
caccagcagt ttgtggagca ctgctgcatg cgctgctgct cgccttcac ctctctcgtc 240
aacaccaagc gccagtgtgg agattgcaaa ttcaatgtct gcaagagctg ctgctcctac 300
cagaagcacg aaaaggcctg ggtctgctgc gtctgccagc aagcgaggct tctgaggggc 360
caatctctgg aatggttcta caataatgtg aagagccgct tcaagcgctt tggcagtgca 420
aggttctgaa gaacctgtac agggagcacc ggctggagag tggcgctgct ttcgacattc 480
taggaggaag ctttttgacg tcaaccctgg agatgagggg gcattctggc agtgattcac 540
atttataggc agtcagagga catagtgtgt g

```

<210> 54

<211> 1293

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No.: 5402418CB1

<400> 54

```

cccagctcta gcgaaaagcc gccggtatctt ctccatctgg ctctcctcta cctccaggca 60
ggctcaccgc agatccccgc cccgaacccc cctgcacac tcggcccagc gctgttgccc 120
ccggagcgga cgtttctgca gctattctga gcacacctg acgtcggctg agggagcggg 180
acagggtcag cggcgaagga ggcaggcccc gcgcggggat ctcggaagcc ctgcggtgca 240
tcatgaagtt ccagtacaag gaggaccatc cctttgagta tcggaaaaag gaaggagaaa 300
agatccggaa gaaatatccg gacagggtcc ccgtgattgt agagaaggct ccaaaagcca 360
gggtgcctga tctggacaag aggaagtacc tagtgccctc tgaccttact gttggccagt 420
tctacttctt aatccggaag agaattccacc tgagacctga ggacgcctta ttcttctttg 480
tcaacaacac catccctccc accagtgcta ccatgggcca actgtatgag gacaatcatg 540
aggaagacta ttttctgtat gtggcctaca gtgatgagag tgtctatggg aaatgagtgg 600
ttggaagccc agcagatggg agcacctgga cttgggggta ggggaggggt gtgtgtgccc 660
gacatgggga aagaggggtg ctcccaccgc aaggagacag aagggtgaaga catctagaaa 720
cattacacca cacacaccgt catcacatct tcacatgctc aattgatatt ttttgctgct 780
tcctcggccc agggagaaaag catgtcagga cagagctgtt ggattggctt tgatagagga 840
atggggatga tgtaagtta cagtattcct ggggtttaat tgttgtgcag tttcatagat 900
gggtcaggag gtggacaagt tggggccaga gatgatggca gtccagcagc aactccctgt 960
gctcccttct ctttgggcag agattctatt tttgacattt gcacaagaca ggtagggaaa 1020
ggggacttgt ggtagtggac catacctggg gaccaaaga gaccactgt aattgatgca 1080
ttgtggcccc tgatcttccc tgtctcacac ttcttttctc ccatcccggt tgcaatctca 1140
ctcagacatc acagtaccac cccaggggtg gcagtagaca acaaccaga aatttagaca 1200
gggatctctt acctttggaa aataggggtt aggcatagaag gtggttgtga ttaagaagat 1260
ggttttggtta ttaaataaca ttaaactagg att 1293

```

<210> 55

<211> 375

<212> PRT

<213> Homo sapiens

<300>

<308> g3002527

<400> 55

```

Met Glu Phe Ser Leu Leu Pro Arg Leu Glu Cys Asn Gly Ala
1      5      10      15
Ile Ser Ala His Arg Asn Leu Arg Leu Pro Gly Ser Ser Asp Ser
20     25     30
Pro Ala Ser Ala Ser Pro Val Ala Gly Ile Thr Gly Met Cys Thr
35     40     45
His Ala Arg Leu Ile Leu Tyr Phe Phe Leu Val Glu Met Glu Phe
50     55     60
Leu His Val Gly Gln Ala Gly Leu Glu Leu Pro Thr Ser Asp Asp
65     70     75
Pro Ser Val Ser Ala Ser Gln Ser Ala Arg Tyr Arg Thr Gly His
80     85     90
His Ala Arg Leu Cys Leu Ala Asn Phe Cys Gly Arg Asn Arg Val
95    100    105
Ser Leu Met Cys Pro Ser Trp Ser Pro Glu Leu Lys Gln Ser Thr
110   115   120
Cys Leu Ser Leu Pro Lys Cys Trp Asp Tyr Arg Arg Ala Ala Val

```

| | | | | | |
|-----------------|-------------------------|---------------------|-----|--|-----|
| | 125 | | 130 | | 135 |
| Pro Gly Leu Phe | Ile Leu Phe Phe Leu Arg | His Arg Cys Pro Thr | | | |
| | 140 | | 145 | | 150 |
| Leu Thr Gln Asp | Glu Val Gln Trp Cys Asp | His Ser Ser Leu Gln | | | |
| | 155 | | 160 | | 165 |
| Pro Ser Thr Pro | Glu Ile Lys His Pro Pro | Ala Ser Ala Ser Gln | | | |
| | 170 | | 175 | | 180 |
| Val Ala Gly Thr | Lys Asp Met His His Tyr | Thr Trp Leu Ile Phe | | | |
| | 185 | | 190 | | 195 |
| Ile Phe Ile Phe | Asn Phe Leu Arg Gln Ser | Leu Asn Ser Val Thr | | | |
| | 200 | | 205 | | 210 |
| Gln Ala Gly Val | Gln Trp Arg Asn Leu Gly | Ser Leu Gln Pro Leu | | | |
| | 215 | | 220 | | 225 |
| Pro Pro Gly Phe | Lys Leu Phe Ser Cys Pro | Ser Leu Leu Ser Ser | | | |
| | 230 | | 235 | | 240 |
| Trp Asp Tyr Arg | Arg Pro Pro Arg Leu Ala | Asn Phe Phe Val Phe | | | |
| | 245 | | 250 | | 255 |
| Leu Val Glu Met | Gly Phe Thr Met Phe Ala | Arg Leu Ile Leu Ile | | | |
| | 260 | | 265 | | 270 |
| Ser Gly Pro Cys | Asp Leu Pro Ala Ser Ala | Ser Gln Ser Ala Gly | | | |
| | 275 | | 280 | | 285 |
| Ile Thr Gly Val | Ser His His Ala Arg Leu | Ile Phe Asn Phe Cys | | | |
| | 290 | | 295 | | 300 |
| Leu Phe Glu Met | Glu Ser His Ser Val Thr | Gln Ala Gly Val Gln | | | |
| | 305 | | 310 | | 315 |
| Trp Pro Asn Leu | Gly Ser Leu Gln Pro Leu | Pro Pro Gly Leu Lys | | | |
| | 320 | | 325 | | 330 |
| Arg Phe Ser Cys | Leu Ser Leu Pro Ser Ser | Trp Asp Tyr Gly His | | | |
| | 335 | | 340 | | 345 |
| Leu Pro Pro His | Pro Ala Asn Phe Cys Ile | Phe Ile Arg Gly Gly | | | |
| | 350 | | 355 | | 360 |
| Val Ser Pro Tyr | Leu Ser Gly Trp Ser Gln | Thr Pro Asp Leu Arg | | | |
| | 365 | | 370 | | 375 |

<210> 56

<211> 309

<212> PRT

<213> Homo sapiens

<300>

<308> g847722

<400> 56

| | | |
|-----------------|-------------------------|---------------------|
| Met Val Ser Phe | Val Ser Asn Tyr Ser His | Thr Ala Asn Ile Leu |
| 1 | 5 | 10 |
| Pro Asp Ile Glu | Asn Glu Asp Phe Ile Lys | Asp Cys Val Arg Ile |
| | 20 | 25 |
| His Asn Lys Phe | Arg Ser Glu Val Lys Pro | Thr Ala Ser Asp Met |
| | 35 | 40 |
| Leu Tyr Met Thr | Trp Asp Pro Ala Leu Ala | Gln Ile Ala Lys Ala |
| | 50 | 55 |
| Trp Ala Ser Asn | Cys Gln Phe Ser His Asn | Thr Arg Leu Lys Pro |
| | 65 | 70 |
| Pro His Lys Leu | His Pro Asn Phe Thr Ser | Leu Gly Glu Asn Ile |

| | | | | | |
|---|-----|--|-----|--|-----|
| | 80 | | 85 | | 90 |
| Trp Thr Gly Ser Val Pro Ile Phe Ser Val Ser Ser Ala Ile Thr | | | | | |
| | 95 | | 100 | | 105 |
| Asn Trp Tyr Asp Glu Ile Gln Asp Tyr Asn Phe Lys Thr Arg Ile | | | | | |
| | 110 | | 115 | | 120 |
| Cys Lys Lys Val Cys Gly His Tyr Thr Gln Val Val Trp Ala Asp | | | | | |
| | 125 | | 130 | | 135 |
| Ser Tyr Lys Val Gly Cys Ala Val Gln Phe Cys Pro Lys Val Ser | | | | | |
| | 140 | | 145 | | 150 |
| Gly Phe Asp Ala Leu Ser Asn Gly Ala His Phe Ile Cys Asn Tyr | | | | | |
| | 155 | | 160 | | 165 |
| Gly Pro Gly Gly Asn Tyr Pro Thr Trp Pro Tyr Lys Arg Gly Ala | | | | | |
| | 170 | | 175 | | 180 |
| Thr Cys Ser Ala Cys Pro Asn Asn Asp Lys Cys Leu Asp Asn Leu | | | | | |
| | 185 | | 190 | | 195 |
| Cys Val Asn Asp Ser Glu Thr Lys Ser Asn Val Thr Thr Met Leu | | | | | |
| | 200 | | 205 | | 210 |
| Tyr Ile Arg Leu Ala His Ile Ser Thr | | | | | |
| | 215 | | | | |

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|---|---|
| (51) International Patent Classification 7 : C12N 15/12, C07K 14/47, C12Q 1/68, A61K 38/17, C07K 16/18 | | A3 | (11) International Publication Number: WO 00/34477 |
| | | | (43) International Publication Date: 15 June 2000 (15.06.00) |
| (21) International Application Number: PCT/US99/30408 | | (72) Inventors; and (75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). AU-YOUNG, Janice [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). YANG, Junming [CN/US]; 7136 Clarendon Street, San Jose, CA 95129 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). | |
| (22) International Filing Date: 10 December 1999 (10.12.99) | | (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). | |
| (30) Priority Data: Not furnished 09/210,083 11 December 1998 (11.12.98) US 60/119,365 11 December 1998 (11.12.98) US 60/119,365 9 February 1999 (09.02.99) US 60/124,687 16 March 1999 (16.03.99) US | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). | |
| (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US --- Not furnished (CIP) Filed on 11 December 1998 (11.12.98) US 60/119,365 (CIP) Filed on 9 February 1999 (09.02.99) US 60/124,687 (CIP) Filed on 16 March 1999 (16.03.99) US 09/210,083 (CIP) Filed on 11 December 1998 (11.12.98) | | Published With international search report. | |
| (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). | | (88) Date of publication of the international search report: 9 November 2000 (09.11.00) | |
| (54) Title: NEURON-ASSOCIATED PROTEINS | | | |
| <p>1 MA-----GSPSRAAGRRLOLP----- 2417014 1 MEFSLLLPRLECNGAISAHRNLRLLPGSSDS GI 3002527</p> <p>17 -----L L C L F L O----- 2417014 31 PASASPVAGITGMCTHARLILYFELVEMEF GI 3002527</p> <p>24 -----GATAVLFAVF-----VRYNHKT 2417014 61 LHVQAGLELPTSDDPSVSASQSARRYRTGH GI 3002527</p> <p>41 D A A L-----W H----- 2417014 91 H A R L C L A N F C G R N R V S L M C P S W S P E L K Q S T GI 3002527</p> <p>47 -----R S N H S N A D N E F Y F R Y-----P K E S H S 2417014 121 C L S L P K C W D Y R R A A V P G L F I L F F L R H R C P T GI 3002527</p> <p>68 V A Q A G V Q R R N L G S L Q P S P P R----- 2417014 151 L T Q D E V Q W C D H S S L O P S T P E I K H P P A S A S Q GI 3002527</p> <p>88 -----W-----S F A L V A 2417014 181 V A G T K D M H H Y T W L I F I F I F N F L R Q S L N S V T GI 3002527</p> | | | |
| (57) Abstract | | | |
| The invention provides human neuron-associated proteins (NEUAP) and polynucleotides which identify and encode NEUAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of NEUAP. | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/30408

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/12 C07K14/47 C12Q1/68 A61K38/17 C07K16/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| P,X | WO 99 06554 A (LACROIX BRUNO ;DUCLERT AYMERIC (FR); GENSET (FR); DUMAS MILNE EDWA) 11 February 1999 (1999-02-11) SEQ ID NO 45,313, --- | 1-6,9,10 |
| X | NATIONAL CANCER INSTITUTE, CANCER GENOME ANATOMY PROJECT (CGAP): "Homo sapiens cDNA clone" EMEST DATABASE ENTRY AI022447, ACCESSION NUMBER AI022447, 19 June 1998 (1998-06-19), XP002136735 sequence --- -/- | 3-6,9-11 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

2 May 2000

Date of mailing of the international search report

31.08.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

ESPEN, J

International Application No

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/30408

B x I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 19 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 17, 18, 20
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

B x II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

See additional sheet, Invention 1.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FR M PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17,18,20

Claims 17 and 18 refer to an agonist/antagonist of the polypeptide of claim 1 without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6, PCT).

No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the result to be achieved. In addition, claim 20 refers to a method for treating or preventing a disorder comprising administering to a subject the antagonist of claim 18. In consequence, the above comment also applies to claim 20.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: in part: 1-16,19; all as far as applicable

Neuron-associated polypeptide and polynucleotide relating to SEQ ID NOs 1 and 28, and fragments thereof. Expression vector and host cells comprising at least a fragment of such a polynucleotide. Method for detecting such a polynucleotide. Methode for producing such a polypeptide. Pharmaceutical composition comprising such a polypeptide, and method for treating or preventing a disorder by using said composition. Antibody specifically binding with such a polypeptide.

2-27. Claims: in part: 1-16,19; all as far as applicable

— as invention 1 but limited to subject-matter relating to SEQ ID NOs 2-27, and 29-54; wherein
invention 2 is limited to SEQ ID NOs 2 and 29
invention 3 is limited to SEQ ID NOs 3 and 30, etc...
invention 27 is limited to SEQ ID NOs 27 and 54.

INTERNATIONAL SEARCH REPORT

Information on patient family members

Internal Application No.

PCT/US '99/30408

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|--|
| WO 9906554 | A | 11-02-1999 | AU 8555798 A 22-02-1999 EP 1000152 A 17-05-2000 |
| ----- | | | |